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ABSTRACT OF THE DISSERTATION
The Origins & Functional Effects of Postzygotic Mutations Throughout the Human Lifespan
by
Nicole B. Rockweiler
Doctor of Philosophy in Biology & Biomedical Sciences
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Washington University in St. Louis, 2021
Professor Donald F. Conrad, Chair
Professor Barak A. Cohen, Co-Chair

Mosaicism is pervasive in humans and yet we understand little of its causes and functional
consequences across the lifespan. To help solve these mysteries, we developed a suite of
tools, called Lachesis, to analyze postzygotic mutations (PZMs). LachesisDetect is a novel and
accurate method to detect PZMs with VAFs as low as 0.04% from bulk RNA-seq samples.
LachesisMap is an innovative supervised method to reconstruct postzygotic mutation
phylogenies from putative prenatal PZMs. We applied Lachesis to 17,382 samples derived from
948 donors across 54 diverse tissues and cell types from the NIH’s Genotype-Tissue
Expression (GTEx) project to produce the most comprehensive atlas of PZM variation in normal
tissues. PZMs were pervasive and their burden and spectra were highly variable across donors
and tissues. Postzygotic technical and biological variables contributed substantially to variance
in mutation burden; however, only a minority of the variance was attributable to donor-specific
effects. By mapping putative prenatal mutations to a developmental tree, we observed that
mutation burden, spectra, and functional impact vary throughout time and space with the
xix

majority of prenatal mutations occurring during embryogenesis. Strikingly, we identified a class
of prenatal mutations predicted to be more deleterious than any other broad category of human
genetic variation and to be under positive selection as strong as somatic mutations in cancers.
Comparing postzygotic germline mutations in testis and ejaculated sperm and de novo
mutations in live offspring revealed that germ cell mutation deleteriousness appears to decrease
during the germ cell life cycle. Together, these results suggest that PZMs may experience
differential selective pressures throughout the human lifecycle to result in a complex and
dynamic myriad of genomes within an individual. Uncovering the impacts of these PZMs on
human health and disease will be an exciting and valuable endeavor.
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Chapter 1
Introduction
In this chapter, we will first review postzygotic genetic variation by describing 1) the types of
postzygotic mutations (PZMs), 2) the key questions in postzygotic genetic variation, 3) the
potential mechanisms of postzygotic mutations, 4) current PZM detection methods, 5) the
prevalence of PZMs in normal and disease phenotypes, and 6) implications of postzygotic
genetic variation in research and medicine. Due to limited space, somatic mutation in cancer will
not be discussed at length. See refs. 4,5 for reviews.

1.1 Types of PZMs
A PZM is defined as a genetic alteration that occurs after fertilization of an ovum. Thus, the PZM
will be present in some, but not all, cells of a multicellular organism(1). In contrast, a germline
variant is defined as a genetic alteration that is inherited from one of the parent’s germ cells and
thus will be present in all cells of the individual. (In this dissertation, we primarily use the word
mutation to reflect a genetic change that occurred postzygotically in an individual and the word
variant to reflect a genetic change that is inherited.) There are four main subtypes of PZMs,
each differing on when and where the mutation arose and thus have important implications for
inheritance and disease(1). 1) A gonosomal mutation is a mutation in the nuclear genome of a
cell that gives rise to both germ and somatic cells. 2) Gonadal and 3) somatic mutations are
mutations in the nuclear genome of a cell that give rise to only germ or somatic cells,
respectively. 4) Lastly, a mitochondrial heteroplasmic mutation is a mutation in the mitochondrial
genome (Figure 1-1). Individuals carrying PZMs are called mosaics. Zlotnikoff coined this term
1

in 1945(2) to describe the collection of multiple genomes within a single organism, much like the
assembly of various pieces of glass and stones used to create mosaic artwork.

Figure 1-1: Overview of the four classes of PZMs and their relationships to inherited
variants. mtDNA = mitochondrial DNA.

1.2 Key questions in postzygotic genetic variation
Mutation lies at the foundation of genetics, evolution, and our very existence and demise. Until
recently, genetics has focused on germline mutation(3) and less so on postzygotic genetic
variation. This is partially due to technological limitations and the long-standing assumption that
all cells in a multicellular organism share the same genome. With recent advancements in
sequencing and bioinformatics, one of the final frontiers in genetic variation — spatiotemporal
resolution of postzygotic genetic variation — is upon us.
At the heart of this young field is trying to define the function, phenotype = 𝑓(genotype), i.e.,
how genotype leads to phenotype. Before we even begin to define the function, there are
several prerequisite questions that need to be answered. The first set of largely unanswered
questions are simply characterizing the input argument: the genotype. Can we accurately
detect PZMs? How much postzygotic genetic variation exists within an individual?
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Between individuals? Where does it occur? When does it occur? Does postzygotic
genetic variation change across space and time? Hidden beneath these questions are
underlying why and mechanistic questions: how do postzygotic mutations occur? The
second set of outstanding questions examine the connection between genotype and phenotype:
to what extent does postzygotic genetic variation affect phenotypic variation? With
answers to these and other related questions, we will finally be able to help answer one of the
most important questions in genetics: how does genotype lead to phenotype?

1.3 Mechanisms of postzygotic mutation
Over the course of an individual’s lifetime, the estimated 10E16 cells that arise from the single
cell are exposed to a multitude of endogenous and exogenous mutagenic factors(1). The
identification of such factors and the associated mechanisms that result in mutations is still an
open area of investigation(1). Nevertheless, the emerging result is that PZM mechanisms can
generate genomic alterations involving DNA segments that span orders of magnitude in length
and can be constrained both spatially and temporally during development and aging(4).
The following mechanisms have been implicated in postzygotic mutation. 1) Single-nucleotide
mutations and small indels can result from exogenous and endogenous mutagens (e.g., UV
damage, tobacco smoke, oxidative damage, alkylating agents, hydrolytic deamination) and DNA
replication errors(5). 2) DNA replication slippage can result in expansions or contractions of
variable number tandem repeats. This mechanism creates mutations on the order of 1 to 100
bp(1, 4). 3) Mobile element insertions (MEIs) are caused by retrotransposition of transposable
elements and result in insertions on the order of 100 to 10 kbp. While the majority of mobile
elements are unable to insert new copies(6), postzygotic LINE-1, Alu, and SVA insertions have
been observed in humans(1, 4). 4) Non-homologous end joining (NHEJ), a mechanism used to
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repair double-stranded breaks (DSBs), can produce small indels (1-4 bp). The indel is the result
of removing damaged bases at the breakpoint before ligation of the two strands. Additionally,
this repair mechanism can insert free DNA, e.g., from mitochondria and retrotransposons(1). 5)
Homologous recombination is also used to repair DSBs and can result in loss of
heterozygosity(1). 6) Non-allelic homologous recombination (NAHR) can create large insertions
and deletions on the order of 100 kbp to 1 Mbp as result of homologous recombination between
two DNA sequences with high similarity(7). 7) Missegregation of whole chromosomes, e.g.,
through nondisjunction and anaphase lagging, results in aneuploidy(1). 8) Lastly, fork stalling
and template switching and microhomology-mediated break-induced replication
(FoSTeS/MMBIR) can create complex rearrangements during replication(4, 8). Thus, PZMs can
occur at various steps of cell division as well as time periods where the cell is not dividing. It
appears that most of the mechanisms that create PZMs in normal tissue are also operative in
cancer cells, suggesting that the baseline for genome fragility may be independent of normal
and diseased states.

1.4 Detection of PZMs
The sensitivity and specificity of detecting PZMs greatly depends on the study design and
bioinformatic method. These variables are described in more detail below.

1.4.1 Sample preparation methods
The main sample types are 1) bulk tissue, 2) microdissected tissue, 3) sorted cell populations,
and 4) single-cells. These methods vary on several key aspects e.g., the ability to detect rare
PZMs (single-cell have the highest sensitivity), throughput (bulk tissues profile the largest
population of cells — which can be both advantageous and disadvantageous for detecting
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PZMs), and sample preparation methods. The research questions, cost, and available
resources often dictate which sample type is appropriate.
Typically, DNA is used for variant calling and as a result there are many mature methods for
detecting PZMs from DNA. Methods to detect PZMs from RNA-seq are less mature. This likely
stems from downstream bioinformatic challenges, e.g., more alignment errors due to spliced
reads, lower power to detect PZMs in non- and lowly expressed genes, and difficulties in
distinguishing RNA modifications from DNA mutations. Nonetheless, RNA-seq based methods
have several advantages over DNA-based methods, e.g., expression information can be used
to answer additional questions about the samples, power can be extremely high for highly
expressed genes, and the type of cell carrying the mutation can be predicted (from single-cell
data, or cell deconvolution methods from bulk data). Due to the popularity of DNA-based
methods, we will focus on DNA sample preparation and analysis methods.
While there is generally enough genomic DNA in bulk tissue and sorted cell populations to
generate sample libraries, single-cell methods usually rely on in vivo or in vitro methods to
amplify the entire genome. The methods vary in their genome coverage (e.g., breadth and
uniformity), allelic dropout rate, chimera rates, alignment rates, and false positive rates(9, 10).
Examples of in vivo amplification methods include somatic cell nuclear transfer (SCNT)(11),
reprogramming cells to create an induced pluripotent stem cell (iPSC) line(12), and organoid
technology(13). Due to inefficiencies in reprogramming and potential selection biases, only a
subset of single cells may be successfully expanded and thus may give an inaccurate
representation of the diversity of cell types and PZMs in the original sample.
Unlike in vivo methods, in vitro methods can be directly applied to cells that are post-mitotic and
cells that are challenging to culture. Examples of in vitro amplification methods include
Degenerate Oligonucleotide Primed PCR (DOP-PCR) (first reported in 1992)(14), Multiple
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Displacement Amplification (MDA) (first reported in 2001)(15), and Multiple Annealing and
Looping Based Amplification Cycles (MALBAC) (first reported in 2012)(16). These in vitro
methods primarily differ in their scale of amplification: DOP-PCR and MDA rely on exponential
amplification whereas MALBAC uses quasi-linear amplification. The latter amplification method
is advantageous because it minimizes sequence-dependent bias in the amplified product and
thus improves CNV detection accuracy and improves SNV sensitivity(10).

1.4.2 Mapping platforms
Cytogenetics was the first major technology used to detect large PZMs(1). Pioneering
cytogenetic studies in postzygotic genetic variation include detecting mosaic loss of
chromosome Y in aging males by Jacobs et al. in 1963(17) and detecting the Philadelphia
translocation in chronic myeloid leukemia by Rowley et al. in 1973(18). Advantages of
cytogenetic methods include well established methods and the ability to analyze single
cells(19). The disadvantages of cytogenetics include low throughput and low resolution. At its
highest resolution, fiber fluorescent in situ hybridization (FISH) can only detect structural
variants (SVs) as small as 5 kbp(19).
With the initial release of human genome reference sequence in 2001(20), expansive germline
variation surveys e.g., HapMap(21) and the 1000 Genomes Project(22), and concurrent
advancements in microarray technology in the 2000’s, SNP microarrays and microarray-based
comparative genomic hybridization (aCGH) became popular methods for detecting genetic
variation(1). SNP microarrays can detect copy number variants (CNVs) and copy-numberneutral loss of heterozygosity (LOH) events whereas aCGH can only detect CNVs. Array-based
methods are high-throughput (both in processing samples and detecting variants genome-wide)
and are inexpensive. Disadvantages include limited resolution (10-100 kbp for standard
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designs), low sensitivity (variant allele frequency (VAF) > 5%), and limited utility on
understudied populations due to array designs(3).
The advent of next-generation sequencing (NGS) in the 2000’s and maturation in the 2010’s
has revolutionized genetics in throughput (e.g., population-scale genome sequencing
projects(23)), quality, cost (e.g., the $1000 genome(23)), accessibility (e.g., benchtop and
portable sequencers(24)), and resolution (e.g., breakpoint resolution of SVs(25)). One of the
remaining obstacles in detecting rare PZMs with NGS is read quality. Illumina’s sequencing-bysynthesis technology, arguably the most widely used sequencing technology, has an error rate
of ~0.1%(25). Detecting rare PZMs with VAFs below the error rate is computationally
challenging. Error-corrected sequencing is an area of rapid development and has shown
promising results to detect mutations with VAFs below the Illumina sequencing error rate(26).

1.5 Algorithms for detecting PZMs
Over the past decade, there has been a plethora of new methods to detect PZMs (see (27) for a
review). The majority of these algorithms have been developed for detecting somatic mutations
in tumors. The methods come in two basic study designs: single-sample and paired sample
(e.g., matched tumor-normal) variant calling. (We note that the former also includes algorithms
that use cohorts of control samples to estimate various kinds of error models.) The general
algorithmic backbones include heuristic approaches, models to calculate genotype and allele
frequency likelihoods, machine learning methods, and noise level estimation methods. To
improve variant calling accuracy, some studies only use variants called by multiple independent
variant callers(28, 29).
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1.5.1 Validation methods
Due to the potential rarity of PZMs in bulk tissues and the numerous potential issues in whole
genome amplification and clonal expansion methods, it is imperative that putative PZMs are
validated by an orthogonal method, ideally in a biological replicate. This, of course, requires the
mutation to be in the validation sample. This assumption may not be true when the PZM is
rare(30) and/or the underlying cell type has limited cell migration(31). Orthogonal methods to
WGS include Sanger sequencing, targeted resequencing, amplicon sequencing, and droplet
digital PCR (ddPCR)(32). Of note, ddPCR is not based on sequencing and thus serves as a
truly orthogonal approach to validating PZMs detected from sequence data. These methods
differ in their sensitivity (ddPCR has the highest and can detect mutations with VAFs as low as
0.001%(32)), throughput (ddPCR is the lowest), and cost(9). Single-cell methods pose a unique
challenge in validation in that all the original genomic DNA is used in the assay. Potential
solutions are to detect variants in the RNA of the same cell(33) or the amplified product by an
orthogonal method(9).

1.6 PZM prevalence
Pioneering theoretical studies by Lynch and Frank estimated an enormous burden (>1E10) of
postzygotic point mutations in healthy tissues(34, 35). Despite its importance and the predicted
high prevalence, there have only been a limited number of studies on postzygotic genetic
variation in normal tissues.

1.6.1 PZMs in normal physiology
There are several well-known types of PZMs in normal tissues. In 1909, Milne made the first
discovery of PZMs in normal physiology with the identification of multinucleated liver cells(36).
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Since then, polyploidy has been detected in a substantial number of hepatocytes in the adult
liver. This phenomenon is thought to result from aborted mitoses and may function as a buffer
against DNA damage(1, 37).
PZMs are surprisingly common during human embryogenesis. In 2002, Bielanska et al. used
FISH to screen 216 human embryos for chromosomal aneuploidies of several chromosomes
during each stage of cleavage division(38). The frequency of mosaic embryos increased from
15% in the 2-4 cell stage to a staggering 91% in blastocysts. In 2009, Vanneste et al. used
aCGH to screen human blastomeres for CNVs genome-wide, providing the first comprehensive
and high-resolution view of postzygotic genetic variation during early embryogenesis(39). 70%
of blastomeres had mosaic CNVs. Another related phenomenon is confined placental
mosaicism (CPM) in which chromosomal differences arise between the fetus and placenta.
CPM is most commonly the result from the placenta acquiring PZMs(1). CPM is observed in 12% of placenta tissues(40) and is associated with poor obstetric outcome(1). CPM has
important implications in genetic counseling in prenatal diagnostic studies(41).
V(D)J recombination is a postzygotic genomic rearrangement event that occurs in
immunoglobulin and T-cell receptor genes in developing B and T lymphocytes through an
enzymatic mutation process catalyzed by RAG1 and RAG2. Susumu Tonegawa was awarded
the 1987 Nobel Prize in Physiology or Medicine for his discovery of V(D)J recombination. This
process of augmenting the genome gives the organism the ability to produce a diverse set of
antibodies, a key feature of adaptive immunity.
Shortening of telomeres is another well-known example of PZMs. Telomeres are repetitive
sequences at the ends of chromosomes. Due to the inherent nature of replicating linear
chromosomes, the ends of chromosomes degrade over multiple rounds of replications.
Telomeres altruistically prevent the erosion of genes and other functional sequences by having
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themselves eroded over time. Telomere length varies both within and among individuals(4). The
gradual shortening of telomeres may act as a cellular clock and signal senescence.
With the advent of higher resolution technologies, postzygotic SNVs and SVs in several healthy
tissues have been observed and are described below.

1.6.1.1 Blood
Due to the ease of biospecimen collection and abundance of archived biospecimens, blood is
often used in mosaicism studies(42–47). The burden of postzygotic SNVs(42, 43, 47) and
CNVs(44–46) in blood has been shown to increase with age in normal individuals. Using whole
exome sequencing data, Genovese et al. found that 1% of donors < 50 years had detectable
postzygotic SNVs in their blood whereas 10% of donors > 65 years had detectable postzygotic
SNVs(42). Using aCGH, Forsberg et al. detected kilobase- to megabase-range postzygotic
CNVs in donors ≤ 55 years and megabase-range postzygotic CNVs in 3.4% of donors ≥ 60
years(44). (We note that this study included a small number of donors with chronic lymphocytic
leukemia.) Many PZMs identified in blood are located in genes related to hematological and
non-hematological cancers(42, 43, 45). This phenomenon is known as clonal hematopoiesis of
indeterminate potential (CHIP). CHIP is associated with subsequent development of
hematologic cancer, cardiovascular disease, and death(48).

1.6.1.2 Skin
Several groups have studied PZMs in sun-exposed and unexposed skin(12, 28, 30, 49). A
landmark study by Martincorena et al. in 2015 was one of the first papers to show that
postzygotic SNVs are pervasive and highly variable between and within physiologically normal
tissues. The authors profiled over 200 small eyelid biopsies (i.e., sun-exposed skin) from four
donors for postzygotic SNVs using ultra-deep targeted sequencing of bulk tissue. On average,
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2-6 mutations per Mb per sample were detected and the mutations showed characteristic signs
of UV damage (i.e., C>T and CC>TT)(50). Approximately 25% of cells were predicted to carry
cancer-causing mutations. Using iPSCs derived from the inner area of the upper arm (i.e.,
unexposed skin) and WGS, Abyzov et al. detected large (>10 kbp) postzygotic CNVs in 30% of
skin samples. On average, the mosaic samples contained two large CNVs(30). Abyzov et al.
published a similar study on postzygotic SNVs. The authors found ~1,000 mostly benign PZMs
per sample. However, they did not find an association of mutation burden and age(12). Saini et
al. used iPSCs derived from paired samples from the lower arm (i.e., sun-exposed) and hip (i.e.,
unexposed skin) and WGS to detect various PZMs(28). 100% of samples had at least one
postzygotic CNV (median length: 33 kbp) and the average burden of postzygotic SNVs was
~3,000 mutations per sample. Zero MEIs were detected. As expected, but nonetheless exciting,
the burden of mutations associated with UV damage was higher in sun-exposed samples
compared to unexposed samples. Small differences in the conclusions among these studies
may be attributable to experimental design, e.g., targeted sequencing versus WGS.
Nonetheless, all studies have found PZM to be common in skin.

1.6.1.3 Brain
Nearly all forms of PZMs — including MEIs (including L1, Alu, and SVA retrotransposons)(51,
52), aneuploidies(53), CNVs(53), and SNVs(29) — have been detected in normal brain
samples. It is thought that these PZMs may function by modifying the transcriptional or
epigenetic landscape of individual or small populations of neurons and thus increase the
functional diversity of the brain(53) and possibly act as a buffer against deleterious postzygotic
mutations(29). McConnell et al. used single-cell approaches to map postzygotic CNVs and
aneuploidies in 100 neurons from the prefrontal cortexes of three neurotypical donors(53).
Postzygotic CNVs were ubiquitous: 41% of neurons contained megabase-range CNVs. All
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detected CNVs were unique to each neuron, which the authors suggested to be evidence that
the mutations are not early clonal events. Complex migratory patterns of neurons or sampling
error could also explain the lack of shared mutations. Another single-cell study investigated
postzygotic SNVs of 36 neurons from the cerebral cortex of three neurotypical donors(29). The
authors estimate there are >1,000 postzygotic SNVs per neuron, some of which were shared by
multiple neurons within a donor. For one of the donors, an additional 226 neurons and several
bulk tissues derived from the mesoderm or endoderm were genotyped at the PZM loci to create
a developmental cell lineage tree. This impressive study demonstrated that PZMs can be used
to reconstruct the developmental history within a donor and provided biological insight on the
complex process of tissue development and the mutational processes therein.

1.6.1.4 Liver
Several studies have examined PZMs in normal liver(31, 54, 55). Brunner et al. analyzed
microdissections of 100-500 hepatocytes from 5 normal and 9 cirrotic livers for PZMs. Mutation
burden varied considerably both within and between patients and was higher in cirrotic livers.
Mutation burden was not significantly associated with age. Interestingly, they found little overlap
of mutation calls between microdissections that were within close proximity to each other.
Brazhnik et al. used single-cell multiple displacement amplification to analyze PZMs in
hepatocytes and liver stem cells (LSCs) from 12 normal donors. Hepatocytes had a higher
mutation burden than LSCs and the burden increased with donor age. Mutations in hepatocytes
were associated with oxidative stress. Together, these studies suggest that PZMs may
contribute to the age-related functional decline and disease incidence in the human liver.
Additionally, stem cells may have mechanisms to maintain genome integrity that differentiated
cells do not possess.
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1.6.1.5 Esophagus
Martincorena et al.(56) and Yokoyama et al.(57) published surveys of PZMs in normal
esophageal epithelium. The former study used deep targeted sequencing of multiple small
(average = 0.2 mm2) samples from nine normal donors and the latter used WES of multiple
small (0.2 – 4 mm2) samples from 40 normal donors. Results were largely the same: PZM
burden increased with age and positive selection of cancer driver genes was detected. The agedependent PZM burden was acceleterated in patients who heavily consumed alcohol and
smoked. Strikingly, normal esophagus had more NOTCH1 mutations than esophageal cancer.
This is surprising since NOTCH1, which plays a role in cell proliferation and cell death, is often
mutated early during esophageal tumorigenesis(58).

1.6.1.6 Multi-tissue studies
Several recent studies have examined multiple tissues from the same individual(59–63). For
ethical reasons, these studies are generally limited to postmortem donors or easily accessible
tissues (e.g., blood and sperm(63)). Both Yizhak et al.(61) and García-nieto et al.(62) detected
PZMs in bulk RNA-seq data from an early data freeze of the Genotype-Tissue Expression
Project (GTEx)(64). The former study analyzed ~6,700 RNA-seq samples across 488 GTEx
donors and 29 tissue types. The later study analyzed ~7,600 RNA-seq samples across 547
GTEx donors and 36 tissue types. Both studies reached similar conclusions: PZMs were
common; PZM burden was variable across donors and tissues; variation was attributed to
variables such as age, tissue, chromatin state, and cell proliferation rates; and mutations in
cancer associated genes were detected in normal tissue.
In recent work by Michael Stratton’s group(60), PZMs (point, small indels, SVs, and CNVs) were
detected from 389 microdissections across 3 donors and 29 anatomical structures. While agerelated mutational signatures were ubiquitous, the proportion varied across cell types,
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suggesting that mutagenesis and repair may be cell dependent. Interestingly, germ cells in the
testis had lower mutation rates than the profiled somatic cell types. It’s currently unknown how
the germline protects itself from mutation. A superset of this data was reanalyzed by the group
in (59). The purpose of the second study was to analyze the mutational patterns of embryonic
PZMs and reconstruct cell phylogenies. Mutation rate was highest early in embryogenesis.
Using VAF and phylogenetic topology information, the data suggests that daughter cells
contribute unequally to the adult body.

1.6.2 PZMs in disease
One of the most studied cases of PZMs causing disease is cancer(65, 66). However, for this
introduction, we have chosen to restrict our focus to diseases other than cancer. More than 30
diverse monogenic and complex diseases are associated with postzygotic mosaicism(37, 67)
and the rate of additional discoveries of mosaic manifestations of inherited diseases is
increasing(1). Generally, patients with mosaic forms of the disease have milder phenotypes
than those who inherit the disease variant(s) through the germline(44). One extreme of this
spectrum is the hypothesis that mutations that are embryonically lethal may be tolerable as
PZMs. Turner Syndrome is consistent with this hypothesis due to the discordant rates of 45,X
conceptions and Turner syndrome live births as well as the high prevalence of mosaic forms of
this syndrome. The severity of the phenotypes may depend on which tissues contain the PZM
and the prevalence of the mutation in the tissues.
The role of PZMs in neurological disorders is an active area of research. PZMs are implicated in
both complex neurological disorders, e.g., epilepsy, autism spectrum disorder, and intellectual
disabilities(68), and monogenic disorders, e.g., hemimegalencephaly (HMG)(69). HMG is a rare
developmental brain disorder characterized by enlargement of a cerebral hemisphere. In 2012,
two independent groups identified putative causal PZMs for HMG in the mTOR pathway using
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brain tissue resected during epilepsy surgery(70, 71). The VAF of the putative causal variants
ranged from 8-35% across donors yet 50% of the cerebral cortex was malformed in each donor.
These studies exemplify how a minority of cells carrying a postzygotic mutation can disrupt the
function of neural circuits and lead to extensive disease. Given the complex migration, neural
circuitry, and the extraordinarily large cell division rate in the developing brain, detection and
functional characterization of PZMs in the brain is a challenging, but promising endeavor(9).

1.7 Implications of postzygotic genetic variation for
research & medicine
The concept that the genome of a multicellular organism is not only variable but also dynamic
has many implications for both research and medicine. Below are a few examples of the
ramifications.
In research, donor-derived lymphoblastoid cell lines are routinely used for in vitro studies;
however, the cell line may provide an unfaithful representation of the genetic variation in the
original donor, e.g., by bottleneck growth conditions and other tissue-culture artifacts(1). To
quantify mosaicism, biospecimens from multiple tissues and/or multiple timepoints will be
needed. These new study designs will have many ethical, legal, and social implications,
especially in human subjects research(1).
In medicine, careful attention to the timing of PZMs is critical for preconception genetic
counseling and de novo mutation discovery. Knowledge of whether the PZM occurred in the
parents germline or postzygotically in the offspring is important for estimating the risk of passing
the apparent de novo mutation to future children(72, 73). Estimates for the prevalence of PZMs
in the offspring being misinterpreted as inherited de novo germline mutations vary widely, from
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0.1%(72) to 95%(73). Another cause of concern is the ability of stem cell lines to acquire and
expand pathogenic mutations in culture(74). Despite being a rare event, it still has far reaching
implications in disease modelling and regenerative medicine. Lastly, additional surveys of PZMs
in embryogenesis may lead to improvements in embryo selection and better outcomes in in vitro
fertilization.

1.8 Scope of thesis
While the studies reviewed above have begun to shed light on PZMs, many large gaps in our
knowledge remain. The aim of this thesis is to help fill in such gaps.
In chapter 2, we answer the question, can we detect PZMs? Here, we describe the development
of methods to accurately detect PZMs in bulk RNA-seq samples and to reconstruct PZM
phylogenies. In chapter 3, we answer the questions of where do PZMs occur, when do PZMs
occur, and begin to uncover the functional consequences of PZMs by characterizing the spatial
and temporal patterns of PZMs in an extremely large database of bulk RNA-seq samples.
Finally, in chapter 4, we summarize the work presented and offer our opinions on where the
mosaicism field should go next.
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Chapter 2
Accurate detection and phylogenetic
reconstruction of DNA PZMs from bulk
RNA-seq
2.1 Methods
Despite the importance and the predicted high prevalence of PZMs, there have only been a
limited number of studies on postzygotic point mutations in normal tissues (e.g., blood(42, 43,
75), brain(29), and skin(12, 28, 49), and more recently, early versions of GTEx(61, 62)). We
hypothesized that analysis of GTEx v8, an enormous catalog of RNA-seq samples from
hundreds of normal donors across thousands of tissue samples, would enable detection of
PZMs to produce the most comprehensive database of normal tissues assembled to date. This
atlas and its subsequent characterization would greatly expand knowledge of PZMs in normal
tissues. This amazing opportunity was not without challenges, namely, the need to develop a
method to detect DNA PZMs from bulk RNA-seq data, the main data modality in GTEx.

2.1.1 Algorithm for calling PZMs (LachesisDetect)
2.1.1.1 Motivation and overview of method
While there are a multitude of variant calling algorithms, at the time of starting this project, there
was no appropriate method to detect DNA PZMs from bulk RNA-seq data. Therefore, we
developed a novel method called LachesisDetect to identify DNA postzygotic point mutations
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from bulk RNA-seq data. As mutations can cause disease and eventually mortality, we named
the algorithm after the Greek goddess, Lachesis, who measures the thread of life and chooses
a person’s destiny.
LachesisDetect contains four basic steps: 0) preprocess alignment files, 1) identify putative
PZMs, 2) remove false positive PZMs, and 3) recover false negative PZMs (Figure 2-1.a). The
method’s power to detect PZMs is derived from jointly analyzing data from within and between
donors. In the first steps, we leverage cohort-wide information by analyzing all samples
simultaneously to accurately model the error rate at each position in the transcriptome and to
identify and remove sources of false positives e.g., putative RNA editing sites. In the last step,
we leverage donor information by jointly analyzing all samples in a donor to detect rare
mutations and mutations with low detection power. Additionally, LachesisDetect uses statistical
frameworks for many of the steps, thereby giving the user precise control on how conservative
to make the variant calling. While we designed LachesisDetect with GTEx data in mind, the
method is generalizable to other medium-to-large cohort studies (see Error models may be
generalizable to other datasets).
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Figure 2-1: Overview of study design and variant calling method. a: The input consists of
WGS and RNA-seq BAMs and the output is a VCF of the putative PZMs. b: Error rate versus
genomic position for a representative region on chr22. Three PZMs were detected in this region
(marked with coral dots). Error rate is defined as the fraction of non-reference allele coverage
versus total coverage across all samples. VAF is defined as the fraction of alternative allele
coverage versus total coverage in a sample. Thus error rate and VAF are both unitless and are
supported on [0,1]. A PZM is detectable when the VAF is significantly greater than the error rate
at a given position. c: Overview of step 3. Mutant allele information for all samples in a given
donor are used as input, including tissues with the PZM detected (red) and tissues with no PZM
detected (blue) (left panel). Step 3 estimates the posterior probability that each donor tissue
contains the PZM (middle panel). Tissues that did not previously have the mutation detected
may have been false negatives (purple) that are now detected. Random tissue-matched
controls are used for modelling and model evaluation (right panel). Data is from simulation.
BAM = binary sequence alignment/map. PZM = postzygotic mutation. VAF = variant allele
frequency. VCF = variant call format. WGS = whole-genome sequencing.
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2.1.1.2 Basic tenets of the method
An RNA-seq alignment containing a non-reference allele is the result of one of two mutually
exclusive processes: 1) a postzygotic mutation event (a true positive) or 2) a non-postzygotic
mutation event (a false positive). False positives can be due to 1) an experimental error, 2) a
germline variant (with or without allele-specific expression), or 3) an RNA-editing event. When
viewed as a whole, the fraction of non-reference reads to all reads at a position represents the
signal-to-noise ratio and is defined as the variant allele frequency.
In a bulk RNA-seq sample, the fraction of cells containing the PZM can be very small and
therefore, the VAF can also be very small. To detect variants accurately, the signal must be
greater than the noise. Of the false positive processes listed above, experimental error can be
the most challenging to discriminate against because the PZM VAF and experimental error
distributions can overlap considerably (Figure 2-2). In this regime, the PZM VAF is very low
(e.g., VAF < 1%) and the error rate is high (error rate < 1%). Since many PZMs are rare in bulk
tissue, we chose to focus our efforts in detecting rare PZMs and discriminating putative
mutations from noise. Specifically, we first scanned the transcriptome for positions where the
VAF was significantly larger than the experimental error rate, thereby removing false positives
due to experimental error. We then ruled out false positives due to germline variants and RNAediting events with conservative filtering. By eliminating all false positive processes, we are left
to conclude that the position is a putative PZM.

20

Figure 2-2: Example of overlapping VAF distributions of PZMs, experimental errors,
germline heterozygous variants, and germline homozygous variants. Allele-specific
expression of germline heterozygous variants and sampling error diffuses the expected VAF of
0.5 to [0, 1]. Thus, there can be substantial overlap of experimental errors, PZMs, and germline
heterozygous variants at low VAFs. VAF of RNA-editing spectrum not shown. Data is from
simulation. Het = heterozygous. Hom = homozygous.

2.1.1.3 Step 0: Preprocess alignment files
To minimize the number of false positive variant calls, we only included the highest quality data.
For each sample’s alignment file, we excluded non-uniquely mapped alignments, duplicate
alignments, vendor failed alignments, alignments with > 20 soft-clipped bases, alignments with
soft-clipping on both ends, alignments with > 2 mismatches, and alignment read pairs with > 3
mismatches. Additionally, for each base within the sequencing read, we excluded those with
base qualities < 20. If read 1 and read 2 overlapped, the overlapping bases with the lower base
qualities were excluded to avoid double-counting the same cDNA molecule in the coverage
calculations. These thresholds were determined by evaluating the reproducibility of mutation call
sets made from two different versions of the data (GTEx v6 and GTEx v8). The preprocessing
pipeline used custom scripts (https://github.com/conradlab/lachesis), SAMtools v1.9(76), and a
modified version of samclip (https://github.com/tseemann/samclip).
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2.1.1.4 Step 1: Identify putative PZMs
There are several sources of experimental error that can contribute to a non-zero VAF: nucleic
acid damage during sample preparation (e.g., from reactive oxygen species(77)), amplification
errors during sample preparation and sequencing, and alignment errors(78)). These sources of
error can be modeled en masse as a binomial random variable for each sample 𝑠 and position 𝑖
(79) as, 𝐸𝑠,𝑖 ∼ 𝐵𝑖𝑛𝑜𝑚(𝑛𝑠,𝑖 , 𝑒𝑖 ), where 𝑛𝑠,𝑖 (the number of trials) is the total coverage in sample 𝑠
at position 𝑖 and 𝑒𝑖 (the probability of success, i.e., an experimental error occurred) is the
experimental error rate at site 𝑖 (Figure 2-3).

Figure 2-3: Overview of some of the sources of experimental error. Sources of
experimental error (𝑒𝑖,𝑥 ) that can arise when a biospecimen is converted to aligned sequencing
reads. These sources of error can be modeled en masse as (𝑒𝑖 ).
Since the GTEx dataset contains thousands of samples, we hypothesized that using information
from all samples would lead to a more accurate estimate of experimental error rate than what
could be obtained from a single sample. We defined the experimental error rate at site 𝑖, 𝑒𝑠,𝑖 , as
the ratio of non-reference coverage across all samples excluding sample 𝑠 to the total coverage
across all samples excluding sample 𝑠 at position 𝑖. To maintain a high level of conservatism,
we included all GTEx v8 RNA-seq samples, including those that did not pass quality control, in
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the background error model (N = 17,382). In total, we generated a position-specific error model
for over 115 Mb of the transcriptome (Figure 2-1.b).
For a given sample 𝑠 and position 𝑖, we defined the putative PZM alternative allele as the nonreference allele with the highest coverage and then tested if the alternative allele coverage was
significantly higher than expected given 𝑒𝑠,𝑖 (binomial test) (Figure 2-1.b). P-values were
corrected using the Benjamini-Hochberg procedure. Putative PZMs were defined as sites with q
≤ 0.05. To reduce the number of hypothesis tests (and therefore increase our detection power),
we corrected the P-values after several filters were applied (see Step 2: Remove false positive
PZMs).
Of note, this approach assumes the PZM is rare in the population of samples (i.e., the nonreference coverage is assumed to primarily come from false positive events rather than PZM
events). This assumption is appropriate because PZMs are expected to be rare events(34) and
our sample set is large (17,382 samples across 948 donors).
This framework could be extended to model arbitrary types of correlation structures that might
exist in the error processes, e.g., batch effects across sequencing runs and base- and strandspecific error models(49). Given the algorithm’s reasonably high validation rate (see PZM
validation), we concluded the relatively simple model was sufficient to accurately detect PZMs.

2.1.1.5 Step 2: Remove false positive PZMs
In the next step, false positive PZMs are removed using sample-, position-, and variant-specific
filters. These filters are described in detail below. A list of all the filters applied and how many
variants they removed is in Table 5-1.
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2.1.1.5.1 Remove low quality samples
Using GTEx recommendations, we removed any sample with a RNA integrity number (RIN) < 6
(N = 1,674 samples)(80) or was from a tissue type whose collection was discontinued during the
GTEx pilot phase due to quality issues (Bladder, Cervix - Ectocervix, Cervix - Endocervix,
Fallopian Tube, Kidney - Medulla, and Spleen) (N = 230 samples)(80, 81). The remaining
tissues are referred to as the GTEx pass quality control (QC) tissues. Additionally, we
checked that no tissue sample was from a transplanted tissue/organ using the donor metadata.
There were 15,478 tissue samples after filtering (Table 5-2).
2.1.1.5.2 Remove genomic regions with potential mappability issues
Genomic regions prone to incorrect read alignments could lead to false positive variant calls. To
minimize this issue, we removed several genomic regions. Immunoglobulin genes were
removed since they are structurally diverse and polymorphic due to V(D)J recombination, classswitch recombination, and somatic hypermutation. Regions within 10bp of an exon boundary
were removed since splice junctions can have inaccurate alignments(82)). Segmental
duplications and repetitive sequences (annotations downloaded from the UCSC genome
browser, http://genome.ucsc.edu/) were also removed since reads may map to an incorrect
copy in the genome.
2.1.1.5.3 Remove RNA editing sites
In RNA editing, the nucleotide sequence of an RNA is modified post- or co-transcriptionally. The
most common type of RNA editing in mammals is the deamination of adenosine into inosine
(A>I) by the ADAR family of enzymes(83). After library preparation and sequencing, the original
editing event will be read as an A>G change. Another type of editing, although much rarer, is
the conversion of cytosine to uracil via the family of cytidine deaminases (AID/APOBEC)(84).
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To minimize the number of false positives from RNA editing events, we removed all genomic
sites known to harbor RNA editing in humans using version 2 of the Rigorously Annotated
Database of A-to-I RNA editing (RADAR) (http://rnaedit.com), a curated and comprehensive
source of RNA-editing sites in humans(85). The RADAR database was converted from hg19 to
GRCh38 coordinates using the liftover utility(86). Genomic sites that were not A or T in GRCh38
were excluded.
Additionally, since databases can be incomplete, we conservatively removed any putative A>G
PZM on the coding strand that was seen in at least two donors. Our approach will most likely
miss rare, donor-specific RNA editing events, to the extent such events exist. Since most sites
have a low level of RNA editing (<1%)(87), we don’t expect RNA editing events to be a major
source of error for higher VAF PZMs.
2.1.1.5.4 Remove germline variants
2.1.1.5.4.1

Known germline variants filter

To remove false positive PZMs due to germline variants, we removed all genomic sites with a
germline SNV or within 10bp of a germline indel in any of the donors’ whole blood genotyping
datasets. To increase our sensitivity of removing germline variants, we used all available
genotyping datasets: v8 WGS data (838 donors), v6 WES (520 donors and 11 GTEx flagged
donors), v6 WGS (148 donors), and v6 microarray data (191 donors for the pilot microarray and
275 donors from the midpoint microarray). v6 datasets were converted from hg19 to GRCh38
using the liftover utility(86). In our effort to be conservative, our variant calling method will not be
able to call PZMs at sites that are polymorphic in the cohort.
Of note, only 853 of the 946 donors had any genotyping data. To minimize the number of false
positive PZMs due to both rare germline variants in non-genotyped donors as well as missed
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germline variants in the genotyped donors, we used two additional germline filters which are
described below.
2.1.1.5.4.2

Putative germline variants filter

This filter removes all putative PZMs that appear to be a putative germline variant in at least one
donor. To test if a putative PZM is actually a missed germline variant, we first calculated the
cumulative alternative and cumulative total coverage in the donor with 𝑆 total samples at
position 𝑖 using the following equations:
𝑆
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𝑑𝑜𝑛𝑜𝑟 𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑙𝑡 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒𝑖 = ∑ 𝑎𝑙𝑡 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒𝑖,𝑠
𝑠

𝑆

2-2

𝑑𝑜𝑛𝑜𝑟 𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜𝑡𝑎𝑙 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒𝑖 = ∑ 𝑎𝑙𝑡 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒𝑖,𝑠 + 𝑟𝑒𝑓 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒𝑖,𝑠
𝑠

In the null model (variant is a heterozygous germline variant), the cumulative alternative read
coverage at position 𝑖 follows a binomial distribution with parameters 𝑁 (the donor cumulative
total coverage), and 𝑝 (the expected VAF of true heterozygous germline variants in RNA-seq
data). In the alternative model (variant is a PZM), the cumulative alternative coverage is less
than expected of true heterozygous germline variants. The 𝑝 parameter was estimated from the
RNA-seq data of all high-confidence heterozygous germline SNVs from 838 donors using all of
the donors’ GTEx pass QC tissue samples (𝑝 = 0.45). High-confidence heterozygous germline
SNVs were defined as SNVs found in at least 1% of donors in the GTEx germline variant VCF.
For each donor variant, we tested if we could reject the null hypothesis using a binomial test.
These P-values (denoted as donor germline P-values) were reused in the next filter. In an
effort to be conserative, at each position, the largest P-value across all donors was retained.
This intermediate list of P-values was corrected for multiple tests using the Benjamini-Hochberg
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procedure with a cutoff of q-value ≤ 0.05. Putative PZMs that overlapped a genomic site with a
nonsignificant q-value were removed. Of note, this approach will also filter out homozygous
germline variants because if the donor cumulative VAF is less than 𝑝 = 0.45, it will also be less
than 𝑝 ≈ 1, the expected VAF of homozygous germline variants.
2.1.1.5.4.3

Allowable transcriptome definition

Of note, we defined the allowable transcriptome as the transcriptome after applying the
genomic filters above. Ancillary datasets were filtered to the allowable transcriptome in order to
make fair comparisons with the PZM dataset.
2.1.1.5.4.4

Match donor mutation burden in genotyped and non-genotyped donors filter

We assumed the true mutation burden in a donor was independent of whether the donor was
genotyped. However, prior to applying this filter, non-genotyped donors had higher mutation
burdens than genotyped donors suggesting they may have an excess of false positive germline
variants. This second germline variant filter specifically corrects for the fact that not all donors
were genotyped.
We defined the donor mutation burden in donor 𝑖 (𝑑𝑖,𝛼 ) as the total number of putative PZMs in
all GTEx pass QC tissues from donor 𝑖 at a donor germline P-value cutoff of 𝛼. 𝑑𝑖,𝛼 is a mixture
of true PZMs and false positives, including false positive germline variants. Of critical note, 𝑑𝑖,𝛼
can be decreased/increased by using a more/less restrictive P-value cutoff (𝛼) on the donor
germline P-values. (Recall that the donor germline P-values were calculated in the previous
germline variants filter.)
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We modeled the donor mutation burden as
√𝑑𝑖,𝛼 = 𝛽0,𝛼 + 𝛽1,𝛼 ∗ 𝑁𝑖 + 𝛽2,𝛼 ∗ 𝐴𝐺𝐸𝑖 + 𝛽3,𝛼 ∗ 𝑠𝑒𝑙𝑓_𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑑_𝑎𝑛𝑐𝑒𝑠𝑡𝑟𝑦𝑖 + 𝛽4,𝛼
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∗ 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒_𝑠𝑡𝑎𝑡𝑢𝑠𝑖 + 𝑒𝑖,𝛼
where 𝑁𝑖 is the number of GTEx pass QC tissues in donor 𝑖; 𝐴𝐺𝐸𝑖 is the age of donor 𝑖;
𝑠𝑒𝑙𝑓_𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑑_𝑎𝑛𝑐𝑒𝑠𝑡𝑟𝑦𝑖 is the self-reported ancestry of donor 𝑖; 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒_𝑠𝑡𝑎𝑡𝑢𝑠𝑖 is the
genotyping status of donor 𝑖 (genotyped or not genotyped); 𝛽i,𝛼 ’s are model coefficients at Pvalue cutoff 𝛼; and 𝑒𝑖,𝛼 is the residual error. The square root of the donor mutation burden
distribution was applied to transform residuals to a normal distribution.
We performed the linear regression on a large range of P-value cutoffs (𝛼) and selected the
cutoff that corresponded to the least significant genotype status regression coefficient (𝛽4,𝛼 ). As
expected, 𝐴𝐺𝐸 was significant across the germline variant significance cutoffs. The log10 Pvalue of 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒_𝑠𝑡𝑎𝑡𝑢𝑠 had a global maximum, suggesting cutoffs that are too small or too
large could lead to over- or undercalling variants, respectively. The final donor germline P-value
cutoff was 𝛼 = 1E-30, corresponding to a non-significant P-value = 0.98 for the 𝛽4 coefficient
(Figure 2-4). Thus, in the final model, donor mutation burden was independent of genotype
status.
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Figure 2-4: Selection of the appropriate donor germline P-value cutoff, 𝜶. 𝛼 was chosen
such that the P-value of 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒_𝑠𝑡𝑎𝑡𝑢𝑠 was minimized (log10 P-value maximized). The
maximal log10 P-value of 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒_𝑠𝑡𝑎𝑡𝑢𝑠 is marked by dashed purple line 𝑥 = -log10 1E-30. At
this cutoff, 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒_𝑠𝑡𝑎𝑡𝑢𝑠 was not significantly associated with donor mutation burden (value
above gray dashed line at 𝑦 = log10 0.05 = −1.3). The effect of 𝛼 on the significance of other
covariates in the model is also shown.
2.1.1.5.5 Remove variants with low coverage
We used the standard strategy in variant calling to remove mutations with low sequencing
coverage. We removed mutations with ≤ 20× total coverage and ≤ 5× alternative coverage. In
step 3 (below), this alternative coverage constraint was dropped, since less alternative coverage
is more tolerable when there is strong evidence of a mutation in a different tissue from the same
donor.
2.1.1.5.6 Remove variants at genomic positions with high nucleotide diversity
Since we are calling mutations at non-germline variant sites, a genomic position with coverage
for more than two alleles in a sample is an indication of experimental and/or bioinformatic error.
Therefore, we removed mutations at genomic positions where there was at least 3× coverage
for more than two alleles in a sample. This conservative filter should remove problematic
genomic positions not caught by upstream filters.
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2.1.1.5.7 Remove variants with biased alignment metrics
When manually inspecting alignment files in a genome browser for false positive variants, a
common heuristic to look for is whether the putative variant is supported by “diverse”
alignments, e.g., alignments that map to both strands of the genome and alignments that
contain the mutant allele at different positions relative to the start of the sequencing read. Since
the RNA-seq protocol used to generate the data was unstranded, we conservatively removed
variants that did not have at least 1× coverage on each of the Watson and Crick strands.
Additionally, we removed variants that were only supported by alignments where the alternative
allele was found near (within 25 bases) the start or end of the sequencing read.
2.1.1.5.8 Remove hypermutated samples
We conservatively defined a sample as hypermutated if its mutation burden was greater than
𝑄3 + 5 ∗ 𝐼𝑄𝑅, where 𝑄3 is the third quartile and 𝐼𝑄𝑅 is the interquartile range of the sample
mutation burden distribution (Tukey’s fence method for outlier detection). This corresponded to
a cutoff of 63 mutations and labeled 806 (5.2%) samples as hypermutated. Due to their extreme
mutation burden, we removed these samples from the downstream analyses.
We used a variety of experimental validation methods to ascertain if this hypermutation
phenomenon was biological or a technical artifact (see PZMs in hypermutated samples are
likely false positives). Based on the low positive predictive value (PPV) in the hypermutated
samples, the observed hypermutation is most likely a technical artifact and thus removal of
these samples is well justified.
2.1.1.5.9 Remove variants at sites with large background error rates
We observed a higher false discovery rate when the background error rate was high in all four
independent sequencing-based validation datasets (Figure 2-5) and in silico read-based
phasing validation. (See PZM Validation for a description of the validation methods.) To improve
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the accuracy of the mutation call set, we calculated the maximum background error rate that
maximized the validation rate of the four validation datasets (background error rate cutoff = 6E4). Putative PZMs at positions with a background error rate greater than this cutoff were
removed. In total, 13% (9.8 Mb) of the allowable transcriptome was removed by this filter.

Figure 2-5: Validation rate as a function of background error filter threshold. The
threshold was chosen to maximize the validation rate (annotated as a dashed vertical line at y =
6E-4). Meta validation rate defined as the average positive predictive value across all validation
datasets. Bg = background.

2.1.1.6 Step 3: recover false negative PZMs with EM
Step 1 may miss some PZMs, e.g., when there is low total coverage and/or low alternative allele
coverage. Therefore, we implemented a more sensitive mutation calling strategy to identify false
negative variants for the third step of the algorithm. The power to detect false negative
mutations comes from jointly analyzing data from all tissue samples in a donor.
PZMs that were detected in step 1 of the algorithm have appreciable VAFs and thus represent
either 1) a clone that rose to high frequency in a tissue or 2) a PZM that occurred early in
development. In the later case, depending on the timing of the mutation, the mutation may exist
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in multiple tissues. Thus, if a PZM is found at position 𝑖 in tissue 𝑡 of donor 𝑑 (step 1), there is
an increased likelihood that the PZM also exists in tissue 𝜏 of donor 𝑑. We refer to these PZMs
as multi-tissue PZMs. Multi-donor PZMs are specified by a unique combination of genomic
coordinates, alternative allele, and donor ID.
We modeled the distribution of alternative allele read coverage from each tissue in a donor at
position 𝑖 as a mixture of two binomial distributions: one where the alternative reads are
generated from a true PZM and the other where the alternative reads are generated from
experimental errors. We used expectation maximization (EM) to calculate for each tissue, the
posterior probability that the tissue contains the multi-tissue PZM. This process is described in
more detail below. PZMs in tissues with a posterior probability of at least 0.95 were added to the
mutation call set. PZMs in tissues that failed to meet this constraint were removed. Of note, this
included removing a small fraction (1.5%) of PZMs that were originally detected in step 1
(Figure 2-1.c, Table 5-1).
Specifically, we parameterized the multi-tissue PZM and error distributions as 𝐵𝑖𝑛𝑜𝑚(𝑛𝑖,𝑠 , 𝑉𝐴𝐹𝑖 )
and 𝐵𝑖𝑛𝑜𝑚(𝑛𝑖,𝑠 , 𝑒𝑖 ), respectively, where 𝑛𝑖,𝑠 is the total coverage of tissue 𝑠 at position 𝑖, 𝑉𝐴𝐹𝑖 is
the (latent) PZM VAF at position 𝑖, and 𝑒𝑖 is the (latent) error rate at position 𝑖. To avoid local
minima in the likelihood space, we used multiple initializations and selected the model with the
highest likelihood. Additionally, to ensure that the set of tissues was indeed a mixture of both
tissues with and without the variant, a set of matched tissues randomly selected from the
remaining donors was added to the modeling (denoted as negative samples). Since donor
samples were required to have at least 10× coverage, the same constraint was also used for
the negative samples. For each tissue, 20 attempts were made to find a matched negative
sample with sufficient coverage. Matched tissues were also used to control for tissue-specific
issues, e.g., alignment errors due to tissue-specific isoforms.
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2.1.1.6.1 Empirical FPR and FDR estimates
The matched negative tissues were also used to estimate the FPR (false positive rate) and FDR
(false discovery rate) of the mutation call set. FPR was defined as:

𝐹𝑃𝑅 =

∑𝐷
𝑑=1 # 𝑜𝑓 𝑛𝑒𝑔. 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑤𝑖𝑡ℎ 𝑝𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟 𝑝𝑟𝑜𝑏. ≥ 𝑝 𝑖𝑛 𝑚𝑢𝑙𝑡𝑖-𝑡𝑖𝑠𝑠𝑢𝑒 𝑃𝑍𝑀𝑑
∑𝐷
𝑑=1 # 𝑜𝑓 𝑛𝑒𝑔. 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑖𝑛 𝑚𝑢𝑙𝑡𝑖-𝑡𝑖𝑠𝑠𝑢𝑒 𝑃𝑍𝑀𝑑
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where 𝐷 is the total number of multi-tissue PZMs and 𝑝 is posterior probability cutoff (set to
0.95).
FDR was defined as:

𝐹𝐷𝑅 =

∑𝐷
𝑑=1 𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 # 𝑜𝑓 𝐹𝑃𝑠 𝑖𝑛 𝑑𝑜𝑛𝑜𝑟 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑖𝑛 𝑚𝑢𝑙𝑡𝑖-𝑡𝑖𝑠𝑠𝑢𝑒 𝑃𝑍𝑀𝑑
∑𝐷
𝑑=1 # 𝑜𝑓
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𝑑𝑜𝑛𝑜𝑟 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑤𝑖𝑡ℎ 𝑝𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟 𝑝𝑟𝑜𝑏. ≥ 𝑝 𝑖𝑛 𝑚𝑢𝑙𝑡𝑖-𝑡𝑖𝑠𝑠𝑢𝑒 𝑃𝑍𝑀𝑑

where FPs = false positives.
The 𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 # 𝑜𝑓 𝐹𝑃𝑠 𝑖𝑛 𝑑𝑜𝑛𝑜𝑟 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑖𝑛 𝑚𝑢𝑙𝑡𝑖-𝑡𝑖𝑠𝑠𝑢𝑒 𝑃𝑍𝑀𝑑 was defined as
𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 # 𝑜𝑓 𝐹𝑃𝑠 𝑖𝑛 𝑑𝑜𝑛𝑜𝑟 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑖𝑛 𝑚𝑢𝑙𝑡𝑖-𝑡𝑖𝑠𝑠𝑢𝑒 𝑃𝑍𝑀𝑑
# 𝑜𝑓 𝑛𝑒𝑔. 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑤𝑖𝑡ℎ 𝑝𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟 𝑝𝑟𝑜𝑏. ≥ 𝑝 𝑖𝑛 𝑚𝑢𝑙𝑡𝑖-𝑡𝑖𝑠𝑠𝑢𝑒 𝑃𝑍𝑀𝑑
=
# 𝑜𝑓 𝑛𝑒𝑔. 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑖𝑛 𝑚𝑢𝑙𝑡𝑖-𝑡𝑖𝑠𝑠𝑢𝑒 𝑃𝑍𝑀𝑑
∗ # of donor samples
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2.1.1.7 Step 1 PZM detection power
The power to detect a PZM in step 1 depends on the VAF, coverage, and background error
rate. We estimated the power to detect a PZM mutation as a function of these variables through
simulation.
For each simulated PZM, we randomly selected a tissue sample, genomic position, and VAF.
Using the selected sample’s coverage at that position (denoted as 𝑁), we simulated the
alternative allele read coverage as ⌊𝑁 ∗ 𝑉𝐴𝐹⌋ and calculated if the simulated PZM would be
detected given the alternative allele read coverage, 𝑁, and the background error rate at that
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position (binomial test). This process was repeated 240,000 times for each chromosome and
preselected VAF (37 VAFs in the range [1E-4, 1].) Only male samples were used for simulated
mutations on chrY. Mutations on chrX were originally simulated for males and females
separately; however no sex-difference in power was detected, so the chrX data was combined.
Since the total coverage is not known a priori, after all simulations were run, we split the
simulations into quantiles of sample coverage bins.
PZM mutation detection power was defined as the fraction of simulations where the simulated
mutation was correctly recovered at a given VAF and coverage bin. Power curves were fit to
sigmoid functions using the Levenberg-Marquardt nonlinear least-squares algorithm from the
minpack.lm R package (v 1.2-1) (https://CRAN.R-project.org/package=minpack.lm).
To estimate the average PZM mutation detection power in a given sample 𝑠 from tissue 𝑡
(denoted as 𝒔𝒂𝒎𝒑𝒍𝒆_𝒎𝒖𝒕𝒂𝒕𝒊𝒐𝒏_𝒅𝒆𝒕𝒆𝒄𝒕𝒊𝒐𝒏_𝒑𝒐𝒘𝒆𝒓), we first estimated the joint distribution of
VAF and coverage of all detected PZMs in tissue 𝑡 (denoted as the tissue-VAF-coverage
distribution). (Here, we assumed that all samples in a given tissue have the same tissue-VAFcoverage distribution. This assumption allowed us to more accurately estimate the distribution
due to the larger sample size.) Next, we estimated the distribution of coverage in the
transcriptome in sample 𝑠 (denoted as the sample-coverage distribution). We simulated 5000
PZMs for each sample. For each simulated PZM, we randomly sampled a coverage bin from the
sample’s sample-coverage distribution and then randomly sampled a VAF from the tissue-VAFcoverage distribution corresponding to that coverage bin. We estimated the power to detect the
PZM by using the PZM detection power curves for that coverage bin and VAF.
𝑠𝑎𝑚𝑝𝑙𝑒_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟 in sample 𝑠 was defined as the average power of all
simulated PZMs in that sample. Nine quantiles were used to define the coverage bins.

34

2.1.2 PZM Validation
We performed several orthogonal validation experiments to quantify the FDR of the mutation
calling algorithm. These efforts included both in silico and experimental approaches and
involved analysis of both DNA and RNA from the tissues used for mutation detection. A
summary of the validation results is in Table 5-3.

2.1.2.1 In silico read-based phasing
Read-based phasing is an in silico technique to estimate the FDR of a variant call set and has
been used in somatic mutation validation(88, 89). Under the assumption that PZMs are rare
events, it is unlikely that two PZMs will occur at the same position on each of the maternal and
paternal copies of the genome. Therefore, if a PZM does not segregate/phase with one parental
haplotype, it is likely a false positive. This can be determined bioinformatically by analyzing
sequencing reads that physically span both the putative PZM and a nearby heterozygous
germline variant (Figure 2-6).

Figure 2-6: Overview of in silico read-based phasing. A red PZM occurs on the black
haplotype of the cell’s diploid genome. The PZM is near a blue heterozygous germline which is
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T on the black haplotype. In the sequencing data, reads that contain the PZM and the T allele
are in phase. However, reads that contain the PZM and reference allele (on the gray haplotype)
are not in phase and likely represent a false positive PZM. Het = heterozygous. PZM =
postzygotic mutation.
For each putative PZM, we scanned the corresponding sample’s RNA-seq BAM for sequencing
reads that overlapped the PZM and a heterozygous germline variant within 1,000,500 bp (the
length of the largest human intron (~1 Mb) plus the length of the sequencing read). We defined
these reads as phasable sequencing reads. We calculated the number of phasable
sequencing reads that contained each combination of alleles at the PZM and germline variant
loci. We used Fisher’s exact test to test if the PZM segregated with one parental haplotype, i.e.,
whether the PZM variant allele was associated with one of the heterozygous alleles. To reduce
noise due to low power, we ignored PZMs with ≤ 10 phasable sequencing reads. P-values were
corrected using the Benjamini-Hochberg procedure. Using this approach, 41 PZMs had
sufficient phasable sequencing reads.
Fisher’s exact test is advantageous over simpler threshold-based methods because it uses a
statistical framework allowing the researcher to tune significance cutoffs and allows for
experimental errors at both the PZM and germline variant loci. Of note, false positive PZMs can
still appear to segregate with one haplotype due to misalignments. For example, reads
containing a germline variant can look like a phased PZM when aligned to the wrong copy of a
segmental duplication(90). To minimize this issue, our variant calling method removed
sequencing reads that mapped to multiple locations, PZMs that overlapped with repeat masked
regions and segmental duplications from the call set (see Step 2: Remove false positive PZMs).

2.1.2.2 ENCODE DNA and RNA validation
The ENCODE consortium profiled several tissues from four GTEx donors using a variety of
genomic, transcriptomic, and epigenomic assays. We hypothesized that we could use this rich,
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and importantly, independent dataset to validate our variant calls. The database of available
ENCODE BAMs was queried in June 2019 and BAMs were downloaded at the same time.
We excluded DNA-based assays that used bisulfite treatment to avoid the increased complexity
of aligning and calling mutations in bisulfite-treated DNA. We also excluded BAMs that failed
ENCODE quality control and RNA-derived BAMs with RIN < 6. For a given sample, we excluded
BAMs that had zero coverage at all PZMs in the sample. After filtering, 57 GTEx tissue samples
were profiled by 245 ENCODE DNA assays and 20 GTEx tissue samples were profiled by 67
ENCODE RNA assays. The ENCODE data also included one hypermutated sample. After
filtering, 1 hypermutated GTEx tissue sample was profiled by 7 ENCODE DNA assays and 3
ENCODE RNA assays (Table 5-3). ENCODE RNA and DNA BAMs were filtered using the BAM
preprocessing pipeline (see Step 0: Preprocess alignment files).
To increase the power to detect mutations, we combined all BAMs from DNA-based assays that
were generated from the same tissue and donor and combined all RNA-based assays that were
generated from the same tissue and donor. By combining BAMs, the coverage at a given site
may increase, and thus we may have higher power to detect mutations. An additional benefit of
combining the data is that by analyzing data produced with many different technical variables
(e.g., different assay protocols, different sequencing centers, different aligners, etc.) the noise in
the data should increase. Thus, when a putative PZM is supported by the ENCODE data, we
can be very confident that the mutation is a true positive and not the result of a systematic
artifact that occurred in both the GTEx and ENCODE datasets.
2.1.2.2.1 Validation method
For each putative PZM in GTEx, we calculated the coverage of each allele in the corresponding
combined ENCODE BAM. If the PZM alternative allele had the highest non-reference allele
coverage, we then tested if the alternative allele coverage was significantly higher than
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expected given the GTEx RNA-seq error rate at that position (binomial test) (see Note on the
ENCODE validation error model). P-values were corrected using the Benjamini-Hochberg
procedure. Variants with q-values < 0.1 were defined as validated. If the q-value ≥ 0.1 and the
PZM was defined as callable but not validated (see Callability definition). Furthermore, if the site
was callable but the alternative allele did not have the highest non-reference allele coverage,
the site was not validated.
2.1.2.2.2 Callability definition
To calculate an accurate FDR, it is important to exclude variants where there is not enough
power to detect the mutation in the validation data. We defined such variants as not callable.
To determine if a variant was callable in the validation data, we simulated the distribution of
alternative allele coverages that would be expected given the validation coverage and the
putative PZM’s VAF (estimated from the original GTEx data). We next calculated the fraction of
simulations where we could detect the variant (N = 10,000 simulations). A simulated variant was
detected if the simulated alternative allele coverage was significantly higher than expected given
the GTEx RNA-seq error rate at that position (binomial test, 𝛼 < 0.05) (see Note on the
ENCODE validation error model). If at least 95% of the simulations identified the variant, we
concluded the PZM was callable.
2.1.2.2.3 Note on the ENCODE validation error model
In the ideal case, we would have used the error model generated from the ENCODE data to
validate PZMs. However, since the number of GTEx donors and samples profiled in ENCODE
was small and the ENCODE datasets sometimes had orders of magnitude lower coverage than
the GTEx dataset, we used the GTEx RNA-seq error model instead. Using ENCODE-based
error models may lead to overestimated and/or inaccurate error rates. For example, since each
sample can contribute a large percentage of the background error rate, a small number of poor
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quality samples could lead to an overestimate of the error rate. Similarly, regions with low
coverage may lead to inaccurate error estimates due to sampling error. In the DNA-based
amplicon-seq validation studies where we had many samples and had high coverage, the DNAbased error model and RNA-based error models were very similar; and thus we felt justified to
use an error model derived from RNA to validate variants from DNA data.

2.1.2.3 Pilot validation study
We generated a pilot mutation call set from an earlier version of the GTEx data (v3 data freeze)
using two variant calling methods distinct from the one used for v8 data(91). On the basis of the
preliminary mutation call set, we designed a validation experiment using amplicon sequencing,
and subsequently used these validation data for optimizing the final calling pipeline. Briefly,
PCR primers were designed for 317 amplicons, targeting a total of 384 v3 mutations in 365
samples. Three control samples not related to the GTEx project were also included. Libraries
were generated for all samples by multiplex PCR using the Fluidigm platform, and the resulting
amplicons were pooled and sequenced on 4 lanes of MiSeq using a 2x150 bp protocol to an
average read depth of approximately 200× per amplicon. A list of the amplified regions can be
found in Table 5-4. In the final mutation call set, we attempted to validate 47 PZMs across 22
non-hypermutated samples and 14 PZMs across 9 hypermutated samples (Table 5-3).

2.1.2.4 Large-scale validation study
Due to improvements in our mutation calling algorithm and the large increase in the number of
samples from the pilot study to the GTEx v8 data freeze, we performed another round of
validation. The purpose of this validation was twofold: 1) to estimate the accuracy of the PZM
calling algorithm and call set and 2) to clarify the source of the hypermutated phenotype
observed in a small number of GTEx samples. We designed an amplicon-seq library to validate
variants from a randomly selected set of donors (Cohort 1) and a random subset of variants
39

from randomly selected donors with hypermutated samples (Cohort 2). GTEx samples were
requested from the GTEx Biobank (https://gtexportal.org/home/samplesPage).
2.1.2.4.1 Donor selection
We randomly selected four donors from the pool of donors without hypermutated samples
(Cohort 1) and two donors from the pool of donors with hypermutator samples (Cohort 2). Since
we were interested in validating if multiple tissues from the same donor share the same PZM,
we removed donors with fewer than eight tissues profiled for cohort 1 fewer than three tissues
profiled for cohort 2. To increase the generalizability of the results, for each cohort we
constrained the selection to produce 1) 50% male donors, 2) 50% with self-reported Caucasian
ancestry donors and 50% with self-reported African-American ancestry (representing the two
largest self-reported ancestries profiled in GTEx), and 3) donors from different age quartiles.
Random selection should minimize the potential for introducing bias in the validation.
2.1.2.4.2 Tissue selection
For each donor in Cohort 1, we randomly selected eight tissues that had RNA-seq data. In order
to improve classification of PZMs as somatic, gonadal, or gonosomal, we selected a testis
sample as one of the eight tissues for each male donor. For each donor in Cohort 2, we
randomly selected three hypermutated tissues. The database of available biospecimens was
downloaded on 04/02/2018.
A list of the samples selected for validation is in (Table 5-3). A small number of samples were
dropped from the initial study design due to sample quality or withdrawal from GTEx. For
brevity, only samples that had PZMs in the final call set are reported in the table.
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2.1.2.4.3 AmpliSeq library preparation and sequencing
Primer pairs were designed to validate mutations using Illumina’s Design Studio
(https://designstudio.illumina.com/). The following parameters were used: Assay Technology =
AmpliSeq for Illumina Hotspot; Species = Homo sapiens (grch38.p2); Sample Type = Regular;
Max Amplicon Length = 275bp; Max Amplicon Length = 275bp; Stringency = High.
Mitochondrial variants were excluded since Design Studio only allows regions in the nuclear
genome. A list of the primer pairs is in Table 5-6 and a list of the locations targeted is located in
Table 5-5.
The regions of interest were amplified using 100 ng of genomic DNA and an AmpliSeq for
Illumina Custom DNA Panel kit. Sample libraries were sequenced by Illumina NovaSeq (S1
Flow Cell) using 2x150 bp reads to a median coverage of ~38,000×. 4/712 (0.6%) amplicons
failed (defined as > 75% of samples with 0× coverage.)
Adapters were trimmed from sequencing reads using trimmomatic (v0.38)(92) with options PE baseout. Sequencing reads were aligned to GRCh38 using BWA (v0.7.17)(93) with options
MEM -t 4. BAMs were filtered using the same preprocessing pipeline in section Step 0:
Preprocess alignment files with the following exceptions: duplicate alignments were not
removed since the data was from an amplicon-seq library and alignments with alignment scores
< 20 were removed.
In total, we attempted to validate 43 PZMs across 15 non-hypermutated samples and 1,628
PZMs across 5 hypermutated samples (Table 5-3).
2.1.2.4.4 Validation method
Mutations were validated using the same validation method as the ENCODE datasets (see
section ENCODE DNA and RNA validation) except that the error model was generated from the
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GTEx DNA amplicon-seq dataset since this validation study had high coverage and a large
number of donors.
2.1.2.4.5 Sensitivity of method
We designed a dilution experiment to calculate the sensitivity of the validation method across a
range of VAFs (0.0005 - 0.01). Two genomic DNA samples, unrelated to GTEx, were genotyped
by WES. The dilution samples were created by diluting one of the samples (the foreground
sample) into the other sample (the background sample) at various ratios. The sensitivity of the
validation method was estimated at genomic positions where the foreground sample had a
germline variant (heterozygous or homozygous) and the background sample had a homozygous
reference genotype.
The dilution samples were prepped with the same amplicon-seq kit used for the large-scale
validation study, sequenced on the MiSeq platform (2x150bp reads) to a median amplicon
~2,800× coverage, and processed using the same analysis pipeline.

2.1.3 Algorithm for reconstructing PZM phylogenies (LachesisMap)
2.1.3.1 Phylogenetic reconstruction assumptions and their justifications
Since a PZM is inherited by all descendent cells, PZMs offer a natural lineage tracing
experiment. We hypothesized that the PZMs in our atlas could be resolved spatiotemporally
through phylogenetic reconstruction. To ensure the highest quality of data, we only used PZMs
that were found in at least two tissues in the same donor for phylogenetic reconstruction as
these have the highest probability of occurring prenatally (see section Evidence suggesting
multi-tissue PZMs occurred prenatally). We use the phrases multi-tissue PZMs and prenatal
PZMs to describe this class of PZMs. We also confirmed that we had adequate power for
detecting prenatal PZM events (see section Tree mutation detection power).
42

Since our dataset and study design had complex patterns of missing and uncertain data due to
differential mutation detection power across the body, genome, and developmental spacetime,
we deemed off-the-shelf tools for phylogenetic reconstruction to be inappropriate for this dataset
(see section Challenges in PZM phylogenetic reconstruction). Therefore, we developed a novel
method to reconstruct the evolutionary history of the PZMs that specifically accounted for these
complexities.
Unlike other applications of phylogenetic reconstruction where the underlying topology is
unknown and is thus the outcome of interest, for this application, we knew a priori what the
topology should approximately look like from developmental biology literature. Therefore, we
were interested in mapping the PZMs on this scaffold. The choice to use a mapping method
rather than a building method was cemented by the fact that developmental relationships
among tissues are well supported in the literature whereas using PZMs for the foundation of the
tree would require using a dataset with complex patterns of uncertainty and limited size. We
derived two developmental tissue trees that represent the phylogenetic relationships among
GTEx tissues during human development from the literature: the full tree, and the simplified
germ layer tree (see section Derivation of developmental tissue trees).
The method is based on Kimura’s infinite sites model(94) which is commonly used in molecular
and cancer evolution fields. In this parsimonious model, if a PZM is observed in more than one
tissue, then it is assumed there was one mutagenic event in a common ancestor of the tissues.
The common ancestor of any two or more GTEx tissues existed before the end of
organogenesis, and thus represents a time point during prenatal development. The infinite sites
model is a reasonable assumption since the PZM mutation rate was low (Figure 3-3) and PZMs
are expected to be under neutral selection(95).
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We excluded multi-tissue PZMs that were found in just lung and blood as these may be bloodspecific variants that were erroneously identified in the lung due to the high vascularization of
the lungs. Non-lung tissues were less likely contaminated with blood since blood vessels were
avoided during biospecimen collection (BBRB ID PR-0004-W1)(96). Therefore, we did not
remove other tissue-whole blood doubletons. Cell lines were also ignored as cell line PZMs may
have occurred postnatally, e.g., a multi-tissue PZM in blood and lymphoblasts may have
occurred during aging.
2.1.3.1.1 Evidence suggesting multi-tissue PZMs occurred prenatally
Akin to cancer evolution and under the assumption of neutral selection, a PZM that occurs
earlier in development will likely be in more tissues and at a higher VAF than a PZM that occurs
later. We found a significant positive correlation between VAF and the fraction of the donor’s
tissues that had the multi-tissue mutation detected (Spearman’s ρ = 0.34, P-value = 9.7E-56,
Spearman’s rank correlation test, Figure 2-7). These results suggest that the multi-tissue
mutations occurred prenatally.
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Figure 2-7: VAF is significantly associated with the fraction of tissues containing multitissue PZMs. To mitigate the effect of reduced mutation detection power for tissues with low
coverage, the number of tissues in a donor was adjusted to only include tissues with at least
10× coverage at the mutation locus. VAF was defined as the median VAF across all tissues with
the mutation. Top and bottom of boxes denote first and third quartiles, respectively; horizontal
black lines denote medians; whiskers denote 1.5× the interquartile range; and outliers are
plotted with transparency to disambiguate overlapping values. Number of multi-tissue mutations
in each boxplot is annotated above the whiskers.
Another feature of prenatal mutations is that the number of prenatal mutations in a tissue should
be independent of the donor’s age since all donors spent approximately the same time in utero
(Figure 2-8.a). To show we have power to detect an age association, we also modelled the
number of single tissue mutations (a proxy for postnatal mutations) in a tissue. For each tissue 𝑡
and donor 𝑖, we modeled the multi-tissue burden as:
# 𝑜𝑓 𝑚𝑢𝑙𝑡𝑖-𝑡𝑖𝑠𝑠𝑢𝑒 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛𝑠𝑡,𝑖
# 𝑡𝑖𝑠𝑠𝑢𝑒𝑠 𝑝𝑟𝑜𝑓𝑖𝑙𝑒𝑑 𝑖𝑛 𝑑𝑜𝑛𝑜𝑟 𝑖
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= 𝛽0,𝑡 + 𝛽1,𝑡 𝐴𝐺𝐸𝑖 + 𝛽2,𝑡 𝑎𝑛𝑐𝑒𝑠𝑡𝑟𝑦𝑖 + 𝛽3,𝑡 𝑆𝐸𝑋𝑖 + 𝛽4,𝑡 𝑖𝑠_𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑑𝑖
+ 𝛽5,𝑡 𝑑𝑜𝑛𝑜𝑟_𝑡𝑟𝑎𝑛𝑠𝑐𝑟𝑖𝑝𝑡𝑜𝑚𝑒_𝑠𝑖𝑧𝑒𝑖 + 𝛽6,𝑡 𝑠𝑎𝑚𝑝𝑙𝑒_𝑡𝑟𝑎𝑛𝑠𝑐𝑟𝑖𝑝𝑡𝑜𝑚𝑒_𝑠𝑖𝑧𝑒𝑡,𝑖
+ 𝛽7,𝑡 𝐵𝐴𝑇𝐶𝐻𝑡,𝑖 + 𝛽8,𝑡 𝑅𝐼𝑁𝑡,𝑖 + 𝛽9,𝑡 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟𝑡,𝑖 + 𝜀𝑡,𝑖
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A similar model was used for single tissue mutations except that the predictor variable was
changed to

# 𝑜𝑓 𝑠𝑖𝑛𝑔𝑙𝑒 𝑡𝑖𝑠𝑠𝑢𝑒 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛𝑠𝑡,𝑖
# 𝑡𝑖𝑠𝑠𝑢𝑒𝑠 𝑝𝑟𝑜𝑓𝑖𝑙𝑒𝑑 𝑖𝑛 𝑑𝑜𝑛𝑜𝑟 𝑖

and 𝑆𝐸𝑋 was dropped for sex-specific tissues.

Consistent with our predictions, age was not significantly associated with multi-tissue mutation
burden for the majority of tissues but was significantly associated with single tissue mutation
burden for a large number of tissues (Figure 2-8.b). Additionally, the multi-tissue age regression
coefficients (𝛽1,𝑡 ) were significantly smaller than the single tissue age regression coefficients (Pvalue = 0.016, Wilcoxon signed-rank test) (Figure 2-8.c). Together, these results suggest that
multi-tissue mutations are likely prenatal mutations since they have little to no dependence on
the donor’s age.
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Figure 2-8: Prenatal PZM burden is not associated with donor age. a. The number of
multi-tissue mutations (a proxy of prenatal PZMs) is expected to be independent of age whereas
the number of single tissue mutations (a proxy of postnatal PZMs) is expected to be dependent
on age. b. Significance versus effect size of age regression coefficients by mutation type.
Horizontal dashed line at -log10 0.1 = 1 denotes an FDR of 10%. Only tissues with significant
single tissue age coefficients and their matched multi-tissue age coefficients are shown (e.g.,
the significant lung single tissue coefficient and the matching [non-significant] lung multi-tissue
age coefficient are plotted). These tissues have an age association with single tissue burden
and thus likely have the highest power to detect an age association with multi-tissue burden. c.
Distribution of age regression coefficients for multi-tissue and single tissue burden models. Pvalue from Wilcoxon signed-rank test.
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2.1.3.1.2 Derivation of developmental tissue trees
Since mammalian development is immensely complicated with many aspects still unknown, we
used several assumptions to simplify the modelling of mutational dynamics during development.
Akin to Sulston et al.’s seminal cell lineage map of C. elegans(97), we assumed development of
tissues could be modelled as a rooted tree with directed edges (i.e., an arborescence). In this
arborescence, each node represents a spatial-temporal region of an organism. The root node is
the zygote and each directed edge represents the developmental relationship between a parent
node and a child node. By definition, there is only one directed path from the root to any other
node. Thus, this model assumes each primordial tissue is created from a single parental
primordial tissue. While this assumption simplifies the complexities of real development, in the
face of limited data and additional restrictive assumptions required for more sophisticated
modeling, we deemed this simplified model to be sufficient for capturing high-level summaries of
prenatal PZMs.
We defined an arborescence with the zygote as the root node, primordial tissues as the internal
nodes, and the GTEx tissues as the leaves. To focus on strictly prenatal mutations, we excluded
cell lines since the MRCA of a cell line and the tissue it was derived from may have occurred
postnatally. Sex-specific tissues were also omitted so that data from both females and males
could be easily combined together. (Of note, gonosomal PZMs (i.e., PZMs detected in both
somatic and germ cells) were analyzed separately (see section Characterization of germ cell
PZMs).) A variety of literature sources were used to define the internal nodes and edges of the
developmental tissue tree(98–102).
Parent nodes with fewer children have higher spatial-temporal resolution than nodes with more
children but are more reliant on the simplifying assumption that development can be modelled
as an arborescence. We strove to balance these opposing forces by defining the arborescence
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to have mostly bifurcating nodes. The arborescence was pruned to remove internal nodes that
only had one child node since mutations cannot be mapped to such edges without additional
data or additional modelling assumptions. For example, the directed path from zygote → 2-cell
embryo → 4-cell embryo → … → gastrula was simplified to zygote → gastrula. The final tree
(referred to as the full tree) is shown in Figure 2-9.

Figure 2-9: The full tissue tree. The full tissue tree has 70 nodes and 69 edges. The root
node is the zygote, primordial tissues are the internal nodes, and the GTEx tissues are the
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leaves. Each directed edge represents a developmental relationship such that the child node is
a developmental descendant of the parent node. Each node is labeled with a number. A lookup
table for converting node number to tissue name is shown. GTEx tissue nodes are colored
using the GTEx coloring convention.
To reduce the potential impact of incorrectly modelling development as an arborescence — but
at the cost of decreasing the spatial-temporal resolution — we defined a simplified tree with only
4 internal nodes (gastrula and the three germ layers) (referred to as the germ layer tree) (Figure
2-10). Here, we started with the full tree and recursively merged internal nodes until only the
gastrula and germ layer internal nodes were left. All downstream analyses were performed on
both the full and germ layer trees.

Figure 2-10: The germ layer tissue tree. The germ layer tree has 46 nodes and 45 edges.
The root node is the zygote, primordial tissues are the internal nodes, and the GTEx tissues are
the leaves. Each directed edge represents a developmental relationship such that the child
node is a developmental descendant of the parent node. Each node is labeled with a number. A
lookup table for converting node number to tissue name is shown. GTEx tissue nodes are
colored using the GTEx coloring convention.
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2.1.3.2 Challenges in PZM phylogenetic reconstruction
There are several challenges to address when reconstructing PZM phylogenies with the GTEx
study design. The challenges stem from three types of systematic differential power:
1. Differences in detection power across the body: since no donors had all GTEx tissues
sequenced, a PZM may be undetected in a tissue simply because the tissue was not
sequenced. Additionally, a PZM may be undetected in a tissue because the PZM was
not present in the tissue biopsy and/or sequenced library.
2. Differences in detection power across the genome: since PZMs are identified from RNAseq, a PZM may be undetected in a tissue because the gene was not expressed highly
enough. Such effects are exacerbated for low VAF variants which require higher
expression levels to be detected.
3. Differences in detection power across the developmental tissue tree: due to the
incomplete and variable tissue profiling structure of the donors, specific subsets of
tissues can be commonly or rarely profiled together in the cohort. Thus, different edges
will have different power to detect the mutation on the edge. Additionally, since earlier
mutations are expected to 1) have higher VAF and 2) be present in more tissues than
later mutations, earlier edges may have higher power than later edges in the tree. On
the other hand, later mutations may be easier to detect despite being in fewer tissues
because the tissues they’re detected in may have more similar transcriptomes. For
example, a PZM in a heart-specific gene that occurred during the formation of the heart
tube may be easily detected since its expression may be high in all descendant tissues
(i.e., left ventricle and atrial appendage).
We addressed these complex challenges by designing a method to control for differential power
and uncertainty in the data when mapping the mutations.
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2.1.3.3 Algorithm for reconstructing PZM phylogenies
We developed an algorithm, LachesisMap, to reconstruct the phylogenetic history of multi-tissue
PZMs. The algorithm jointly analyzes all multi-tissue PZMs and accounts for missing data as
well as differential PZM detection power due to differences in VAF, expression level, and tissue
profiling in the dataset.
LachesisMap takes as input 1) a developmental tissue tree with edges 𝐸 = {𝑒1 , . . . , 𝑒𝑁 } and 2)
metadata on the 𝑀 multi-tissue variants (𝐴 = {𝑎1 , . . . , 𝑎𝑀 }). The algorithm outputs a list of tree
edge weights (𝑊 = {𝑤1 , . . . , 𝑤𝑁 }) that represent the estimated probability of a PZM occurring in
that spatiotemporal window of development.
Briefly, in step 0, the algorithm maps each multi-tissue PZM to a set of edges in the tree using
parsimony and uncertainty rules. Next, in step 1, the edge weights are initialized. In step 2, the
edge weights are updated by simultaneously analyzing all multi-tissue PZMs and incorporating
mutation detection power. Step 2 is repeated until the edge weights converge or the maximum
number of iterations is reached. The method is described in more detail below and is visualized
in Figure 2-11.
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Figure 2-11: Algorithm for reconstructing PZM phylogenies. VCF = variant call format.
MRCA = most recent common ancestor. NA = not applicable
In order to improve our estimation of edge weights, we aggregated PZMs from all donors prior
to running the algorithm. This simplification assumes that mutation dynamics are similar across
donors. For datasets with large mutation burdens (e.g., from WGS datasets), it may be possible
to estimate donor-specific edge weights.
2.1.3.3.1 Step 0: Define the 𝑼𝒋 edge sets
In the first step of the algorithm, each multi-tissue PZM is mapped to a set of possible edges
where a mutation could have occurred using parsimony and uncertainty rules.

53

For each multi-tissue mutation 𝑎𝑗 , label the leaves and root with their mutation status. The
mutation status of a leaf is either reference (PZM not detected in tissue) alternative (PZM
detected in tissue) or NA (tissue was not profiled or coverage was too low (< 10× coverage)). By
definition, the root is labelled as reference.
Let 𝑈𝑗 be the set of edge(s) that are predicted to contain the origin of the variant 𝑎𝑗 . To Initialize
𝑈𝑗 , identify the most recent common ancestor (MRCA) node of all leaf nodes (i.e., GTEx tissues)
containing the variant 𝑎𝑗 . Add the incident edge of the MRCA node to 𝑈𝑗 . Update the MRCA
node to the parent of the MRCA node. Repeat the previous steps of adding edges and updating
the MRCA. Terminate when the MRCA node is the root node (i.e., the zygote) or the MRCA
node has one or more descendant leaves that were reference.
Step 0 highlights one of the ways LachesisMap incorporates missing data: leaf nodes with
unknown mutation status have the effect of spreading their uncertainty towards the root of the
tree, i.e., they have the potential to add more edges to 𝑈𝑗 .
2.1.3.3.2 Step 1: Initialize the 𝑾 edge weights
Define the variant-edge likelihood, 𝑝𝑖𝑗 , as the likelihood that variant 𝑎𝑗 occured on edge 𝑒𝑖 . Let
𝑛𝑗 = |𝑈𝑗 |. For each variant 𝑎𝑗 , initialize the variant-edge likelihoods with a uniform distribution:
set 𝑝𝑖𝑗 = 1/𝑛𝑗 for each edge in 𝑈𝑗 . After all variants have been initialized, normalize the tree
edge weights to 1: 𝑤𝑖 =

∑𝑀
𝑗 𝑝𝑖𝑗
𝑀

.

2.1.3.3.3 Step 2: Update the 𝑾edge weights until convergence
In this step, the method analyzes all multi-tissue PZMs simultaneously to update the weights,
taking into account differential PZM detection power due to differences in VAF, expression level,
and tissue profiling in the dataset.
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For each iteration, for each multi-tissue variant 𝑎𝑗 , for each 𝑒𝑖 in 𝑈𝑗 , update the variant-edge
likelihoods 𝑝𝑖𝑗 : if 𝑛𝑗 = 1, set 𝑝𝑖𝑗 = 1, otherwise, set 𝑝𝑖𝑗 = 𝑤𝑖 . Next, adjust these variant-edge
likelihoods for incomplete power. Here, we made the simplifying assumption that the observed
variant-edge likelihood was proportional to the expected likelihood via the following equation:
𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑_𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 = 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑_𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 ∗ 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟. Calculate the
mutation detection power to detect the variant 𝑎𝑗 at edge 𝑒𝑖 given the multi-tissue variant’s
median VAF and median coverage using the tree power functions (see section tree mutation
𝑝

detection power). Update the variant-edge likelihood 𝑝𝑖𝑗 to 𝑃𝑜𝑤𝑒𝑟(𝑒 ,𝑉𝐴𝐹𝑖𝑗 ,𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒 ).
𝑖

𝑖

𝑖

After updating all variant-edge likelihoods for all 𝑀variants, normalize the weights to 1: 𝑤𝑖 =
∑𝑀
𝑗 𝑝𝑖𝑗
𝑀

.

Repeat step 2 until 𝑊converges or the maximum number of iterations is reached.
Step 2 integrates information across mutations. For example, if a particular mutation has a lot of
mapping uncertainty, other mutations with more certainty will help direct which edges should
have their uncertainty decreased. This feature is another way the algorithm incorporates
missing data and other ascertainment biases in the data.
2.1.3.3.4 Tree mutation detection power
The power to detect a mutation on a tree depends on the VAF, coverage, profiled tissues, and
the tree topology. We estimated the power to detect a mutation on each edge of a tree as a
function of these variables.
We defined the tissue profiling vector as the set of tissues that are profiled in a given GTEx
donor and defined the mutation vector as the set of tissue mutation statuses. A mutation status
is either reference or alternative. Of note, since we are simulating mutations, all tissues,
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regardless if they’re profiled, will have a mutation status. We made the simplifying assumption
that a mutation that occurs on a given tree edge will be present in all descendant tissues (see
section Justification for not requiring monophyletic relationships during PZM mapping). Without
this assumption (i.e., allowing incomplete penetrance of the mutation), it was computationally
intractable to simulate all possible mutations for the large number of GTEx tissues. (To relax this
assumption, one could model mutation penetrance across the nodes as a random variable, e.g.,
each child node has a 80% chance of inheriting the mutation.) Each edge uniquely specifies a
mutation vector.
To simulate a mutation for a given edge 𝑒𝑗 and VAF, we randomly selected a tissue profiling
vector from the distribution of tissue profiling vectors used in GTEx and then randomly selected
GTEx samples to fit that profiling vector. Next we randomly selected a position in the allowable
transcriptome. For each tissue sample, we simulated the alternative read coverage as a random
binomial variable with 𝑝 = VAF and 𝑁 = the sample’s coverage at that genomic position. We
defined a multi-tissue mutation’s coverage as the median coverage of tissues with the mutation
and then discretized the coverage into one of four coverage bins.
We next ran the variant detection algorithm on the simulated multi-tissue mutations and mapped
the mutation on the tree to identify the edge(s) where the mutation was predicted to have
occurred (i.e., 𝑈𝑗 ). We conservatively defined a mutation to be predicted correctly if 𝑈𝑗 = 𝑒𝑗 . We
defined the power to detect a tree mutation as the fraction of simulations that were predicted
correctly for a given VAF, coverage bin, and mutation vector.
For each edge in a given tree and VAF, we simulated ~1.6M multi-tissue mutations (all chr22
positions in the allowable transcriptome), and calculated the tree mutation detection power for
the full and germ layer trees. To examine how GTEx tissue profiling affected mutation detection,
we also simulated mutations using tissue profiling vectors where all tissues were profiled.
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2.1.3.3.5 Justification for not requiring monophyletic relationships during PZM mapping
Using parsimony, our model assumes that if a mutation was detected in multiple terminal
tissues, then the mutation occurred in a common ancestor edge (𝑈𝑗 ). However, the model does
not assume the converse, i.e., if a mutation occurred in a common ancestor edge, then the
mutation was detected in all terminal tissues (i.e., a monophyletic group).
There are several biological and technical reasons why a mutation may be predicted to occur in
edges 𝑈𝑗 but is unobserved in all descendent tissues. First, the internal and terminal nodes of
the tree may have been seeded with cells from the parent node that did not contain the
mutation. Second, the mutation may have been later eliminated in the lineage that gave rise to
that tissue (e.g., from gene conversion, mitotic recombination, apoptosis, etc.(1)). Third, the
mutation may be present in the tissue, but absent in the subset of cells that were sequenced.
Lastly, the mutation may be present in the tissue and the cells that were sequenced, but still
unobserved due to limited power to detect the mutation.
The lack of monophyletic relationships in PZM phylogenetic reconstruction has been previously
reported. For example, Behjati et al. identified putative embryonic mutations predicted to occur
before gastrulation but were absent from some of the profiled adult tissues(13). In Martincorena
et al., skin tissue biopsies that were taken < 5 mm apart did not always contain the same
PZMs(49).
We quantified the effect of mutation detection power to explain why a prenatal PZM may be
missing from some of the descendent tissues. For this analysis, we focused on gonosomal
PZMs, a subset of prenatal PZMs. (Recall that gonosomal PZMs are PZMs detected in both the
germline and soma (Figure 1-1).) We used gonosomal PZMs for several reasons: since
gonosomal PZMs are predicted to occur very early (within approximately the first 10 cell
divisions of life (103)), these multi-tissue mutations are expected to be detected many tissues
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and have high VAFs and thus are likely to have 1) high power to detect the mutation in each
tissue and 2) high power to be mapped correctly onto a tissue tree.
We first defined a gonosomal tissue tree which included nodes for the germline (as proxied by
testis (see section Germ cell PZMs can be detected in bulk male gonads)) and the MRCA of the
germline and soma (referred to as MRCA(germline, soma)) (Figure 2-12).

Figure 2-12: Gonosomal tissue tree. For brevity, individual labelling of somatic tissues has
been omitted.
Similar to the previous tree mutation power simulations, we simulated mutations on the Zygote
→ MRCA(germline, soma) edge (i.e., gonosomal PZMs) at a variety of VAFs and coverages.
Only samples from male testis donors were used. By definition, these gonosomal PZMs are
present in all profiled tissues of the donor. For each simulated gonosomal PZM, we calculated
the fraction of profiled tissues where the mutation was detected (referred to as the tissue
detection rate) (Figure 2-13). Power curves were fit to sigmoid functions using the LevenbergMarquardt nonlinear least-squares algorithm from the minpack.lm R package (v 1.2-1)
(https://CRAN.R-project.org/package=minpack.lm).
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Figure 2-13: Power to detect simulated gonosomal PZMs in all tissues is variable.
Detecting a simulated gonosomal PZM in a given fraction of tissues depends on the simulated
VAF and coverage (defined as the median coverage across all tissues). For a given coverage,
as the simulated gonosomal PZM VAF increased, the power to detect mutations at a given
minimum tissue detection rate increased. For a given simulated VAF, as the coverage
increased, the power to detect mutations at a given minimum tissue detection rate also
increased. Of note, power curves do not all saturate at 100%.
Using the observed gonosomal PZMs (median VAF = 0.037; mode coverage group = [100,
1000)), we predict that only 19% of gonosomal PZMs will have the mutation detected in all
profiled tissues. This value jumps to 97% if the constraint is relaxed to at least 50% of profiled
tissues to have the mutation detected (Figure 2-13). Since mutation detection power is higher
for gonosomal PZMs than all prenatal PZMs, these estimates likely represent an upper bound
for the tissue detection rate in prenatal PZMs. Thus, failure to detect prenatal PZMs in all
descendant tissues is likely very large and further justifies why we did not require PZM
monophyly during PZM mapping.

2.1.4 PZM phylogeny validation
To test if prenatal PZMs were the result of shared developmental history rather than
experimental error or multiple independent mutations, we randomly shuffled the mutation status
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labels of the mutation catalog 20,000 times, mapped the randomized PZMs to the tree, and
calculated the distribution of expected edge weights under the null hypothesis. We used a
multinomial goodness-of-fit test to test if the observed edge weight vector was likely sampled
from the distribution of edge weight vectors from random mutations. Due to the large sample
size, we used Monte-Carlo simulations to estimate the P-value using the XNomial R package
(v1.0.4) (https://cran.r-project.org/package=XNomial). Since a fraction of a mutation can be
mapped to an edge, both observed and expected mutation counts were rounded to the nearest
integer. Edges with edge mapping power < 5% were excluded from the hypothesis tests since
these edge weight estimates may be noisy.
To perform the post-hoc tests for testing which individual edges had significantly different
burdens than the null model, we used permutation tests. For a given edge 𝑒 and edge weight 𝑤,
the test statistic was defined as the absolute difference between 𝑤 and the median of all
random 𝑒 edge weights. The P-value was defined as the percent of test statistics that were as or
more extreme than the observed test statistic. P-values were corrected for multiple tests using
the Benjamini-Hochberg procedure. q-values ≤ 0.05 were defined as significant.

2.1.5 Code availability
The Lachesis suite of tools is freely available at https://github.com/conradlab/lachesis.

2.2 Results
As RNA is transcribed from DNA, we hypothesized it would be possible to accurately identify
DNA PZMs using bulk tissue RNA-seq data. At the start of this project, there were no suitable
methods for calling DNA PZMs from RNA-seq, therefore we developed a novel method, called
LachesisDetect. (We note that in the interim, the field has seen a burgeoning in methods(61,
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62)). As mutations can cause disease and eventually mortality, we named the algorithm after
the Greek goddess, Lachesis, who measures the thread of life and chooses a person’s destiny.
Briefly, LachesisDetect contains four basic steps: 0) preprocessing of alignment files, 1)
identification of putative PZMs, 2) removal of false positive PZMs, and 3) recovery of false
negative PZMs. The method’s power to detect PZMs is derived from jointly analyzing data from
multiple donors and within donors (Figure 2-1a). Additionally, LachesisDetect uses statistical
frameworks for many of the steps, thereby giving the user precise control on how conservative
to make the mutation calling.
We used LachesisDetect to call DNA PZMs in 17,382 RNA-seq samples from the GTEx v8 data
freeze. After filtering alignments for extremely high quality alignments, the algorithm leverages
cohort-wide information by simultaneously analyzing all samples to estimate position-specific
error models for over 115 Mb of the transcriptome. LachesisDetect uses these models to detect
putative PZM with single-sample calling (Figure 2-1b). Next, the method removes sources of
false positive PZMs such as RNA editing and allele-specific expression of germline variants
using > 15 filters based on theoretical and experimental validation metrics. In the last step, the
method leverages donor information by jointly analyzing all tissue samples from a donor to
detect mutations with low power and estimate empirical false positive rates (Figure 2-1c). In
total, we identified 56,585 mutations across 14,672 pass QC samples (Table 5-1, Table 5-7).

2.2.1 Evaluation of LachesisDetect
The estimated error models generated in step 1 indicated that the position-specific error rate
varies by orders of magnitude across the transcriptome (minimum error rate = 0.0, maximum =
1.0, median = 3.0E-4, Figure 2-14, Figure 2-1b). Due to careful modelling of error rates, we
were able to detect putative mutations with VAFs as low as 4.0E-4.
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Figure 2-14: Distribution of position-specific error rates at PZMs and distributions of
PZM VAFs that were identified after step 1 (true positives) and step 3 (false negatives).
For the former VAF distribution, only the subset PZMs that were retained after the completion of
the pipeline were plotted, i.e., false positive PZMs were removed.
The cross-sample calling in step 3 allowed us to identify variants that had lower total coverage
and lower alternative allele coverage than those identified in step 1 (both P-values < 2.2E-308,
Mann-Whitney U test) (Figure 2-15). These newly detected PZMs also tended to have higher
VAFs (P-value = 6.4E-268, Mann-Whitney U test) (Figure 2-14). As expected, step 3 increased
the prevalence of multi-tissue PZMs (P-value = 3.2E-314, McNemar’s Chi-square test with
continuity correction) and increased the number of tissues containing the multi-tissue PZMs by
56% on average. By including a random set of matched GTEx samples in the step 2 calling, we
estimated the FDR to be 9.3% and the FPR to be 1.0%.
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Figure 2-15: Distribution of step 1 and step 3 PZM statistics. Distribution of total coverage
(a) and alternative coverage (b) for PZMs detected in step 1 and step 3. Top and bottom of the
boxes denote first and third quartiles, respectively; horizontal black lines denote medians;
whiskers denote 1.5× the interquartile range; and outliers are plotted with transparency to
disambiguate overlapping values.

2.2.2 PZM detection power
2.2.2.1 PZM detection power estimated from simulation
Power simulations demonstrated that PZM detection in step 1 of LachesisDetect was sensitive
to coverage and VAF. As expected, simulated PZMs with larger VAFs and higher coverage had
higher PZM detection power. At the middle quintile of coverage([673, 1395) fold coverage),
PZMs with VAFs as low as 6.6E-3 could be detected in at least 90% of simulations (Figure
2-16).

63

Figure 2-16: Step 1 PZM detection power as a function of VAF and RNA-seq coverage
quintile.

2.2.2.2 PZM detection power estimated from experimental dilution of germline
variants
We designed an experiment to calculate the sensitivity of mutation detection across a range of
low VAFs (0.0005 - 0.01) by diluting germline variants of one sample in another unrelated
sample. The correlation between the expected VAF and the observed VAF was high (Pearson’s
correlation coefficient = 0.95, P-value = 6.5E-30, Pearson correlation test). The sensitivity of the
mutation calling method was 100% (23/23), suggesting that the mutation calling algorithm
estimates VAF accurately and is sensitive to detect mutations with VAFs as low as 0.05% given
sufficient sequencing coverage. The apparent difference in sensitivity between the power
simulations and this experiment is likely explained by the extremely deep coverage in the latter.

2.2.3 DNA PZMs are accurately detected in bulk tissue RNA-seq
We next estimated the FDR of mutation calls by performing in silico and experimental validation
using orthogonal data sources. For in silico validation, we phased PZMs to nearby germline
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variants and estimated the FDR to be 24% (Figure 2-6, Table 5-3). For experimental validation,
we obtained four independent validation datasets generated from the same tissues as the
primary data: a DNA-sequencing dataset (N = 57 samples) and an RNA-sequencing dataset (N
= 20 samples) from the ENCODE project and two new DNA-sequencing datasets (pilot and
large-scale) that we generated for this study (N = 22 and 15 samples, respectively). The
ENCODE validation datasets provided low coverage across a large number of samples and
genomic sites whereas the latter two provided deep coverage across a small number of
samples and genomic sites.
The validation datasets covered 296 unique genomic sites across 95 samples. In total,
validation status could be determined for 167 PZMs. Summing across all sources, the original
RNA-seq VAF was correlated with the validation VAF (all informative sites: Spearman’s ρ =
0.65, P-value = 1.3E-21; validated sites: Spearman’s ρ = 0.82, P-value = 2.3E-25). PZMs with
VAFs as low as 0.0016 were validated. Of the six multi-tissue PZMs that were informative, 83%
(5/6) were validated in all tissues predicted to have the mutation. Furthermore, one inter-donor
PZM was informative and was validated in 100% (4/4) donors with both RNA- and DNA-based
validation evidence. Interestingly, this mutation on chrM was validated in the adrenal gland of all
donors at very low VAF (median validation VAF = 0.005). Lastly, of the three PZMs that were
informative across two experimental validation datasets, 100% (3/3) were validated in both
validation datasets. The average FDR across all validation datasets was 27% (Figure 2-17,
Table 5-3).
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Figure 2-17: Validation VAF versus VAF in the original GTEx RNA-seq data for PZMs
where validation was attempted. PZMs are annotated by their validation status and the
validation dataset.
Variability in FDR by validation dataset was likely driven by differences in PZM metrics, e.g., the
pilot validation dataset was biased towards larger VAFs which likely have an inherently lower
FDR due to the high signal-to-noise ratio. Since the nucleic acid used for validation was
extracted from a different region of the tissue than what was used for the original RNA
extraction, true variants may fail to validate due to spatial variation in mosaicism (e.g., the
validation sample may not contain enough cells with the variant to be detectable). Therefore,
these validation data likely overestimate the true FDR.

2.2.4 PZM phylogeny reconstruction power
We estimated the power to reconstruct PZM phylogenies via simulation. PZM phylogeny
reconstruction power was dependent on the tree topology, profiled tissues, coverage and VAF.
Power was greatest when coverage was high and VAF was high (Figure 2-18). The high
variability in power across the tree provides additional evidence that mutation burdens along
tree edges should be adjusted for power.
66

Given that only a subset of GTEx tissues were profiled in a given donor, to examine how GTEx
tissue profiling affected mutation mapping power, we also simulated mutations using tissue
profiling vectors where all tissues were profiled. These power curves represent the upper bound
for detecting mutations in RNA-seq in the GTEx tissues and illustrate that low mapping power
was primarily driven by only profiling a subset of tissues in each donor rather than differences in
tissue transcriptomes. The power curves may also be a useful reference when designing future
experiments to detect prenatal PZMs.
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Figure 2-18: Edge mutation mapping power is variable. Edge mutation mapping power
depends on tree topology (full tree in a, germ layer tree in b), edge (facet), tissue co-profiling
strategy (line type), coverage (line color), and VAF (x-axis). Edges are referenced by the
incident node name. Some facets do not have the highest coverage bin plotted because zero
such mutations were encountered during simulation.

2.2.5 PZM phylogeny validation
The following lines of evidence suggest that the reconstructed phylogenies are likely correct.

2.2.5.1 Mapped prenatal PZMs are explained by shared developmental history
rather than random sharing patterns
We confirmed that the observed mapping of the prenatal PZMs could not be explained by
random mapping of mutations. If the prenatal PZMs truly did not share developmental histories
(and thus were the result from experimental error or multiple independent mutation events), then
we would expect the observed edge weights to be no different than those generated from
randomized prenatal PZMs catalogs.
The ensemble of observed edge weights was significantly different from random (P-value =
2.2E-308, multinomial goodness-of-fit test) and the majority of individual edge weights (56%,
14/25) were significantly different from random after Benjamini-Hochberg correction
(permutation tests) (Figure 2-19.a). Similar results were observed for the germ layer tree
(ensemble different from random P-value = 2.2E-308, multinomial test; 100% (4/4) of individual
edge weights were different from random; Figure 2-19.b). These results suggest that the multitissue PZMs are developmentally acquired mutations and furthermore, the observed edge
weights likely estimate the true mutational burdens during development. It is important to note
that these are estimates for mutations that are detectable in adulthood — the data does not
allow for extrapolating to all developmentally acquired mutations since some fraction is likely
lost through cell death, revertant mosaicism, etc.
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Figure 2-19: Majority of edge weights are significantly different than expected by
chance in the full tissue tree (a) and germ layer tree (b). Edge color represents the log2 ratio
of observed to expected mutation burden. Edges that are significantly different from random are
annotated by “*” (q-values ≤ 0.05). Thick gray edges are edges with limited mutation detection
power. See Figure 2-9, Figure 2-10 for the full set of vertex labels. GTEx tissue vertices
(leaves) are colored using the GTEx coloring convention (see Figure 5-1 for a complete
legend).

2.2.5.2 Observed mutation edge weights are independent of edge mapping power
Since edge mapping power is variable across the tree, it is important to determine if the
observed edge weights can be explained by differential edge mapping power. For both the full
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tissue tree and germ layer tree, there was no significant correlation between edge weight and
edge mapping power at any coverage level (Figure 2-20). These results imply that edge
weights are independent of ascertainment bias.

Figure 2-20: Observed mutation edge weights are independent of edge mapping power.
Since edge mapping power is dependent on coverage, the prenatal mutations were partitioned
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into three coverage bins. a and c. The observed mutation edge weight versus the edge mapping
power for mutations with low (left panel), medium (middle panel), and high (right panel)
coverage for each edge in the full tissue tree (a) and germ layer tissue tree (c). b and d. Results
from testing for a correlation between the observed edge weights and the edge mapping power
for each coverage level (Spearman’s rank correlation test) for the full tissue tree (b) and germ
layer tissue tree (d). Only edges with at least 10% edge mapping power were used since edge
weights with low edge mapping power may be noisy. The number of edges refers to the number
of edges that had the minimum power that were used for the correlation calculation. To
calculate an edge mapping power for each edge and coverage level, we first calculated the
median VAF of PZMs mapped to that edge and coverage level. Using the edge mapping power
curves, we then estimated the power to detect PZMs of that median VAF.

2.2.5.3 Prenatal PZMs mapped to earlier timepoints have larger VAFs than later
timepoints.
Assuming neutral selection, a PZM that occurs earlier in development will likely have a higher
VAF than a PZM that occurs later. Using the reconstructed phylogenies, we calculated the
distribution of VAFs mapped to each edge of the germ layer tree. The VAFs of mutations that
mapped earlier in the tree (parent edge) were larger than the VAFs of mutations that mapped
later in the tree (child edges) (P-value range 4.5E-41 - 3.8E-5, Mann–Whitney U test; Figure
2-21). These results suggest that the reconstructed phylogenies are correct.

Figure 2-21: PZMs mapped to earlier timepoints have larger VAFs than later timepoints.
Edges are colored by edge name and are sorted parent edge to child edges. “*” denotes
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statistical significance in VAF between parent and child edges (Mann–Whitney U test). Top and
bottom of the boxes denote first and third quartiles, respectively; horizontal black line denotes
median; whiskers denote 1.5× the interquartile range; and outliers are plotted with transparency
to disambiguate overlapping values.
Additionally, the tree mutation detection power is generally high for mutations with sufficient
coverage suggesting that the method is able to map mutations well (Figure 2-18).

2.3 Discussion and future directions
2.3.1 Error models may be generalizable to other datasets
Even though LachesisDetect was developed for RNA-seq datasets with a large number of
samples such as GTEx, it can also be used on smaller datasets. We compared the error models
from GTEx and TwinsUK, a smaller multi-tissue RNA-seq dataset. With only ~2.3k samples,
TwinsUK is 0.14× the size of GTEx and was sequenced to lower coverage. (See TwinsUK
dataset for a description of the dataset.) Despite differences in the tissues profiled, library
preparation, sequencing, aligner, etc., we observed remarkable similarity in error models, e.g.,
the Pearon’s correlation was 0.67 when both error models had at least 10k background
coverage (i.e., the total coverage across all samples in the cohort at a given genomic position).
The correlation increased as the minimum background coverage increased, suggesting that
correlation may be underestimated due to sampling error (Figure 2-22). These data suggest
error models derived from large datasets may be reused to detect PZMs in other, smaller
datasets. Of note, both GTEx and TwinsUK were produced via Illumina sequencing technology.
Error models generated by different sequencing technologies may be less generalizable since
different technologies tend to have different error profiles(104).
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Figure 2-22: Pearson’s correlation between GTEx and TwinsUK error models as a
function of the background coverage. The size of the datapoint is proportional to how many
genomic sites were used in the correlation calculation. Data shown for chr22.
Given that there was high similarity between RNA-seq VAF and validation VAF observed from
DNA-based assays, it may be possible to use RNA-seq based error models on DNA data and
vice versa. However, when detecting PZMs, care must be taken to address sources of
experimental error that are specific to each nucleic acid. For example, it may be prudent to not
call PZMs near exon-exon junctions in RNA data when the error model was derived from DNA
since the DNA error model will not capture alignment errors due to splicing.

2.3.2 Limitations & improvements to the Lachesis suite of tools
2.3.2.1 LachesisDetect
The detection of DNA PZMs from bulk RNA-seq is challenging. Due to the low signal-to-noise
ratio and litany of noise sources, false negatives and false positives have the potential to
contaminate a mutation call set. For example, PZMs that are in unexpressed or lowly expressed
genes, are under strong negative selection, or are very recent PZMs may be undetected.
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Additionally, all intergenic and the majority of intronic regions will also not be detected. On the
other hand, cryptic alignment errors, germline variants, and contamination of blood PZMs in
other tissues may result in false positives.
While we attempted to thwart most of these issues, e.g., applying three filters to remove
germline variant contamination and quantifying the ascertainment bias with simulations,
additional efforts could be made. For example, modelling the error rate at a position as a beta
binomial random variable rather than a binomial random variable may be more accurate. This is
especially true at sites with extremely high background coverage where the error rate may be
overdispersed. Additionally, error models that are specific to the alternative base, alignment
strand, and/or sequencing position may produce more accurate models. Similar models have
been used by ShearwaterML(49) and SPLINTER(105). With such error models, it may be
possible to accurately detect PZMs with even smaller VAFs.
Nonetheless, some of these challenges of detecting DNA PZMs in RNA can actually be
reframed as advantages. Although PZMs can only be detected in polyA genes (~1% of the
genome(106)), this ~1% may represent > 60% of PZMs in the genome due to the enrichment of
CpGs in exons and the high mutation rate of methylated cytosines(35). Additionally, knowledge
that the PZMs are expressed may allow straightforward inferences about the potential effect of
PZMs on cell function.
In the ideal case, more of the false positive filters used in step 2 of LachesisDetect would be
based on experimental data rather than theoretical estimates and arbitrary cutoffs. To do so
would require a large and accurate training dataset, which unfortunately, does not yet exist for
PZM datasets. We did attempt to do this with an iterative approach to the background error
filter: as we obtained more validation data, we updated the filter to optimize the mutation call
set. However, the small size of the validation dataset may have resulted in overfitting.
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This method is limited to detect single nucleotide PZMs. Given the mounting evidence that
postzygotic small indels and SVs play a role in disease, it is important that an accurate mutation
caller for detecting other forms of postzygotic genetic variation in RNA-seq be developed. For
example, existing methods that detect subtle allelic imbalance for postzygotic CNV detection
could be adapted to RNA-seq.

2.3.2.2 LachesisMap
One of the most impactful assumptions in the algorithm to reconstruct PZM phylogenies was the
use of a predefined tissue tree that represented the phylogenetic relationships among the
tissues. This is a gross simplification of mammalian development. However with limited PZM
detection power and a relatively small number of PZMs to analyze, we believe mapping PZMs
to an ab initio tree rather than deriving de novo trees is well justified. With larger datasets (e.g.,
more positions (e.g., WGS), deeper coverage, more biospecimens per donor (e.g., from bulk
tissue, microdissections, or single-cells)), it may be possible to derive PZM phylogenies for each
donor without the restrictive mapping framework. Indeed, de novo phylogenetic reconstruction
of PZMs detected from DNA has been successfully applied when the sample mutation burden is
high in cancer samples(107), microdissections(56), and single-cells(29). Unlike existing DNAbased phylogenetic reconstruction methods, careful attention must be made towards modelling
incomplete power across the transcriptome for RNA-seq based methods. With their larger
degrees of freedom, however, de novo tree methods may have a greater possibility of
overfitting.
An intermediate approach between mapping PZMs to predefined trees and deriving de novo
PZM phylogenies, is to map PZMs to more complicated data structures, e.g., networks. This
would remove some of the restrictive assumptions used in LachesisMap, e.g., assuming no cell
migration
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Chapter 3
Spatial temporal characterization of
PZMs in GTEx
3.1 Methods
3.1.1 GTEx data
We detected variants in the GTEx v8 dataset. To achieve a high quality dataset, we removed
RNA-seq samples with RIN < 6, were derived from tissues with overall poor quality(81) or had
an extremely high PZM mutation burden (see Remove hypermutated samples; Table 5-2). We
also confirmed that none of the analyzed samples were from transplanted tissue. After our
quality control, there were 14,672 samples from 944 donors from 48 diverse tissue and cell
types. Library preparation, sequencing, alignment, and GTEx quality control are described in
detail in (64). Briefly, RNA-seq samples were prepared using a polyA, unstranded RNA-seq
protocol (Illumina TruSeq) and sequenced on Illumina HiSeq instruments (HiSeq 2000 or HiSeq
2500) with 76bp paired-end reads to a median coverage of ~83M total reads. Reads were
aligned to the GRCh38 human reference genome using STAR v2.5.3a(108) and GENCODE
v26 gene models. Duplicate reads were marked with Picard Tool’s MarkDuplicates (v2.9.4)
(https://broadinstitute.github.io/picard/).
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3.1.1.1 PZM variant calling
We ran LachesisDetect on the GTEx RNA-seq BAMs to generate a list of putative PZMs in
GTEx.

3.1.1.2 Germline variant calling
To increase the sensitivity to detect germline variants, we used all genotyping GTEx datasets
that were available at the time of writing: v8 WGS data (838 donors)(64), v6 WES (520 donors
and 11 GTEx flagged donors), v6 WGS (148 donors), and v6 microarray data (191 donors for
the pilot microarray and 275 donors from the midpoint microarray)(81). Detailed descriptions of
the sample preparation, sequencing, alignment, and quality control can be found in their
respective publications.
Briefly for the v8 WGS data, for the majority of samples, DNA was isolated from whole blood. A
non-blood source was used if blood was not available or the blood sample failed quality control.
WGS was performed using 101bp or 151bp paired-end reads on Illumina HiSeq instruments
(HiSeq 2000 or HiSeq X) to a median depth of 32×. Reads were aligned to the GRCh38 human
reference genome using BWA-MEM (http://bio-bwa.sourceforge.net). Germline SNVs and indels
were called using the GATK HaplotypeCaller (v3.5)(109).

3.1.2 Mutation burden modelling
After an initial phase of data exploration and model selection, we fit the following linear model
for mutation burden with eight main effects and three interactions:
𝑠𝑎𝑚𝑝𝑙𝑒_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑏𝑢𝑟𝑑𝑒𝑛 ~ 𝑡𝑖𝑠𝑠𝑢𝑒 + 𝐴𝐺𝐸 + 𝑠𝑒𝑙𝑓_𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑑_𝑎𝑛𝑐𝑒𝑠𝑡𝑟𝑦 + 𝑠𝑒𝑥 + 𝑅𝐼𝑁
+ 𝑏𝑎𝑡𝑐ℎ + 𝑠𝑎𝑚𝑝𝑙𝑒_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟 + 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒_𝑑𝑎𝑡𝑎
+ 𝑎𝑔𝑒: 𝑡𝑖𝑠𝑠𝑢𝑒 + 𝑠𝑒𝑙𝑓_𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑑_𝑎𝑛𝑐𝑒𝑠𝑡𝑟𝑦: 𝑡𝑖𝑠𝑠𝑢𝑒 + 𝑠𝑒𝑥: 𝑡𝑖𝑠𝑠𝑢𝑒
where 𝑏𝑎𝑡𝑐ℎ was the batch ID for when the RNA was isolated and extracted from a sample;
𝑠𝑎𝑚𝑝𝑙𝑒_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟 was the average mutation detection power of simulated
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mutations in the sample; and 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒_𝑑𝑎𝑡𝑎 was the list of genotyping platforms used to call
germline variants in the donor. The R package car (v 3.0-6)(110) was used to calculate type II
ANOVA tables.
To estimate the variation explained by donors, we augmented the model in equation 3-1 to a
mixed effects model by dropping 𝑏𝑎𝑡𝑐ℎ as a fixed covariate and adding 𝑏𝑎𝑡𝑐ℎ and 𝑠𝑢𝑏𝑗𝑒𝑐𝑡 as
random effects. The R package rptR (v0.9.22)(111) was used to fit the model with restricted
maximum likelihood and calculate bootstrapped confidence intervals for the variation explained
by donors. The number of parametric bootstraps (nboot) was set to 500.

3.1.3 Mutation signatures
SigProfilerSingleSample (v0.0.0.27)
(https://github.com/AlexandrovLab/SigProfilerSingleSample) was used to calculate the percent
of mutations in a tissue that are attributable to a given set of mutation signatures. The following
parameters were used: ref="GRCh38", exome=True. COSMIC substitution mutation signatures
from version 3.2 were used. To increase the power to detect mutational signatures, PZMs from
all samples in a tissue were combined. To achieve accurate mutation signature decompositions,
only tissues with reconstruction accuracy ≥ 95% were retained. Putative mutation signature
etiologies were taken from (112).

3.1.4 Genetic variation datasets used for functional annotation
To compare the different genetic variation datasets fairly, we strove to mimic the ascertainment
biases in the PZM dataset in these other datasets. To do this, we only retained mutations that
overlapped the allowable transcriptome (see Allowable transcriptome definition) unless specified
otherwise.
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3.1.4.1 Inherited de novo mutations
De novo mutations were pulled from denovo-db (v1.6.1), a curated database of ~628,000 de
novo mutations from 53 studies(113). We used mutations from both the Simons Simplex
Collection (SSC) and non-SSC subsets of denovo-db. Mutations were filtered for singlenucleotide mutations, lifted over from hg19 to hg38, and filtered for mutations overlapping the
allowable transcriptome. As suggested by the authors, de novos from autism studies with poor
validation were dropped and de novos from monozygotic twins and duplicate individuals were
deduplicated. Mutations whose reference base in hg19 did not match the reference base in
hg38 were excluded. Approximately 50,000 de novo mutations were retained after filtering.
Mutations were partitioned into two mutually exclusive groups using the PrimaryPhenotype
metadata field in denovo-db: 1) mutations observed in control subjects (defined as de novo
controls) and 2) mutations observed in subjects with a disease (defined as de novo cases).
Subjects with unknown disease status were excluded.

3.1.4.2 Inherited germline variants
Inherited germline variants were pulled from gnomAD (v3.0), a comprehensive database of
germline genetic variation from ~125,000 exomes and ~15,000 genomes(114). Due to the large
size of the dataset, we limited our analysis to variants on chr22. Variants were filtered for singlenucleotide variants that overlapped a modified allowable transcriptome. This modified allowable
transcriptome did not have the GTEx germline variations removed. To reflect population allele
frequencies in GTEx (where the majority of donors have self-reported Caucasian ancestry) we
used population allele frequencies from gnomAD’s Non-Finnish European (NFE) population.
Only variants with non-zero NFE allele frequencies were retained. Approximately 359,000
germline variants remained after filtering.
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3.1.4.3 Cancer somatic mutations
Cancer somatic mutations in The Cancer Genome Atlas (TCGA) were pulled from ICGC release
28, a comprehensive genomic database of many cancer types(115). We selected six cancer
types to represent the genetic diversity among cancer types. We selected cancer types whose
tissue of origin was profiled in GTEx. Additionally, we selected cancers such that all three germ
layers were represented by their tissue of origins and had varying degrees of somatic mutation
burden. The following cancer types were selected: breast cancer (BRCA), brain glioblastoma
multiforme (GMB), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD),
pancreatic cancer (PAAD), and skin cutaneous melanoma (SKCM).
The open-access tier of simple somatic mutation datasets were used. The open-access tier
excludes a small fraction of somatic mutations that overlap with the patient’s germline variant.
Since the fraction is small, the data censoring should only have a limited impact on the
analyses. Mutations were filtered for single-nucleotide mutations that overlapped the allowable
transcriptome. For computational ease but without loss of generality, cancer types with more
than 180,000 mutations after filtering were randomly downsampled without replacement to
180,000 mutations. Only SKCM met this criteria. The number of cancer somatic mutations after
filtering varied from ~25,000 to 180,000.

3.1.4.4 Simulated random mutations
The point mutation rate can vary considerably across regions of mammalian genomes
(reviewed in (116)). Therefore, we strove to model these nonuniformities in the simulated
mutation datasets. Since there are many different assumptions and parameters one can use to
simulate mutations, we choose two independent modelling approaches to tackle this problem.
We simulated one dataset of random mutations based on human pseudogene substitutions and
another dataset based on primate substitutions. The details are described below. The
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framework used to create the primate-based dataset was also used to train Combined
Annotation-Dependent Depletion (CADD), a method later used to draw inferences about this
and other datasets. Having two independent methods was one way we mitigated the circular
logic of using CADD for both data simulation and evaluation.
3.1.4.4.1 Mutations simulated from human pseudogenes
We developed a model of DNA sequence evolution based on human pseudogenes. We used a
variant of the General Time-Reversible (GTR) model that specified a substitution rate parameter
for each mutated nucleotide and their 5’ adjacent nucleotide context (N = (4*3)*4 = 48 rate
parameters). These context-dependent substitution rate parameters were derived from >1,700
human ribosomal protein pseudogene sequences comprising >700,000 bases(116, 117).
Approximately 50,000 mutations were simulated in the allowable transcriptome.
3.1.4.4.2 Mutations simulated from primate genome alignments
We next developed a model of DNA sequence evolution based on primate genome alignments.
We used CADD’s mutation simulator program to generate this dataset(118). Similar to the
pseudogene-based simulated dataset, mutations were simulated from a GRT-like model that
included a separate substitution rate parameter for CpGs and local (100kb) adjustment of
mutation rates (N = 5*3 = 15 rate parameters for each region). Mutations were filtered for singlenucleotide mutations that overlapped the allowable transcriptome. Approximately 43,000
mutations were retained after filtering. Since the simulator generated mutations in hg19, we did
not liftover the coordinates to hg38 in order to preserve the nucleotide context and local
mutation rate from which the mutations were generated.
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3.1.5 PZM deleteriousness
We used CADD (v1.6) to predict the deleteriousness of mutations(118). Since methods for
predicting deleteriousness of non-coding mutations are less mature than protein-coding
mutations, we only used protein-coding mutations for the deleteriousness analyses. Additionally,
mutations on chrM and chrY were excluded as these are not annotated by CADD. If a mutation
was mapped to multiple isoforms, we selected the most deleterious prediction. While this may
overestimate the deleteriousness of the datasets, since this approach was used for all datasets,
the relative difference in deleteriousness between datasets should remain unbiased. To avoid
potential issues with model misspecification, we annotated datasets using CADD models that
were trained on the same reference genome as the original dataset. The simulated random
dataset based on primate alignments and the cancer datasets were annotated with CADD
model GRCh37-v1.6; the remaining were annotated with CADD model GRCh38-v1.6.
We used two approaches to compare mutation deleteriousness between datasets. In the first
approach, we plotted the complementary cumulative density function (CCDF) of PHRED-scaled
CADD scores for each dataset, i.e., 𝑃𝑟(𝑋 ≥ 𝑥). Since we were most interested in differences in
the proportion of deleterious mutations which have large scores, CCDFs were an appropriate
method to use because they highlight differences in the right tails of distributions. The greater
the area under the CCDF, the higher the proportion of deleterious mutations in the dataset.
While the CCDF method is simple to interpret, it does not provide a way to find statistically
significant differences in deleteriousness nor does it control for technical covariates. Therefore,
we developed a second method to account for these limitations.
For the second approach, we compared the odds of detecting a deleterious mutation in one
dataset compared to another dataset while controlling for technical covariates using logistic
regression. A mutation was defined as deleterious if the PHRED-scaled CADD score ≥ 20. The
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CADD authors recommend cutoffs between 10-20 for defining deleterious mutations. Results
were generally similar for more stringent cutoffs. The data was fit using the model
𝑖𝑠_𝑑𝑒𝑙𝑒𝑡𝑒𝑟𝑖𝑜𝑢𝑠 ∼ 𝑑𝑎𝑡𝑎𝑠𝑒𝑡 + 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟 and logistic regression. The odds of
detecting a deleterious mutation in one dataset versus another was derived from the fitted
model coefficients.
𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟 was included since PZM mutation deleteriousness may be coupled
to VAF and gene expression level. Since we had already filtered all datasets to the same
allowable transcriptome, which genes the mutations were found in was likely not a technical
confounder so gene was not added to the model. The relative position of the mutation along the
coding sequence was also examined as a potential confounder. Within a dataset, for the CADD
score cutoff of interest (≥ 20), scores were generally similar in the first half of the gene body
compared to the last half. Therefore, the srelative position along the coding sequence was not
added to the model.
For PZM datasets, 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟 was derived from power simulations (see Step 1
PZM detection power). For the remaining datasets, since the variant VAFs were generally
orders of magnitude larger than PZMs VAFs (e.g., germline variants have VAFs ~50% or
~100%), we made the simplifying assumption that 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟 was 100% for all
variants.

3.1.5.1 PZM deleteriousness validation
The same mutation deleteriousness analysis pipeline was used for estimating PZM
deleteriousness in the independent PZM datasets except for the following minor change. When
calculating odds ratios, we dropped 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟 from the model. This is because
mutation detection power was unknown for the validation PZM datasets and could not be easily
estimated.
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For GTEx-based datasets, only PZMs from GTEx pass QC tissues were used. For datasets with
multiple tissues, putative prenatal PZMs were defined as PZMs found in two or more tissues
from the same donor. Putative postnatal PZMs were defined as PZMs found in a single tissue in
a donor. For TwinsUK, lymphoblast cell lines (LCLs) and blood were treated as a single tissue,
e.g., if a PZM was detected in just LCL and blood, the PZM was predicted to be postnatal. (Cell
line data in the Yizhak et al. and García-Nieto et al. datasets was already excluded by the
original authors.)
The following sections describe how the PZM validation datasets were processed.
3.1.5.1.1 TwinsUK dataset
3.1.5.1.1.1

Samples

We used the subset of TwinsUK with RNA-seq profiling data. This data was generated from the
Biomarkers of Ageing using whole Transcriptome Sequencing (EuroBATS) project. Library
preparation, sequencing and quality control are described in detail in (119). Briefly, RNA-seq
samples were prepared using a polyA, unstranded RNA-seq protocol (Illumina TruSeq) and
sequenced on Illumina HiSeq instruments (HiSeq 2000) with 49bp paired-end reads to a median
coverage of ~36M total reads.
We converted BAMs to FASTQ format using Picard Tool’s SamToFastq (v2.9.4)
(https://broadinstitute.github.io/picard/). Fastqs were then processed through the same
alignment and postprocessing steps as GTEx samples. PZM variant calling of TwinsUK
samples was performed in a similar manner as GTEx except that RIN was not used to remove
low quality samples as this information was not readily available. After our quality control, there
were 2,382 samples from 811 donors from 4 tissue and cell types (unexposed skin (derived
from a punch biopsy near the umbilicus), subcutaneous adipose (derived from the same punch
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biopsy), peripheral blood, and LCLs (derived from Epstein-Barr virus (EBV) transformation of Blymphocytes in peripheral blood).
3.1.5.1.1.2

Germline variant calling

Low read depth whole-genome sequencing was performed for a subset of TwinsUK donors as
part of UK10K(120). Library preparation, sequencing, quality control, alignment, and germline
variant calling are described in detail in (120). Briefly, Illumina paired-end DNA libraries were
generated from peripheral blood mononuclear cells and were sequenced on Illumina HiSeqs
with 100bp paired-end reads to an average coverage of 7×. Reads were aligned to GRCh37
using BWA (v0.5.9-r16). SNVs and indels were called using samtools/bcftools (v0.1.18-r579).
An additional subset of TwinsUK donors were re-sequenced to higher depth (> 30× coverage)
through a collaboration with Human Longevity, Inc(121). Sample preparation, sequencing and
analysis is discussed in detail in (122). Briefly, DNA was extracted from serum and sequenced
on Illumina HiSeq X instruments using 2x150 bp paired-end reads. Reads were mapped to
GRCh38 using Isaac Genome Alignment Software and variants were called using ISIS Analysis
Software (v.2.5.26.13)(122).
In total, germline variant calls were available for 405 donors. Using the definition that inherited
germline variants are the same in monozygotic twin pairs, germline variant calls were ostensibly
available for 532 donors.
3.1.5.1.1.3

PZM variant calling

We ran LachesisDetect on the TwinsUK samples to detect PZMs. An additional strand bias filter
was implemented that removed mutations whose alternative allele-containing alignments were
biased to a genome strand (Fisher’s exact test). Strand bias P-values were corrected using the
Benjamini-Hochberg procedure. Mutations with strand bias q-values ≤ 0.05 were retained. This
additional filter removed ~1.3% of the mutations. Approximately 1,700 PZMs were detected.
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3.1.5.1.2 Yizhak et al. dataset
PZMs were taken from Table S3 of (61). PZMs were detected in GTEx v7 data. RNA-MuTect
was used to call PZMs from bulk RNA-seq data. Using the columns of Table S3, VAF was
defined as Alternate. Count / (Alternate. Count + Reference. Count).
3.1.5.1.3 García-Nieto et al. dataset
PZMs were taken from Table S3 of (62). PZMs were detected in GTEx v7 data. A custom
method was used to call PZMs from bulk RNA-seq data. Using the columns of Table S3, VAF
was defined as alt_count/coverage.
3.1.5.1.4 Brazhnik et al. dataset
VCFs of the PZMs were obtained from the authors of (54) (personal communication). PZMs
were detected in DNA from single-cell human liver hepatocytes, liver stem cells, and organoids
derived from them. Putative PZMs were called using VarScan2, MutTect2, and
HapolotypeCaller. A PZM was considered detected if it was detected by three variant callers.

3.1.6 Selection
We used dN/dS to estimate selection pressure for each mutation dataset. dN/dS measures the
relative balance between adaptive and functionally constrained changes in protein-coding
genes. The statistic is widely used in species evolution and cancer evolution fields.
dN/dS was calculated using the R package dndscv (v0.0.1.0)(95) for missense and nonsense
mutations. The dN/dS of splicing mutations was not evaluated because exon junctions were
excluded during variant calling due to the possibility of higher false discovery rates. dndscv
provides three substitution models: 1) the simplest model with N = 2 rate parameters (transitions
and transversions); 2) an intermediate model with N = 12 rate parameters (one for each
combination of the six base substitutions on either the transcribed or non-transcribed strand);
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and 3) a complex model with N = 192 rate parameters (one for each combination of the six base
substitutions, transcription strand, and the sixteen possible bases immediately 5’ and 3’ to the
mutated base). We experimented with all three models. Based on the models’ Akaike
information criterion, potential for overfitting on the dataset sizes, and the importance of
capturing context-dependent heterogeneity in mutation rates across the transcribed exome, we
selected the intermediate 12-rate model (sm=“12r_3w”) for PZM datasets and the complex 192rate model (sm=“192r_3w”) for the non-PZM datasets. dndscv was run without reference
covariates (cv=NULL) since this parameter did not impact on the global dN/dS estimates.
Datasets were analyzed using the reference assembly originally used to call mutations
(refdb=“hg19” for the simulated random dataset based on primate alignments and the cancer
datasets and rebdb=“RefCDS_human_GRCh38.p12.rda” for all other datasets).
RefCDS_human_GRCh38.p12.rda was downloaded from
https://github.com/im3sanger/dndscv_data/blob/master/data/RefCDS_human_GRCh38.p12.rda
on 8/18/2020.
For improved accuracy, when donor-level information was available, we removed contiguous
substitutions, e.g., dinucleotide substitutions, within a donor prior to calculating dN/dS. This is
because complex substitutions can be better modeled with alternative models than those used
for single-base substitutions(95). This filter removed 0-2% of mutations from each dataset.

3.1.6.1 Definition of cancer genes
Table S3 Martincorena et al.(95) was used to define the set of cancer genes. These 369 highconfidence cancer genes were compiled using COSMIC classic genes and genes significantly
mutated in pan-cancer studies. The gene list was filtered to the allowable transcriptome. This
filter removed < 1% of the genes. The set of non-cancer genes was defined as the set
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difference of all genes in the allowable transcriptome minus the cancer genes in the allowable
transcriptome.
Due to the large size of the germline variant dataset, only variants on chr22 were analyzed. The
cancer and non-cancer gene sets were also filtered to chr22 for the germline variant dataset.

3.1.7 Germ cell PZM analyses
3.1.7.1 PZM variant filtering
In a prerequisite analysis, we observed that donors who were not genotyped had slightly more
gonosomal mutations than genotyped donors after accounting for other technical and biological
covariates. Additionally, testis PZMs from non-genotyped donors had slightly larger VAFs than
genotyped donors. These results suggest that mutations from non-genotyped testis donors may
have a higher contamination of inherited germline variants. To avoid systematic bias among the
donors and to minimize contamination from false positive inherited germline variants, we
excluded non-genotyped testis donors from germ cell PZM analyses.

3.1.7.2 Sperm sequencing experiments
3.1.7.2.1 Study design
An overview of the sperm PZM study design is shown in Figure 3-1. Ejaculated sperm and
venous blood were collected from a Caucasian individual. Sperm samples had normal sperm
density, sperm motility and morphology.
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Figure 3-1: Sperm PZM study design. Genomic DNA was extracted from blood of a male
donor and subjected to standard exome sequencing. Genomic DNA was extracted from six
pools of sperm from the same donor with approximately 200 sperm in each pool. These six DNA
samples were amplified using MALBAC followed by standard exome sequencing library
preparation and sequencing. WES = whole exome sequencing. MALBAC = Multiple annealing
and looping–based amplification cycles.
3.1.7.2.2 Sperm staining and FACS
Fresh ejaculates were diluted 1:1 with sperm medium (EmbryMax HTF, Millipore) and incubated
for 30 minutes at 36°C. After this incubation period, 1 ml of the diluted sperm sample was
stained using the LIVE/DEAD Sperm Viability Kit (Invitrogen). 5 µl of a 1:50 dilution in sperm
medium of SYBR-14 stock solution was added to the diluted sperm sample and the mixture was
incubated for 10 minutes at 36°C. Next, 5 µl of the propidium iodide (PI) stock solution was
added to mixture and incubated for another 10 minutes at 36°C.
Sperm samples were then selectively sorted via fluorescence-activated cell sorting (FACS) into
96 well plates (~200 sperm cells per well) and 5 ml Falcon tubes based on their staining, i.e.,
positive for SYBR-14 and PI (i.e., dead cells) or positive for SYBR-14 (i.e., live cells). The
live/dead ratio of the sperm cells was recorded at the start of the FACS session as well as at the
end of the session.
3.1.7.2.3 DNA extraction from sorted sperm cells
DNA was extracted from three pools of live sperm and three pools of dead sperm for a total of
six pools. While live/dead status was used during sample preparation, due to the limited number
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of PZMs detected in each group and the large overlap of PZMs detected in live and dead sperm
groups, the groups were combined during analysis.
DNA was extracted using a lysis protocol as initially described in (123). Briefly, a stock solution
of a lysis buffer was added to the PBS containing the sorted sperm cells resulting in mixture that
had a final concentration of 1 M Tris·Cl, pH 8.0, 3M NaCl, 0.5 M EDTA and 20% SDS. To this
mixture, DTT and proteinase K were added to a final concentration of 40 mM DTT and 10 mg/ml
proteinase K and incubated overnight at 50°C. The following day, 2 volumes of ice-cold EtOH
were added to the sample and a precipitation was performed for 2 hours at -20°C. Next, the
DNA was pelleted by centrifugation for 20 minutes at 15,500xg at room temperature. The
supernatant was removed and the DNA washed with 75% EtOH. The DNA was pelleted by
centrifugation for 10 minutes at 15,500xg at room temperature. Finally, the supernatant was
removed and the pellet was air-dried and dissolved in 50 µl dH20.
3.1.7.2.4 Whole genome amplification and exome sequencing library preparation
We used MALBAC amplification(16) to prepare up to 1.5 µg of DNA from each pool of sperm
using a kit according to the manufacturer’s protocol (Yikon Genomics). Exome library
preparation was performed according to the manufacturer’s protocol (Illumina Nextera Rapid
Capture Exome kit, Illumina) using 50 ng of pre-amplified MALBAC reactions or DNA extracted
from blood. Size distribution of the enriched libraries was assessed by analyzing 1 µl of each
library on an Agilent 2100 Bioanalyzer. The resulting six MALBAC libraries and standard blood
library were sequenced by Illumina sequencing with 2x101 bp paired-end reads (sperm: 14M 24M mapped reads; blood: 87M mapped reads).
3.1.7.2.5 Alignment and mutation calling
The quality of the raw sequencing data was assessed with FastQC
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The first 20 bp of the reads were
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trimmed using TrimGalore (v0.4.5)
(https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Resulting reads were
processed according to the GATK best practices and were mapped to the hg19 reference
genome using BWA-MEM (v0.7.13)(93) and Picard Tools (v2.8.3)
(http://broadinstitute.github.io/picard/). To achieve a high quality mutation call set, only properly
mapped reads (flag 0x2) and alignments with NM ≤ 3 were retained. Single-nucleotide PZMs
were called with MuTect (v1.1.4)(124). Each sperm sample was run against the blood sample
as a reference to identify sperm-specific mutations.
3.1.7.2.6 Validation of sperm PZMs
To validate sperm PZMs, amplicon sequencing of 144 regions was performed using Custom
TargetGxOne amplicon primers and library preparation by GENEWIZ (www.genewiz.com).
Libraries were sequenced on Illumina MiSeq with 2x250 bp paired-end reads. Reads were
aligned using BWA and Picard Tools. Data at mutated loci was collected from the resulting BAM
files with SAMtools mpileup(76). Variant calling was performed using VarScan (v2.4.2)(125). A
PZM was defined as validated if the identical nucleotide change was detected at the same
position as predicted by MuTect and the nucleotide change was not observed in blood. Only
validated PZMs were used for downstream analyses (N = 93 PZMs). Validated PZMs were lifted
over to hg38 and filtered to the allowable transcriptome (N = 84 PZMs).

3.1.7.3 gnomAD allele frequencies of mutations in germ cell mutation datasets
Since allele frequencies are specific to a population of interest, we generated a conservative
meta-population by defining the population minor allele frequency as the maximum allele
frequency observed across all populations (except founder-like populations) in gnomAD.
Mutations that were not observed in gnomAD were defined as novel and represent mutations
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with allele frequencies < 1E-5. All datasets were filtered to the same allowable transcriptome to
make equatable comparisons across the datasets.
The amount of contamination from inherited germline variants in a dataset can artefactually
reduce the percent of novel mutations. Since all datasets were filtered against the donors’
germline variants, germline variant contamination should be limited, although differences in
filtering efficacy among datasets may still exist. Additionally, in an effort to make the variant
calling conservative, PZMs from testis (and all other GTEx tissues for that matter) also had
germline variants from the cohort’s 948 donors removed from all samples. Thus, the tesis PZM
dataset may be missing mutations that occur as PZMs in some individuals and inherited
germline variants in other individuals. This would increase the percent of novel mutations in the
testis PZM dataset. Since the next germ cell time point, i.e., the sperm PZM dataset, did not
have this extra level of filtering and was still enriched for novel mutations compared to de novos,
we expect this technical artefact to be small.

3.1.7.4 Calculation of mutation rates during gametogenesis
We used a similar method as Rahbari et al.(103) to calculate mutation rates during
gametogenesis. Gametogenesis in males can be partitioned into three stages: prior to
primordial germ cell (PGC) specification, after PGC specification, and after puberty.
To calculate the mutation rate after puberty, we used the following linear model to fit the number
of germ cell-specific PZMs in a donor using Poisson regression:
# 𝑔𝑒𝑟𝑚 𝑐𝑒𝑙𝑙 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛𝑠 ~ 𝐴𝐺𝐸 + 𝑠𝑎𝑚𝑝𝑙𝑒_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟
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where 𝐴𝐺𝐸 was the donor’s age and 𝑠𝑎𝑚𝑝𝑙𝑒_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟 was the average
mutation detection power of simulated mutations in the donor’s testis sample. The 𝐴𝐺𝐸 model
coefficient (in units of # of germ cell-specific mutations / year) was divided by 23 (the
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approximate number of cell divisions per year)(103) to get the number of germ cell-specific
mutations / division.
We next calculated the post-PGC mutation rate. There are approximately 24 cell divisions
between post PGC specification and puberty(103). Thus the number of germ cell-specific
mutations that are observed at puberty represent the mutations that occurred during this stage
of gametogenesis. Using the previous model, we estimated the number of germ cell-specific
mutations at puberty using 𝐴𝐺𝐸 = 14 (an approximate age for male puberty) and
𝑠𝑎𝑚𝑝𝑙𝑒_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟 =
𝑀𝑒𝑑𝑖𝑎𝑛(𝑠𝑎𝑚𝑝𝑙𝑒_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟 𝑡𝑒𝑠𝑡𝑖𝑠 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 ). The mutation burden was divided
by 24 cell divisions to calculate the mutation rate.
To calculate the pre-PGC mutation rate, we fit the number of gonosomal PZMs in a donor to a
Poisson distribution. The expected number of gonosomal PZMs in a donor was divided by 10
cell divisions (the approximate number of cell divisions before PGC specification)(103) to
calculate the mutation rate.

3.1.7.5 Germline surrogate tissue analysis
We fit the following general linear mixed effects logistic regression model to predict whether a
gonosomal PZM was detected in a somatic tissue given information about the gonosomal PZM
in the germ cell and the somatic tissue.
𝑖𝑠_𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑. 𝑛𝑜𝑛_𝑡𝑒𝑠𝑡𝑖𝑠_𝑡𝑖𝑠𝑠𝑢𝑒 ~ tissue + log10 𝑉𝐴𝐹. 𝑡𝑒𝑠𝑡𝑖𝑠_𝑡𝑖𝑠𝑠𝑢𝑒
+ log10 (𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒. 𝑛𝑜𝑛_𝑡𝑒𝑠𝑡𝑖𝑠_𝑡𝑖𝑠𝑠𝑢𝑒 + 1) + 𝑝𝑜𝑤𝑒𝑟 + 𝐴𝐺𝐸
+ (1|𝑑𝑜𝑛𝑜𝑟_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛)
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where 𝑑𝑜𝑛𝑜𝑟_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛 was modeled as a random effect and 𝑝𝑜𝑤𝑒𝑟 was the power to detect a
mutation of 𝑉𝐴𝐹 = 𝑉𝐴𝐹. 𝑡𝑒𝑠𝑡𝑖𝑠_𝑡𝑖𝑠𝑠𝑢𝑒 and 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒 = 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒. 𝑛𝑜𝑛_𝑡𝑒𝑠𝑡𝑖𝑠_𝑡𝑖𝑠𝑠𝑢𝑒 in the
somatic tissue.
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The model was fit using the glmer function from the R package lme4 (v1.1-26)(126) and used
option nAGQ=9 to improve the accuracy of the numerical integration.
Importantly, the model controlled for technical covariates such as expression level in the
somatic tissue of interest. The predictions of the model, i.e., the probability of detecting a
gonosomal PZM in a somatic tissue, are the cumulative effect of both the interesting, biological
covariates and the nuisance, technical covariates of the study design. In order to focus on just
the biological features, we analyzed the model coefficients, i.e., the odds of detecting a
gonosomal PZM in one tissue versus another. Since blood is arguably the most common
biospecimen collected for genetic studies and genetic counseling, we compared all tissues to
blood.

3.2 Results
3.2.1 PZMs are pervasive and highly variable among donors and
tissues
We ran LachesisDetect on 17,382 samples derived from 948 donors across 54 diverse tissues
and cell types from the final version of GTEx. Approximately 57,000 PZMs were detected with
PZM VAFs as low as 0.04% and a median PZM VAF of 0.5. 100% of the donors and 77% of the
tissue samples had detectable mosaicism. The median number of PZMs per donor was 49
(range = [1, 418]) and the median number of PZMs per tissue sample was 2 (range = [0, 71])
(Figure 3-2).
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Figure 3-2: Summary of PZMs detected in GTEx. N refers to the total number of passed
quality control samples. Validation rate is the average FDR across experimental and in silico
validation experiments.
We defined the mutation burden of a sample as the number of PZMs in the sample normalized
by its transcriptome size (i.e., the number of Mbs with ≥ 20× coverage). The median mutation
burden per tissue ranged from 0.03 PZMs/Mb in cerebellar hemisphere to 0.47 PZMs/Mb in
liver. Strikingly, the observed mutation burden was more variable within a tissue than between
tissues (mean median absolute deviation within a tissue = 0.07 PZMs/Mb; median absolute
deviation across tissues = 0.02 PZMs/Mb) (Figure 3-3).
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Figure 3-3; Distribution of tissue PZM burdens. Each datapoint represents a single tissue
sample and is colored by tissue. Median PZM burden in a tissue denoted by horizontal black
line. Tissues are sorted by increasing median PZM burden. Only samples with at least one
mutation are plotted due to the log axis. Tissue medians computed with all samples. Tissues are
colored using the GTEx coloring convention (see Figure 5-1 for a complete legend).

3.2.1.1 PZM burden is correlated with biological and technical variables
The observed number of mutations in a sample reflects both biological and technical sources of
variability. We fit a linear model to partition the mutation burden variation. The final model with
eight covariates explained 48% of the variation in mutation burden. Significant sources of
variation were main effects from age, tissue, mutation detection power, and batch and
interactions of tissue with age, sex, and ancestry (Figure 3-4.a).
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Figure 3-4: PZM burden is correlated with biological and technical variables. a. F test
statistics for each covariate in the mutation burden model. As F test statistics incorporate
degrees of freedom, they allow facile comparisons of explanatory power between variables with
many degrees of freedom (e.g., batch) and variables with few degrees of freedom (e.g., age).
Coefficients of tissue-ancestry interactions (Caucasian used for reference level) (b), tissue-sex
interactions (female used for reference level) (c) and tissue-age interactions (d). Tissues are
colored using the GTEx coloring convention (see Figure 5-1 for a complete legend). Dashed
vertical lines at x = 0 denote no association between mutation burden and interaction. In d,
tissues with significant interaction terms are annotated with triangles and labeled in the legend.
Dashed horizontal line at y = - log10 0.05 = 1.3 denotes nominal significance. e. Variation
explained by donor effects in generalized linear mixed models of mutation burden. Three
separate models using just African American donors, just Caucasian donors, and all donors
combined were fit. N refers to the number of donors used in the model. Error bars represent
95% confidence intervals.
The interaction terms in the model identified tissues with significant associations with selfreported ancestry, sex, and age (Figure 3-4.b-d). 8.3% (4/48) of tissues showed significant
associations with self-reported ancestry, including, as expected, a much lower burden of
98

mutation in sun-exposed skin in African Americans and Asians compared to Caucasians(61).
Interestingly, cancer types associated with these tissues also had lower rates of incidence in
African Americans and Asians compared to Caucasians(127). This suggests that variation in
PZM burden across ancestries may partially explain cancer risk. Males had lower burden in skin
related samples (sun-exposed skin and fibroblasts) compared to females, although this effect
was not as strong as the ancestry interactions. Age was positively associated with 15% (7/48) of
tissues and was the strongest for sun-exposed skin, esophagus – mucosa and liver. Power may
have been too low to detect some associations, e.g., there were few young brain donors and
non-Caucasian donors.
By design, most donors had multiple tissues profiled in GTEx. This provided an opportunity to
estimate the amount of variation in mutation burden explained by donor effects. After adding
donor ID as a random effect to the model, we estimate that only 2% of variation in mutation
burden is explained by donor effects (Figure 3-4). More variation was explained in African
American donors, however this was not statistically different from Caucasian donors. Larger
sample sizes may have better power to detect differences. These results suggest that other
factors like age and tissue are better predictors of mutation burden than donor information. The
inability of the models to explain all variation imply there are additional factors that are
associated with mutation burden and/or stochasticity plays a major role in mosaicism(34, 128).

3.2.2 Mutation spectra is variable across tissues and reflect known
biological processes
Mutation mechanisms mutate the human genome with chararacteric mutational signatures(112).
Thus, the observed mutation spectra in a sample can provide insight on the types and relative
frequencies of the unobserved mutation processes that occurred. We estimated the contribution
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of canonical mutation signatures for each tissue. However due to the relatively low number of
detected mutations, mutation spectra were reliably deconstructed for only four tissues/cell types
(sun-exposed skin, unexposed skin, fibroblasts, and lymphocytes) (Figure 3-5). The mutations
were resolved into mutational signatures associated with age (all tissues) and ultraviolet light
exposure (skin-related tissues), consistent with expectations and previous studies(12, 43, 49).

Figure 3-5: Percent of mutations attributed to single nucleotide substitution mutation
signatures across tissues. For all tissues except sun-exposed skin, the majority of mutations
are predicted to be from age-related mutagenic processes (purple shades). All skin-related
tissue/cell types have evidence of mutations from UV light exposure (red shades), with sunexposed skin having the greatest percentage. Only tissues with reconstruction accuracy ≥ 95%
are shown. SBS = substitution mutation signature.
For a higher powered, but coarser-grained analysis of mutation spectra, we assessed the
frequency of the six base substitutions across all 48 tissues (Figure 3-6). Mutation spectra was
highly variable across tissues suggesting that mutational mechanisms and their relative activity
may vary across the human body. C>T was the most common mutation type across tissues
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whereas C>G and T>A were the least common. Hierarchical clustering with bootstrap
resampling of the mutation types revealed two significant large clusters: cluster A (marked by
depleted T>G) and cluster B (marked by elevated T>G). Cluster membership was associated
with mutation burden: tissues in cluster A had higher mutation burden than tissues in cluster B,
suggesting the mutation spectra (and their underlying mutation mechanisms) are coupled to the
frequency of mutagenic events (P-value = 3.8E-2, Mann-Whitney U test). Additionally, Cluster B
was enriched with neural ectoderm tissues compared to cluster A (P-value = 7.7E-6, Fisher’s
exact test).

Figure 3-6:

Mutation spectra of PZMs across tissues.At first glance, the clustering may

have been driven by technical factors as brain samples (excluding Brain – Cortex and Brain –
Cerebellum samples) were processed from frozen tissue whereas the remaining samples were
predominantly processed from PAXgene preserved tissue. However upon further inspection, we
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found that mutation spectra was not associated with preservation method (see Preservation
method does not likely affect mutation burden and spectra). Additionally, the clustering is likely
not confounded by differences in nucleotide composition across tissue transcriptomes as these
differences were very small (standard deviation of %CG content = 0.1%).
Lastly, tissues whose mutation spectra is dissimilar to germline mutation spectra (e.g., tissues in
cluster B) suggest that the forces that create and modify these patterns of mutation spectra
(e.g., transcription-coupled repair and selection) may be different in the soma and
germline(129).

3.2.2.1 PZM features recapitulate known biology
We next compared the mutation burden in sun-exposed skin versus unexposed skin as a
function of self-reported ancestry. Due to the paired nature of the study design, this analysis is
well controlled for technical and biological variables that may vary across groups. As expected,
Caucasisans had a higher mutation burden in sun-exposed skin compared to unexposed skin
(P-value < 2E-16, Mann Whitney U test) whereas there was no detectable difference in African
Americans. Additionally, Caucasians had a higher mutation burden in sun-exposed skin than
African Americans, but no difference in burden in unexposed skin (P-values = 5E-12, not
significant (NS), respectively, Mann Whitney U test) (Figure 3-7.a). Sun-exposed skin had a
greater fraction of both C>T and CC>TT PZMs than non-skin tissues (Figure 3-7.b,c). As
darker skin contains more photoprotective melanin(130) and UV mutagenesis results in C>T
and CC>TT mutations(50), these results support the hypothesis that the PZMs were caused by
UV damage. Together, they add further evidence that LachesisDetect produces high-quality
mutation predictions.
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Figure 3-7: Skin PZMs recapitulate known biology. a. Joint distribution of PZM mutation
burden in sun-exposed skin versus unexposed skin as a function of self-reported ancestry. Y =
X line denotes equal burden across the two skin regions. Paired data used for the joint
distribution (scatterplot) whereas all data (paired and unpaired) used for the univariate
distributions (boxplots). Top and bottom of the boxes denote first and third quartiles,
respectively; horizontal black lines denote median; whiskers denote 1.5× the interquartile range;
and outliers are plotted with transparency to disambiguate overlapping values. b. Fraction of
single-nucleotide mutations that are C>T in sun-exposed and non-skin tissues. c. Fraction of
dinucleotide mutations that are CC>TT in sun-exposed and non-skin tissues. N.S. = not
significant.
Another well supported mosaicism phenomenon is CHIP(48). CHIP PZMs were detected in
blood and EBV-transformed lymphoblasts at expected rates (see Prevalence of expressed
CHIP mutations)(42). This result provides additional evidence that the PZM call set is of high
quality and has moderate sensitivity. To our knowledge, this is the first time CHIP mutations
have been detected at the RNA level and thus suggests these mutations may have a direct
functional role in clonal growth.
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3.2.3 The developmental origins of prenatal PZMs
3.2.3.1 Multi-tissue PZMs exhibit prenatal properties
We defined a multi-tissue PZM as a PZM that was detected in at least two tissues from the
same donor. Since the PZM mutation burden was relatively low across tissues (Figure 3-3) and
PZMs are predominantly under neutral selection(95), we hypothesized that a multi-tissue PZM
is the result of a single PZM that occurred in a common ancestor of the mutated tissues. Since
the common ancestors of any set of GTEx tissues (excluding cell lines) occurred before the end
of organogenesis, multi-tissue PZMs may have originated prenatally. Consistent with this
hypothesis, we found a significant positive correlation between the VAF of a multi-tissue
mutation and the fraction of the donor’s tissues with the PZM (Figure 2-7). Donor age was not
significantly associated with multi-tissue mutation burden for the majority of tissues (Figure 2-7).
See section Evidence suggesting multi-tissue variants occurred prenatally for further details.
Together, these results suggest multi-tissue PZMs may have occurred prenatally. We denote
these mutations as [putative] prenatal PZMs.

3.2.3.2 The phylogenetic history of prenatal PZMs can be reconstructed
Since a PZM is inherited by all descendent cells, we hypothesized that the phylogenetic history
of PZMs could be reconstructed. We developed a method called LachesisMap to reconstruct
the evolutionary history of prenatal PZMs (see Algorithm for reconstructing PZM phylogenies
(LachesisMap)). Briefly, the method takes as input a directed rooted tree representing the
developmental relationships among the tissues and a list of prenatal PZMs. The method maps
the PZMs to tree edges while accounting for differential mutation detection power across the
genome, human body, and developmental tree. The algorithm outputs a list of tree edge weights
that represent the estimated probability of a PZM occurring in that spatiotemporal window of

104

development. Several lines of evidence suggest the mapped PZMs are likely correct (see PZM
phylogeny validation).

3.2.3.3 PZM burden and spectra vary throughout prenatal development with the
majority of mutations occurring during early embryogenesis
To determine when and where PZMs occur in prenatal development, we used LachesisMap to
map the catalog of putative prenatal PZMs to the full tissue tree (Figure 3-8.a, section
Derivation of developmental tissue trees). The catalog was comprised of 6,810 PZMs predicted
to have occurred from 1,864 prenatal mutation events. The mutation burdens across
developmental time and space (as estimated by the edge weights) were highly variable, ranging
from 0.04% to 23% and followed an exponential distribution (P-value = 0.56, Kruskal-Wallis
test). The top two edge weights, representing 41% of prenatal mutation events, were the zygote
to gastrula transition and the ectoderm to neural ectoderm transition, suggesting that the
majority of detectable prenatal mutations occur during early embryogenesis. Of critical note, the
edge mutation burdens were not explained by differential edge mapping power across the
developmental tissue tree as the mapping method adjusted for differential power (see observed
mutation edge weights are independent of edge mapping power). These results are consistent
with recent work by Coorens et al. in which the mutation rate of human embyronic PZMs was
found to decrease over time(59).
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Figure 3-8: Mutation burden and spectra of prenatal PZMs across time and space. Top:
characteristics of PZMs mapped to the full tissue tree; bottom: germ layer tree. a and c.
Prenatal PZM mutation burden as a function of time and space. Edge color represents the
percent of prenatal PZMs that mapped to that period in development. Thick gray edges are
edges with limited mutation detection power.b and d. The predominant mutation type as a
function of time and space. Edge color represents the predominant mutation type of mutations
that mapped to that edge. Thin gray edges are edges with no predominant mutation type (i.e.,
mutation types were tied). See Figure 2-9, Figure 2-10 for the full set of vertex labels. GTEx
tissue vertices (leaves) colored with the GTEx coloring convention (see Figure 5-1 for a
complete legend)
We next asked if the mutational processes, as proxied by their mutation spectra, varied over
development by comparing the mutation spectra across edges. Strikingly, while C>T was the
106

most common mutation type in the full mutation call set (prenatal and postnatal PZMs), C>T
was the most frequent mutation type for only a minority of edges (4 of 16 edges with adequate
power) (Figure 3-8.b). This suggests that the mutational mechanisms may vary over both pre
postnatal timescales. There was a strong dichotomy between ectoderm lineages, which tended
to have T>G mutations, and endoderm and mesoderm lineages which tended to have C>A
mutations.
In addition to global changes in mutation across the tree, we also examined local changes by
comparing mutation spectra between sibling edges (i.e., local spatial differences) and parentchild edges (i.e., local temporal differences) (Figure 3-9.a). Significant spatial and temporal
variation was detected during gastrulation and in ectodermal lineages. Differences in mutation
spectra across developmental space (N = 4/8 (50%) sibling edge comparisons) occurred at
similar rates as differences along developmental time (N = 8/18 (44%) parent-child
comparisons) (P-value = 1.00, Fisher’s exact test).
Together, these results suggest that the mutational mechanisms that operate during
development may vary across space and time. Although published data is limited, others have
detected variation in mutation spectra in fetal stem cells in humans (131) and during early
embryogenesis and gametogenesis in mice(132). Due to the limited number of mapped prenatal
PZMs on some edges, power may have been too low to detect significant differences in
mutation spectra.
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Figure 3-9: Local variation in mutation spectra across developmental space and time.
Each facet represents the mutation spectra observed in a parent edge (leftmost barplot) and all
children edges. Statistically significant differences in mutation spectra are annotated with “*”. a.
Full tissue tree. b. Germ layer tree.
We repeated these analyses using the simplified germ layer tree and observed similar results as
the full developmental tissue tree. This result suggests that the development tree definition does
not substantially affect the results.( Figure 2-20.c,d, Figure 3-8.c,d, Figure 3-9.b).
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3.2.4 The functional consequences of PZMs across the human
lifespan
In the field of germline variation, new germline mutations arise neutrally(133). However with
selection pressure (and genetic drift), the population allele frequency will change over time.
Since negative selection removes germline variants from the population, rarely observed
germline variants are predicted to be deleterious and common variants are predicted to be
benign. Thus aberrations from the neutral model imply functional consequences. We used a
similar framework to evaluate the functional consequences of PZMs.
We hypothesized that all newly created PZMs have the same distribution of functional
consequences. However, due to variation in selection pressure across time and space, different
PZMs are selected for or against resulting in a different distribution of functional consequences
in the final observed population. Thus if variation in PZM functional predictions across different
classes of PZMs is observed, then it implies that PZMs may have functional consequences.
We estimated mutation deleteriousness and selection pressure as proxies of mutation function
for prenatal and postnatal PZMs and then asked if there were differences across spatial and
temporal dimensions. To better understand the magnitude of these estimates, we compared
them to other classes of genetic variation, e.g., germline variation and somatic mutations in
cancer.

3.2.4.1 Prenatal low VAF PZMs may be the most deleterious class of genetic
variation
We first asked if PZM deleteriousness varied across time by comparing prenatal and postnatal
PZMs deleteriousness. We used CADD, a well-established method to estimate mutation
deleteriousness(118). We speculated that deleteriousness may be confounded by PZM VAF, so
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we first determined if deleteriousness varied with VAF within each PZM group (Figure 3-10).
For postnatal PZMs, no difference in deleteriousness was detected between low and high VAF
mutations (odds ratio = 0.97, P-value = 0.24). However, for prenatal PZMs, low VAF PZMs were
more deleterious than high VAF PZMs (odds ratio = 1.9, P-value = 2.6E-7) (Figure 3-11).

Figure 3-10: Low VAF prenatal PZMs are the most deleterious class of PZMs. PHREDscaled CADD score distributions of prenatal and postnatal PZMs stratified by VAF. Distributions
with larger areas under the curve have a larger fraction of deleterious mutations.

Figure 3-11: Relative odds of detecting deleterious PZM mutations as a function of VAF
and time. Gray bars: comparisons across time. Green bars: comparisons across VAF bins.
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Vertical line at odds ratio = 1 indicates no difference in odds of detecting deleterious mutations
across groups. Error bars represent 95% confidence intervals.
Since VAF was found to be confounded with deleteriousness, we compared prenatal and
postnatal PZM deleteriousness as a function of VAF. Intriguingly, we found that for low VAF
PZMs, deleteriousness decreased over time (odds ratio = 0.58, P-value = 1.4E-9), but remained
constant for high VAF PZMs (odds ratio = 1.13, P-value = 0.15) (Figure 3-11). This result
suggests that the fate of PZMs that occur early in development may be constrained by their
functional consequences: more deleterious mutations may be less likely to be transmitted to
many cells of the body since they occur in fewer cells (i.e., have lower VAFs). The data also
suggests that deleterious mutations may actually be beneficial to a growing fetus so long as the
mutation remains in a small fraction of cells. We speculate that deleterious prenatal PZMs that
are high VAF are not observed because they may lead to abnormal fetal growth and would thus
result in an abnormal adult who would have been excluded from GTEx.
We next asked if deleteriousness varied across the developing human body. Using the prenatal
PZMs mapped to the germ layer tree, we detected no differences in deleteriousness among the
gastrula and germ layers (Figure 3-12, Figure 3-13). However, due to the small sample size,
we may have had limited power to detect differences.
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Figure 3-12: PHRED-scaled CADD score CCDFs of prenatal PZMs by primordial tissue
and VAF.

Figure 3-13: Relative odds of detecting deleterious PZM mutations as a function of VAF
and primordial tissue. Odds of detecting deleterious mutations in a given primordial tissue
compared to gastrula for low VAF PZMs (left) and high VAF PZMs (right). Horizontal line at
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odds ratio = 1 indicates no difference in odds of detecting deleterious mutations in a given
primordial tissue compared to gastrula. Error bars represent 95% confidence intervals.
Lastly, we asked if deleteriousness varied across the adult human body by comparing postnatal
PZMs in each adult tissue. PZM deleteriousness was fairly similar across tissues (Figure 3-14),
however there were a few exceptions. PZMs in 6/48 (13%) tissues were significantly less
deleterious than the average tissue and 3/48 (6%) tissues were more deleterious. When
analyzed together, the PZMs from all brain regions were also more deleterious than average (Pvalue = 0.02, Fisher’s exact test). Interestingly, the tissues that contained more deleterious
mutations were tissues composed of a large fraction of postmitotic cells. In contrast, tissues that
contained less deleterious mutations tended to be tissues that rely on renewal from
differentiated cells (liver, pancreas, and salivary gland)(134). This suggests that maintenance of
genome function within a tissue may be coupled with its tissue homeostasis strategy.

Figure 3-14: Histogram of the odds of detecting deleterious postnatal PZMs in each
tissue compared to the average tissue. Tissues are colored using the GTEx coloring
convention (see Figure 5-1 for a complete legend). Tissues with odds ratios significantly
different from 1 (at q-value ≤ 0.05) are marked with “*” and labeled with their name. Vertical
dashed line at odds ratio = 1 indicates no difference in odds of detecting deleterious mutations
compared to the average tissue. Low and high VAF postnatal PZMs were combined within a
tissue since VAF was not associated with postnatal PZM deleteriousness.
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To understand the relative impact of mutation deleteriousness, we compared the
deleteriousness of PZMs to other classes of genetic variation: 1) random mutations (simulated
from two different models of neutral evolution), 2) standing germline variation (from gnomAD, a
comprehensive database of germline genetic variation(114)), 3) inherited de novo mutations
from cases and control probands (from denovo-db, a curated database of de novo
mutations(113)) and 4) somatic mutations observed in cancer (from TCGA, a comprehensive
database of cancer somatic mutations)(115). To compare the different genetic variation
datasets fairly, we only used single-nucleotide variants that overlapped the allowable
transcriptome.
Surprisingly, low VAF prenatal PZMs were the most deleterious class of genetic variation
(Figure 3-15, Figure 3-16). The next most deleterious classes were high VAF prenatal PZMs,
postnatal PZMs, and de novo mutations in cases. These classes were followed by somatic
cancer mutations, simulated neutral mutations, and de novo mutations in controls. The least
deleterious class was inherited germline variants, with deleteriousness inversely proportional to
the minor allele frequency. In summary, excluding classes related to disease (de novo
mutations in cases and somatic mutations in cancer), there was an inverse relationship between
mutation deleteriousness and mutation frequency in a population (i.e., with PZMs being the
rarest (only present in a subset of cells in an individual) and common germline variants being
the most common (in many individuals)). This suggests that selection pressure may be different
across classes of genetic variation. We investigated this hypothesis in section The selective
constraint on the exome throughout the human lifespan.
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Figure 3-15: PHRED-scaled CADD score CCDFs of PZMs versus other classes of
genetic variation. To increase readability of the comparisons, the same PZM data is plotted on
each subplot. Distributions with larger areas under the curve have a larger fraction of
deleterious mutations.

Figure 3-16: Relative odds of detecting deleterious PZM mutations compared to
different classes of genetic variation Left: odds of detecting deleterious mutations in a given
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dataset compared to prenatal low VAF PZMs. Middle: odds relative to prenatal high VAF PZMs.
Right: odds relative to postnatal PZMs. Vertical line at odds ratio = 1 indicates no difference in
odds of detecting deleterious mutations in a given dataset compared to the reference dataset.
Error bars represent 95% confidence intervals.
Similar results were observed using alternative metrics for deleteriousness (SIFT(135) and
PolyPhen(136)) (data not shown).
3.2.4.1.1 The high fraction of deleterious PZM mutations is recapitulated in multiple
validation datasets
To determine if the PZM deleteriousness results were generalizable, we compared the
deleteriousness of GTEx PZMs with PZMs from four other datasets (TwinsUK (unpublished
work), García-Nieto et al.(62), Yizhak et al.(61), and Brazhnik et al.(54)). Importantly, these
validation datasets used a variety of different data sources, nucleic acid types, and variant
calling algorithms (see Table 3-1 for summary). A detailed description of the validation results
are in section PZM deleteriousness validation. Briefly, the deleteriousness patterns were
replicated in three of the four validation datasets (Figure 5-7, Figure 5-8, Figure 5-9, Figure
5-10, Figure 5-11). Deleteriousness patterns observed in García-Nieto et al. were dissimilar to
all other datasets. We suspect this may be due to germline variant contamination and not
biological differences in deleteriousness. Therefore, we have high confidence that the
deleteriousness observations described herein may reflect global properties of PZMs rather
than technical artifacts.
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Table 3-1:
Summary of datasets used to validate deleteriousness patterns and
whether results were validated. NA = Not applicable.
This
study

TwinsUK

García-Nieto
et al.

Yizhak et al.

Brazhnik et
al.

Reference

NA

Unpublished

(62)

(61)

(54)

Uses RNA

Yes

Yes

Yes

Yes

No

Uses GTEx
data

Yes (v8)

No

Yes (v7)

Yes (v7)

No

Variant calling
method

Lachesis

Lachesis

Custom
method

RNA-MuTect

VarScan2,
MuTect2, &
HaplotypeCall
er

Results
validated

NA

Yes

No

Yes

Yes

3.2.5 The selective constraint on the exome throughout the human
lifespan
We next asked if selection pressure on PZMs varied across the human lifespan and
contextualized the strength by comparing selection pressure across different classes of genetic
variation. We used dN/dS, a normalized rate of nonsynonymous to synonymous mutations, to
estimate selection pressure. dN/dS is frequently used to estimate selection in species
evolution(137, 138) and is becoming increasingly more common in cancer biology(95) and
mosaicism fields(49, 139). For completeness, we show dN/dS estimates for PZM nonsense
mutations; however these estimates may be underestimated due to nonsense mediated decay.

3.2.5.1 Positive selection may drive clonal growth of postnatal PZMs, especially
in cancer driver genes.
We first determined if PZM VAF and the genes used for calculating dN/dS confounded dN/dS
estimates. For postnatal missense mutations, dN/dS was higher for high VAF PZMs compared
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to low VAF PZMs (Figure 3-17.a). At the tissue level, dN/dS was higher for high VAF for three
tissues: blood, EBV-transformed lymphocytes, and adrenal gland (Figure 3-17.c). These results
fit the expectation that strong selection on a mutation may result in clonal growth (i.e., increase
its VAF). Since blood and lymphocytes are constantly renewed throughout life and the
hematopoietic lineage constitutes ~90% of the cells in a human over its lifetime(140), these cell
types may be the most susceptible to large clonal growth due to strong selection. Indeed, clonal
hematopoiesis of interdeterminite potential, a condition characterized by the presence of
cancer-associated PZMs in the blood of donors without a hematological malignancy, is
commonly detected in older individuals(42). For the prenatal PZMs (combined, or separated by
primordial tissue), VAF was not associated with dN/dS, however the sample size may have
been too small to detect a significant association (Figure 3-17.a,b).
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Figure 3-17: Comparison of PZMs selection pressure at high and low VAFs as a function
of time and space. a. Prenatal and postnatal PZMs. b. Prenatal PZMs by primordial tissue. c.
Postnatal PZMs by adult tissue. Top rows: Missense dN/dS estimates; bottom rows:
nonsense dN/dS estimates. Left columns: datasets that had stronger selection in high VAF
PZMs compared to low VAFs; middle columns: equal selection; right selection: weaker
selection. Horizontal and vertical dashed lines at dN/dS = 1 represent neutral selection. Y = X
dashed line represents equal selection pressure in low and high VAF mutations. Error bars
represent 95% confidence intervals. GTEx tissues are colored using the GTEx coloring
convention (see Figure 5-1 for a complete legend).
Since selection pressure is higher in cancer driver genes for somatic mutations in cancer(95),
we speculated this might also be true for PZMs in normal tissues. Additionally, since mutations
in cancer driver genes can lead to clonal growth, the power to detect positive selection in PZMs
may be higher for cancer driver genes compared to other gene sets.
For high VAF postnatal PZMs, missense and nonsense dN/dS estimates were higher in cancer
driver genes than non-cancer genes. At the tissue level, dN/dS was higher in cancer driver
genes in sun exposed skin and esophagus mucosa. Additionally, dN/dS estimates were even
higher when subset to just the high VAF mutations in these tissues, suggesting that mutations in
cancer genes may lead to clonal growth (Figure 3-18). Sun exposed skin and esophagus
mucosa are exposed to the environment and are continuously replaced during life and thus may
be susceptible to precancerous clonal growth. This phenomenon has been observed in skin and
esophagus: Martincorena et al. detected strong positive selection in cancer drivers of cutaneous
squamous cell carcinomas in normal skin biopsies(49). Several studies have found positive
selection of cancer genes in normal esophagus epithelium(56, 57). Barrett’s esophagus is an
age-related, common condition (prevalent in 5.6% of US adults) where mucus-secreting
columnar cells replace esophageal squamous cells damaged from gastroesophageal reflux
disease and is associated with an increased risk of developing esophageal cancer(141). While
the etiology of this condition is not entirely known, studies have found Barrett’s esophagus to be
highly mutated and polyclonal(142, 143). This data suggests that clonal growth of PZMs in
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cancer genes may play a role in the development of Barrett’s esophagus and eventual
esophageal cancer.

Figure 3-18: Comparison of postnatal PZM selection pressure in cancer and non-cancer
genes. For clarity, only PZM datasets that had different selection pressure between cancer and
non-cancer genes are shown. Left: PZM datasets that had variable selection when using all
mutations; middle: high VAF mutations; right: low VAF mutations. Horizontal and vertical
dashed lines at dN/dS = 1 represent neutral selection. Y = X dashed line represents equal
selection pressure in cancer and non-cancer genes. Error bars represent 95% confidence
intervals.
For the prenatal PZMs, dN/dS was the same for cancer and non-cancer genes, however the
sample size may have been too small to detect a difference (data not shown). While this
analysis focused on pan-cancer genes, additional power may be gained by analyzing cancer
types separately, i.e., for a given cancer type and its tissue of origin, estimate the selection on
PZMs in the tissue using the cancer driver genes for that particular cancer type.

3.2.5.2 Selection pressure on PZMs varies over time
To determine if selection pressure of PZMs varied over the human lifespan, we compared
dN/dS for prenatal and postnatal PZMs as a function of VAF. For high VAF PZMs, prenatal and
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postnatal PZMs were both under neutral selection (Figure 3-19). However, for low VAF PZMs,
prenatal PZMs were under nominal positive selection (missense dN/dS = 1.25, p-value = 0.047)
and postnatal PZMs were under nominal negative selection (missense dN/dS = 0.97, p-value =
0.045). Thus, there may be small differences in selection pressure on low VAF PZMs over time.
These results may help explain why low VAF prenatal PZMs were more deleterious than
postnatal PZMs: perhaps deleterious PZMs are maintained in the cell population due to
selection.

Figure 3-19: Selection pressure across classes of genetic variation. Solid horizontal line at
dN/dS = 1 indicates neutral selection. Error bars represent 95% confidence intervals and are
plotted behind each datapoint. Some error bars are smaller than the datapoint so are not
directly visible. AF = allele frequency. BRCA = breast invasive carcinoma. GBM = glioblastoma
multiforme. LIHC = liver hepatocellular carcinoma. PAAD = pancreatic adenocarcinoma. SKCM
= skin cutaneous melanoma.

3.2.5.3 Selection pressure on PZMs is similar across the body
We next determined if selection pressure of postnatal PZMs varied across adult tissues. For
both low VAF and high VAF PZMs, dN/dS was not significantly different than 1 for the majority
of tissues (Figure 3-20). These results are consistent with previous work(32) and suggest that
postnatal PZM selection pressure may be approximately the same across the body. There were
a few exceptions. For low VAF postnatal PZMs, missense mutations in adrenal gland were
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under putative negative selection and nonsense mutations in pituitary were under putative
positive selection. (Two tissues had nonsense dN/dS < 1, but these may be type I errors since
nonsense mutations may be undercounted in RNA-seq.) For high VAF postnatal PZMs, blood
and esophagus mucosa had missense mutations under putative positive selection. The
esophagus mucosa result is consistent with previous reports(56). Three tissues had nonsense
dN/dS < 1, but these may be type I errors.
dN/dS was not significantly different than 1 for prenatal PZMs in primordial tissues; however
power may have been too small to detect a difference (data not shown).

Figure 3-20: Volcano plot of dN/dS for postnatal PZMs. a. Low VAF postnatal PZMs. b.
High VAF postnatal PZMs. Tissues are colored using the GTEx coloring convention (see Figure
5-1 for a complete legend). Dashed horizontal line indicates significance at q-value = 0.05.
Dashed vertical line at dN/dS = 1 indicates neutral selection. Tissues with dN/dS significantly
different than 1 after multiple test correction are plotted with 95% confidence intervals.
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3.2.5.4 Selection pressure varies across different classes of genetic variation
To contextualize the selection on PZMs, we compared PZM missense dN/dS estimates to other
classes of genetic variation (Figure 3-19). All PZMs classes were under stronger selection than
inherited germline variants which were under negative selection. Prenatal low VAF and
postnatal high VAF PZMs were under stonger selection than simulated neutral mutations and de
novo mutations in controls which were under neutral selection. (We also note that despite
differences in modelling frameworks, dN/dS estimated that both simulated neutral datasets were
indeed neutral mutations. This provides evidence that the simulations were not biased.)
Remarkably, these two PZM classes had similar selection as somatic mutations in cancer and
de novo mutations in cases which were under weak positive selection. (We note that the
apparent positive selection in de novo mutations in cases may be an artefact due to
ascertainment bias since the mutations were detected in individuals selected to have genetic
disorders. The positive selection may also be biological: genes related to autism (which is the
most common disorder in the de novo cases dataset) are also enriched for cancer genes(144).
Given that a significant fraction of autism cases are the result of PZMs in the proband(145),
clonal growth of PZMs in cancer genes via positive selection is plausible. This hypothesis is also
supported by observation that dN/dS for de novo mutations was higher in cancer driver genes
than all genes (data not shown).)
Together, these data suggest that selection of mutations within an individual is characterized by
neutral to weak positive selection whereas selection on variants within a population is
characterized by negative selection. The data suggest a stark dichotomy between growth within
an individual versus growth within a population: the mutations that are selected for within an
individual may be detrimental to the population.
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3.2.6 Characterization of germ cell PZMs
While a great deal is known about germline variation and de novo mutations, much less is
known about the PZMs that seed these forms of inherited genetic variation. To better
understand PZMs in germ cells, we sought to characterize the mutation burden, spectra, and
putative function of germ cell PZMs in GTEx.

3.2.6.1 The catalogue of germ cell PZMs throughout the germ cell life cycle
PZMs detected in GTEx testis RNA-seq data are a reasonable proxy for germ cell PZMs (see
Germ cell PZMs can be detected in bulk male gonads). We partitioned the germ cell PZMs into
two mutually exclusive groups: gonosomal and germ cell-specific (i.e., gonadal) PZMs. By
definition, gonosomal PZMs occur prior to germ cell specification, and thus are present in both
germ and somatic cells. In contrast, germ cell-specific PZMs occur after germ cell specification,
and thus are only present in germ cells (Figure 1-1). We ran additional quality control checks to
ensure that gonosomal and germ cell-specific PZMs were correctly labeled (see Gonosomal
and germ cell-specific PZM class labels are likely correct).
571 PZMs were identified in bulk testis from 281 male testis donors (median = 0.5 PZMs per
donor; range = 0 – 21 PZMs per donor). 12% (N = 70 PZMs) of testis PZMs were putative
gonosomal PZMs (median = 0 PZMs per donor; range = 0 – 4 PZMs per donor), and the
remaining 88% (N = 501 PZMs) were putative germ cell-specific PZMs (median = 1 PZMs per
donor; range = 0 – 21 PZMs per donor) (Figure 3-21). We caution that these mutation burden
estimates are underestimates of the true burden as germ cell-specific and gonosomal PZM
detection power was low for for lowly expressed and low VAF PZMs (germ-cell specific PZMs:
Figure 2-16, gonosomal PZMs: Figure 5-17).
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Figure 3-21: Distribution of gonosomal and germ cell-specific PZM mutation burdens
across male donors.
Germ cell PZMs identified in the testis represent the full reservoir of mutations that can be
passed to progeny. We hypothesized that the selection pressures on spermatogenesis,
fertilization, and prenatal development may alter the types of mutations that pass through each
of these bottlenecks of life. To examine germ cell PZMs that passed the spermatogenesis
bottleneck, we generated WES data on small pools of ejaculated sperm and identified and
validated 93 PZMs. To examine germ cell PZMs that completed fertilization and prenatal
development, we used de novo mutations from denovo-db, a curated database of ~628,000 de
novo mutations(113).
The mutation spectra for each germ cell mutation dataset was statistically different from the
others, albeit some of the effect sizes were small (Figure 3-22, Table 3-2, Chi-square test).
While C>T was the most common mutation type in all datasets, C>A was the most variable
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mutation type among the datasets, followed by C>T. These differences may be attributable to
differences in the technical and/or biological differences among the datasets. Interestingly,
hierarchical clustering of the spectra nested the classes in developmental order, suggesting that
developmental bottlenecks may leave incremental changes to the mutation spectra (Figure
3-23).

Figure 3-22: Mutation spectra of different germ cell mutation classes. All datasets subset
to the same allowable transcriptome. Number of mutations used in each dataset is listed in the
legend. Error bars denote 95% confidence intervals.
Table 3-2:
Results from testing for differences in germ cell mutation spectra. Mutation
spectra q-value = Benjamini-Hocherberg corrected P-value for testing if a given pair of datasets
have the same mutation spectra (Chi-square test). Mutation type q-value = Benjamini-Hochberg
corrected P-value for testing if the proportion of given mutation type is the same in a given pair
of datasets (Chi-square test). Mutation types colored using the mutation type coloring
convention. Significant statistical results at an FDR of 5% are bolded.
Dataset 1

Dataset 2

De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)

De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
Gem cell-specific
Gem cell-specific
Gem cell-specific

Mutation spectra
q-value

3.60E-02

7.14E-04
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Mutation type
q-value
C>A
1.75E-01
C>G
2.43E-01
C>T
6.43E-03
T>A
1.00E+00
T>C
2.49E-01
T>G
7.72E-01
C>A
2.31E-03
C>G
2.31E-03
C>T
8.82E-03

De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (case)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
De novo (control)
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Sperm
Sperm
Sperm
Sperm
Sperm
Sperm

Gem cell-specific
Gem cell-specific
Gem cell-specific
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Sperm
Sperm
Sperm
Sperm
Sperm
Sperm
Gem cell-specific
Gem cell-specific
Gem cell-specific
Gem cell-specific
Gem cell-specific
Gem cell-specific
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Gonosomal
Sperm
Sperm
Sperm
Sperm
Sperm
Sperm
Gem cell-specific
Gem cell-specific
Gem cell-specific
Gem cell-specific
Gem cell-specific
Gem cell-specific
Sperm
Sperm
Sperm
Sperm
Sperm
Sperm
Gem cell-specific
Gem cell-specific
Gem cell-specific
Gem cell-specific
Gem cell-specific
Gem cell-specific

7.14E-04

7.14E-04

7.14E-04

7.14E-04

7.14E-04

1.83E-02

7.50E-03

7.14E-04
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T>A
T>C
T>G
C>A
C>G
C>T
T>A
T>C
T>G
C>A
C>G
C>T
T>A
T>C
T>G
C>A
C>G
C>T
T>A
T>C
T>G
C>A
C>G
C>T
T>A
T>C
T>G
C>A
C>G
C>T
T>A
T>C
T>G
C>A
C>G
C>T
T>A
T>C
T>G
C>A
C>G
C>T
T>A
T>C
T>G
C>A
C>G
C>T
T>A
T>C
T>G

7.20E-01
2.31E-03
8.00E-03
2.31E-03
5.73E-01
1.04E-01
3.12E-01
1.64E-01
1.00E+00
9.24E-01
2.49E-01
3.67E-01
2.31E-03
7.27E-01
2.43E-01
2.31E-03
2.31E-03
2.31E-03
7.72E-01
2.31E-03
2.31E-03
2.31E-03
5.16E-01
2.43E-01
2.98E-01
1.12E-01
1.00E+00
1.00E+00
1.94E-01
7.72E-01
2.31E-03
8.70E-01
2.43E-01
5.70E-02
5.16E-01
1.00E-02
5.16E-01
9.24E-01
1.79E-01
8.82E-03
8.39E-01
5.73E-01
2.43E-01
1.79E-01
2.97E-01
1.29E-01
1.00E+00
7.85E-02
2.31E-03
3.79E-02
8.41E-01

Figure 3-23: Hierarchical clustering of germ cell mutation spectra.
A limitation of denovo-db and other large catalogs of de novo mutations is that the de novo
mutations are often unphased. The unphased de novo mutations may have arisen in either the
father’s or the mother’s germline, whereas the germ cell datasets used here arose in the male
germline. As a result, the observed de novo mutation properties may be confounded by sexspecific differences in germline mutagenesis. However, since the majority of de novo mutations
are inherited from the father(146), the effect of maternal de novo mutation contamination is most
likely limited.

3.2.6.2 Deleterious mutations are likely purged during the germ cell life cycle.
Given the immense selection pressure during gametogenesis and prenatal development(147,
148), we hypothesized mutation deleteriousness may vary across the germ cell life cycle.
Interestingly, germ cell PZMs (as proxied by testis) were nominally more deleterious than sperm
PZMs (odds ratio = 1.7; P-value = 0.069), were significantly more deleterious than de novos
from controls (odds ratio = 1.8; P-value = 3.1E-5) and were as deleterious as de novos from
cases (P-value = 0.78) (Figure 3-24, Figure 3-25). Based on the CCDFs (Figure 3-24), the
difference in deleteriousness across datasets was strongest for higher CADD scores. Therefore,
a cutoff of 25 was used for this analysis instead of the default CADD score cutoff of 20. Since
the sperm PZM dataset is relatively small, there was limited power to detect differences with
other datasets.
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Figure 3-24: Complementary cumulative distribution of CADD scores across germ cell
datasets.

Figure 3-25: Relative odds of detecting deleterious mutations across germ cell datasets.
Left: odds of detecting deleterious mutations in a given dataset compared to testis PZMs.
Right: compared to sperm PZMs. Error bars represent 95% confidence intervals. Bars colored
by dataset. Horizontal black line at odds ratio = 1 denotes no difference in odds.
130

We also compared the distribution of population allele frequencies of the mutations across
datasets (Figure 3-26). While a simple statistic, the population allele frequency of a variant
offers many insights into the deleteriousness, age, and selection pressure on the mutation. Both
testis PZMs and sperm PZMs were enriched for novel mutations (defined as not seen in
gnomAD) compared to both classes of de novo mutations (odds ratio range = 1.7- 3.7, q-value
range = 4.9E-4 – 1.9E-8, Fisher’s exact test with Benjamini-Hocherberg correction). This
suggests that fertilization and prenatal development may reduce the frequency of novel
mutations to levels that are compatible with life.
Interestingly, sperm PZMs were enriched for novel mutations compared to testis PZMs (odds
ratio = 2.1, q-value = 4.8E-2, Fisher’s exact test with Benjamini-Hochberg correction). This
enrichment may be the result of higher mutation detection power in sperm (mutations were
called in pools of ~200 cells rather than bulk biopsy), reflect variation across individuals, and/or
may indicate biological differences between mature germ cells in the ejaculate and mixtures of
immature and mature germ cells in the testis.
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Figure 3-26: Population allele frequency of mutations across germ cell datasets: Top:
distribution of population allele frequencies across germ cell datasets. Bottom: q-values from
pairwise comparisons testing for an association between proportion of novel mutations and
dataset. Cell i,j represents the result of testing for an association between dataset i and dataset j
and is colored by the resultant – log10 𝑞– 𝑣𝑎𝑙𝑢𝑒. Tests with q-value ≤ 0.05 are annotated with “*.”
AF = allele frequency.
Collectively, these results present an interesting paradox about the fitness of the germ cell
genome. In the testis, germ cell genomes appear to be a reservoir of deleterious mutations —
as deleterious as de novos from cases — yet the majority of germ cell genomes that give rise to
the next generation (i.e., the de novos from controls) are depleted of such deleterious
mutations. Further studies on the validation of the observation and subsequent elucidation of
the molecular mechanisms behind this apparent purging are needed.
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3.2.6.3 The mutation rate during male gametogenesis is dynamic
Given that gametogenesis may select for deleterious mutations, one potential evolutionary force
to control this process is by limiting mutation generation. We estimated the mutation rate
(number of mutations in the transcriptome per cell division) for each of the major stages during
male gametogenesis: before PGC specification, after PGC specification, and after puberty.
Consistent with previous work(103), the mutation rate during male gametogenesis was variable
and had congruent trends: prenatal timepoints were more deleterious than the postnatal
timepoint (Figure 3-27). The observed lower mutation rate during adulthood may be a strategy
to limit the amount of deleterious mutations that are passed to the next generation. Unlike (103)
and other studies which use inheritance of de novo mutations to measure mutation rates(73,
149–151), these estimates reflect mutation rates in germ cells in the testis rather than germ
cells that generated viable offspring and thus offer insight on a novel perspective of germ cell
mutagenesis.

Figure 3-27: Germ cell mutation rate varies during gametogenesis in males. Error bars
represent 95% confidence intervals. PGC = primordial germ cell
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3.2.6.4 Blood is a poor surrogate for measuring mosaicism of gonosomal PZMs
Motivated by the fact that in antemortem human subjects research, only a small subset of tissue
types are easily and ethically accessible, we hypothesized that more accessible tissues may be
useful surrogates for examining prenatal PZMs in other, less accessible tissues. Specifically, we
wanted to determine how frequently gonosomal PZMs could be detected in other tissues and
furthermore, determine if the prevalence (i.e., VAF) of the gonosomal PZMs could be predicted
from the other tissues. The results of such questions have the ability to shed light on the cellular
dynamics of human development and have implications for preconception genetic counseling
and de novo mutation discovery.
We fit a general linear mixed effects logistic regression model to predict whether a gonosomal
PZM was detected in a somatic tissue given information about the somatic tissue and the
gonosomal PZM in the germ cell. Since blood is arguably the most common biospecimen
collected for genetic studies and genetic counseling, we compared the odds of detecting a
gonosomal PZM in a somatic tissue to blood. Surprisingly, 88% (38/43) of tissues had
significantly higher odds of detecting gonosomal PZMs than in blood (Figure 3-28). This result
cannot be explained by overaggressive germline variant filtering in blood (see section Donor
genotype status does not affect prenatal PZM burden).
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Figure 3-28: Majority of somatic tissues have a significantly higher odds of detecting a
gonosomal PZM than blood. Natural log odds ratio for detecting a gonosomal PZM in a given
somatic tissue compared to blood. Tissues are sorted by significance status then increasing
natural log odds ratio. Tissues are colored using the GTEx coloring convention (see Figure 5-1
for a complete legend). Dashed line at Y = 0 denotes no difference in odds. Error bars denote
95% confidence intervals. NS = non-significant. ln = natural log.
In addition to detecting a gonosomal PZM, the VAF of the mutation is also important for
estimating the probability of passing the variant to progeny: higher VAF mutations may be more
likely to be sampled from the germ cell population. We next asked if gonosomal PZM VAFs in
germ cells were similar to the VAF in the somatic tissues. 88% (38/43) of somatic tissues had a
significant linear correlation between the VAF in the somatic tissue and the VAF in testis
(Figure 3-29, Pearson’s correlation test). This suggests that somatic tissues may offer a faithful
representation of gonosomal PZMs in germ cells. We also note that the similarity of somatic and
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germ cell VAFs cannot be explained by assumptions used by the mutation calling algorithm (see
Step 2 of LachesisDetect does not reduce intra-tissue variation in VAF).

Figure 3-29: Correlation between gonosomal PZM VAF in germ cells and somatic
tissues. a. Gonosomal PZM VAF in somatic tissue versus germ cell VAF (as proxied by testis).
b. Distribution of tissue-specific Pearson correlations of log10-transformed gonosomal PZM
VAFs in a given somatic tissue and testis. Significant correlations at q-value ≤ 0.05 marked with
“*.” Tissues are colored using the GTEx coloring convention (see Figure 5-1 for a complete
legend).

3.3 Discussion and future directions
Mutation is arguably the most important of all genetic processes. At the individual level,
mutation can result in disease and eventual death, and at the species level, mutation provides
the fodder for natural selection and drift to create and eliminate species. Here, we shed new
light on mutation at the individual level: we present the most comprehensive and diverse survey
of postzygotic mutation variation across 17,382 samples from 948 donors and 54 diverse tissue
and cell types.
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Genome stability is the foundation of our biology. Despite (or maybe because of?) its immense
importance, we found incredible variation in the burden, spectra, putative function, and selection
of PZMs across spatial and temporal dimensions of human life. This variation suggests
mutational mechanisms are different across space and time, but perhaps the more interesting
implication is understanding why there are differences. This is a lofty challenge. Such
knowledge will require developing sophisticated models that use information about how tissues
maintain homeostasis, intrinsic and extrinsic mutagen exposures, mutation repair mechanisms,
and catalogs of mutated protein function all of which may be needed at cell type resolution.
Hierarchical models of how the cell types integrate to function at the organ and organismal level
will also be needed.
Consistent with prior theoretical and experimental studies(12, 34, 39, 42, 49, 88, 152, 153),
postzygotic mutation is pervasive and highly variable across individuals and tissues. We found
that the majority of detectable postzygotic mutations occur postnatally and often accumulate
with age.
Postnatal mutation deleteriousness varied across tissues. We found a striking pattern that
tissues made largely of post-mitotic cells tended to have more deleterious mutations than other
tissues (odds ratio confidence interval: [1.5, ∞), P-value = 0.01, Fisher's Exact Test). This data
argues that the maintenance of genome integrity in a tissue may be coupled with its tissue
homeostasis strategy and may provide a way for tissues to suppress tumor formation(154).
Follow-up studies are needed to understand if these deleterious mutations impact tissue
function.
There is growing sentiment that embryogenesis is highly mutagenic. Prior studies have found
pervasive mosaic aneuploidy, CNVs, and SNVs in human preimplantation embryos as well as
from lineage tracing of prenatal mutations from adult tissues(39, 88, 155–159). Here, we extend
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this viewpoint by characterizing embryonic mutation in the largest cohort of normal donors and,
importantly, derive patterns of mutagenesis from mutations that survive adulthood. Most
prenatal postzygotic mutations occur early in embryogenesis during gastrulation and the
formation of the neural ectoderm. Gastrulation, as developmental biologist Lewis Wolpert
famously said, “is truly the most important time of your life”(160) and yet it is predicted to be one
of the most mutagenic periods in human development. We find this to be an intriguing and
striking juxtaposition of life and potential peril. This data suggests that mutagenesis may be
benign or even beneficial to a growing embryo. Follow-up studies are needed to understand
how these opposing forces interact with one another.
PZMs, especially low VAF prenatal PZMs, were found to be one of the most deleterious classes
of genetic variation. We found an inverse relationship between mutation deleteriousness and
frequency of the mutation in the population (Figure 3-30). PZMs were highly deleterious but
only present in a subset of cells in an individual. De novo mutations were less deleterious but
present in all cells of a single individual. Lastly, standing germline variation was the least
deleterious and present in the most individuals. This suggests that mutation deleteriousness
and mutation frequency are constrained to lie along this spectrum. We suspect that points off
this trend line are incompatible with cell and individual life. We speculate this is because
selection pressure varies with mutation frequency. Indeed, we found a negative correlation
between mutation frequency and selection pressure. This adds additional evidence to an
emerging paradigm that selection pressure on individual cells is different from the selection
pressures on individuals and populations(161). This may be driven by differences in the rate of
evolutionary change as cells have a larger population size and shorter generation time than
organisms.
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Figure 3-30: Model for the association between variant frequency and deleteriousness
and selection pressure. The data suggests negative correlations between mutation frequency
in a population and 1) deleteriousness and 2) selection. Variation in deleteriousness and
selection may be driven by differential forces that act on cells, individuals, and populations.
Of note, we have used the word selection to describe the forces that affect cellular and
individual survival rather than its more conventional definition of the forces that lead to higher
reproductive fitness.
Here we showed deleterious mutations can be untolerated at the organismal level but
permissible when sequestered to a subset of cells in an orgnanism. This result may explain why
CADD and other selection-based pathogenicity predictors may predict a mutation to have a high
pathogenicity but have no observable effect when measured in vitro, e.g., in deep mutational
screens(162).
We found an excess of deleterious mutations in testicular germ cells compared to de novo
mutations. We hypothesize that this excess of deleterious mutations is purged during
bottlenecks of the life cycle, e.g., spermatogenesis, fertilization, and embryonic development
(Figure 3-31). This dynamicity of apparent germ cell genome fitness suggests that different
selection pressures operate over the course of the germ cell life cycle and thus there may be
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antagonism between germ cell fitness and offspring fitness. Other changes in sperm, e.g.,
genomic integrity, have also been found to vary along the male genital tract(163).

Figure 3-31: Model for how deleterious mutations may be removed during the germ cell
life cycle.
The presence of deleterious mutations in germ cells is consistent with the phenomenon of
selfish spermatogonial selection (SSS). In SSS, pathogenic gain-of-function mutations in
spermatogonial stem cells lead to their clonal expansion and can result in testicular tumors and
fathering children with paternal age effect (PAE) disorders (reviewed in (148)). (As an aside, we
attempted to detect SSS in the testis PZMs but did not detect any canonical mutations. This
negative result may be due to low mutation detection power (see Paternal Age Effect
Mutations).) Additionally, as genetic diversity is the basis of selection, germ cell PZMs may be a
mechanism for a species conservatively experiment with new mutations, i.e., mosaicism and
modulation of the PZM VAF in the germ cell population may affect how many offspring inherit
the mutation, e.g., from 0 to 100%.
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One limitation of the germ cell analysis is that the analyses assumed that de novo mutations
were prezygotic, i.e., the de novo mutation was a PZM in one of the parents. We cannot rule out
the possibility that the mutations were actually acquired postzygotically in the proband. AcunaHidalgo et al. estimate that approximately 7% of apparent germline de novo mutations are
actually postzygotic mutations in the proband(72). Additional large family studies that examine
gonadal mosaicism are required to determine the true nature of de novo mutations. While there
are pioneering studies on this frontier(164), larger gonadal mosaicism catalogs are still needed.
As the mosaicism and genetic medicine communities continue to create these databases, we
stress that which tissue is used for profiling is critical. In typical trio studies, blood is used to
genotype individuals. Surprisingly, we found that 88% (38/43) of tissues had significantly higher
odds of detecting gonosomal PZMs than blood. This suggests that trio family studies that search
for the child’s de novo mutation in the parent’s blood may be ill-equipped to recover such
mutations. Thus, conclusions about potential recurrence of the de novo mutation may be
underestimated, i.e., the mutation is present in the parents germline, but not detectable in blood.
Since gonosomal PZMs occur very early in development and likely before major sex differences
arise, we expect the results, which were derived from males, to be generalizable to females.
Based on these results and the accessibility of tissues, we recommend sperm (a direct readout
of germ cells) should be profiled in males and skin (which is 100× more likely than blood to
contain a gonosomal PZM) should be profiled in females (Figure 3-28).

3.3.1 Study limitations
In this study, detection of PZMs was limited to the ~115 Mb of the genome that is expressed.
This is both a limitation and advantage. While we are not powered to detect mutations outside
the expressed exome, knowing that the PZMs are expressed is incredibly useful. Additionally,
for cell-type specific genes (and in single-cell RNA-seq applications), coupling of a mutation to a
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specific cell type can shed light on cell lineage mapping and potential functional effects. We also
had limited sensitivity when gene expression was low. To mitigate this issue, we carefully
quantified mutation detection power and adjusted for differential detection power in analyses.
Missing and uncertain data were also incorporated into modelling frameworks. For future
studies, deeper sequencing or sequencing single-cells or microdissections may offer improved
sensitivity. Unfortunately, it is not possible to detect PZMs that are lost (e.g., by negative
selection) or reversed (e.g., by revertant mosaicism) using a single timepoint. We recommend
using multiple timepoints to study these ephemeral PZMs and the dynamics of PZMs(75).
Calling PZMs in bulk DNA is incredibly challenging, let alone calling PZMs in bulk RNA. One of
the main difficulties is overcoming the low signal-to-noise ratio. The distributions of mutation
features (e.g., VAF) of PZMs overlap with both experimental error (e.g., sequencing error) and
inherited germline variants (especially those with severe allele-specific expression) (Figure 2-2).
As such, we have taken a conservative approach, prioritizing specificity over sensitivity, e.g., by
removing putative germline variants. In this conservative approach, we used information about
the donors’ germline (usually determined from blood) to remove potential false positives. We
note that germline calls most likely include true high VAF PZMs. In an ideal framework,
information about the germline from the donor’s relatives could be used to help determine if the
variants in blood are germline or postzygotic. In a more moderate approach, all putative PZMs
(ignoring germline status) could be called. Then, assuming mutation signatures of PZMs and
germline are different, one could use expectation maximization or other machine learning
approach to estimate the likelihood of an individual mutation to be postzygotic or germline.
Lastly, the DNA PZMs are called from RNA which may not be a faithful representation of the
DNA sequence. Post transcriptional modifications, e.g., RNA editing, may result in false positive
PZMs. We have tried to limit such sources of contamination by removing both known and
putative RNA editing sites.
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Despite these limitations, there are many reasons to believe the PZM atlas is of high quality. In
silico and experimental validation data suggest a reasonably low FDR. We note that PZM
detection methods with much higher FDRs have been published in high impact journals(61).
Additionally, PZMs show patterns consistent with expectation and previous studies(49, 55, 61,
62) (e.g., UV damage mutational signature in sun exposed skin; postnatal PZM mutation burden
increases with age but prenatal PZM mutation burden does not; the predicted “age” of a
prenatal PZM is correlated with VAF and number of tissues it is detected in; and PZMs have
similar deleteriousness as independent PZM databases).
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Chapter 4
Conclusions and future directions
4.1 Summary
Mutation lays the foundation for genetics, evolution, and our very existence and demise.
Historically, genetics has focused on germline variants and has only recently begun to examine
PZMs. This bias is partially due to technological limitations and the long-standing assumption
that all cells in a multicellular organism share the same genome. With recent advancements in
sequencing and bioinformatics, one of the final frontiers in genomics — spatiotemporal
resolution of PZMs — is upon us.
To begin to understand PZM mechanisms and how aberrant mutational processes can lead to
cancer and other diseases, detailed and comprehensive maps of PZM genetic variation during
normal development and aging and the methods to generate them are greatly needed. In this
thesis, we produced pioneering methods and experimental results for mosaicism and somatic
evolutionary genomics. Together, these deliverables are an invaluable resource for the
community and the results have far reaching implications for understating normal human
development and aging.
We developed novel methodologies to 1) detect postzygotic point mutations from bulk RNA-seq
data and 2) reconstruct PZM phylogenies. We used these methods to quantify PZM variation
within individuals (both spatially and temporally) and between individuals. We found that PZMs
are pervasive and highly variable among normal donors and tissues. Mutation spectra was
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variable across tissues, suggesting that mutational mechanisms may be different across
tissues, e.g., via differential regulation of repair mechanisms. Mutation burden and spectra also
varied throughout prenatal development, with early embryogenesis being the most mutagenic.
While the majority of PZMs were under neutral selection, prenatal PZMs and PZMs in cancer
genes were under positive selection as strong as somatic mutations in cancer. We found the
surprising result that PZMs, especially low VAF prenatal PZMs, were the most deleterious class
genetic variation. Interestingly, we found that the fraction of deleterious PZMs decreased
throughout the male germ cell life cycle. This reduction in mutation deleteriousness may be one
way to safeguard the potentially negative consequences of PZMs that inherently results from
the massive proliferation of a single cell zygote to a complex multicellular adult human with
1E14 cells(34). Alternatively, these results may be illuminating that mutagenesis is not always
harmful, but a fact of normal life.

4.2 Significance
This thesis will impact many areas of genomics by 1) providing novel resources including
methods to profile PZMs from bulk RNA-seq data and the most comprehensive and diverse
atlas of PZMs; 2) unveiling the spatial and temporal dynamics of PZM in normal development
and aging in unprecedented detail; and 3) discovering new examples of how PZMs may relate
to disease. In sum, this thesis expands our understanding of the mutational processes that
occur in normal development and aging and hopefully can be used to improve disease
prevention and therapy.
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4.3 Future directions
Statistician George Box stated that “all models are wrong but some are useful(165).” After
investigating the characteristics of PZMs throughout the human lifespan, we now have sufficient
information to make better models. This process starts with reevaluating some of the long-held
assumptions in human and medical genetics.

4.3.1 Is it time to retire the one-person-one-genome paradigm?
This and other works have clearly demonstrated that the multicellular human body is composed
not of one genome, but of many genomes in both the soma and the germline. In cancer biology,
tumor genomic heterogeneity is also widely known, and it’s heavily relied upon to monitor and
tailor therapy, e.g., presence of drug resistant clones. However, in human genetics, intra-donor
genomic heterogeneity is often ignored: a single germline is defined (usually from blood) for an
individual. This de facto germline is then assumed to exist in all cells of the soma and germline.
This simplifying assumption has led human genetics to achieve seminal knowledge about our
biology, but as we dive deeper into the crevices of our physiology, and especially
pathophysiology, it may be time to let go of this assumption.
Over the past decade, it’s become increasingly clear than PZMs can cause diseases other than
cancer (e.g., neurodevelopmental diseases reviewed in (166), monogenic disorders reviewed in
(167), diseases associated with the receptor tyrosine kinase pathway reviewed in (168),
autoinflammatory diseases reviewed in (169), and skeletal disorders reviewed in (170)).
Additionally, PZMs are also recognized as harbingers of future disease: e.g., detection of CHIP
in normal individuals is used to predict blood cancers and other morbidities(48).
In addition to the known mosaic forms of disease, there are likely many unknown mosaic forms.
Mosaicism offers an additional complexity in disease presentation as the timing and specific
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cells that contain the causal PZMs may result in different phenotypes. While the idea of
mosaicism causing disease is known, a logical next step is that mosaicism may also cause
variation in complex traits and diseases (see Contribution of PZMs to complex traits and
diseases). These unknown mosaic manifestations of diseases and complex traits may have the
possibility to explain missing heritability in genome-wide association studies (GWAS) as well as
explain low diagnostic rates for trio studies of developmental disorders.
Two plausible (and testable) scenarios may explain this lack of power in GWAS and trio studies.
Under this hypothesis, the disease/trait is (at least partially) caused by PZMs. In the first
scenario, canonical PZMs are present but are undetected. In the second scenario, noncanonical
PZMs are present and are undetected.
In the first scenario, the causal canonical PZMs are not detectable in blood (the biospecimen
most often used for GWAS and trio studies) when germline variant callers are used. One
potential remedy is to detect mutations with PZM callers. However, this will still fail if the
mutation is not present in the blood. In this subcase, directly testing affected tissues may be
required. As some tissues are not pragmatically or ethically accessible, if a prenatal PZM is
suspected (e.g., in syndromic cases where multiple parts of the body are affected), it may be
possible to profile more accessible, surrogate tissues as a kind of wormhole to the affected
tissues. Catalogs of natural PZM variation in individuals like the one presented here and cell
lineage maps in model organisms(97, 171), will help us predict suitable surrogate tissue.
In the second scenario, the causal PZMs are noncanonical, i.e., the mosaic form of the disease
is caused by a different genetic etiology than the germline form of the disease. (While some
may argue this would be a different disease, this information would not be known a priori.) In
addition to the strategies listed above, one may need to search genome-wide for candidate
mutations, rather than focusing on a targeted panel of disease associated genes. Analyzing
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many affected families may be required so that recurrence of mutations could be used to
prioritize candidates.
Depending on the research question, we argue that assuming one genome per individual may
hurt instead of help answering the question. Using data-driven approaches to select tissues and
detect rare PZMs may help us answer the remaining thorny questions in human genetics and
genomic medicine.

4.3.2 How do we overcome the challenges of mosaicism in the
diagnosis of children with suspected genetic diseases?
Genetic diseases are a leading cause of death in infants and children under ten(172, 173).
Diagnosis in children with suspected genetic diseases is critical for patient management,
optimal outcomes, and ending the family’s diagnostic odyssey. Over the past decade, clinical
WES and WGS of children and their biological parents have become more common for
diagnosing genetic disease. However, mosaicism in the child or a parent can make data
interpretation more challenging. Here, we provide some recommendations for managing these
challenges in clinical sequencing.

4.3.2.1 The assumption that causal de novo mutations only occur during parental
gametogenesis should be discarded
In trio studies, it’s often assumed that the causal de novo mutation occurred during
gametogenesis in one of the parents, and thus will not be present in the parent’s blood and will
be present in all cells of the child(72). This assumption outlines the study design and analysis
framework: sequence the blood of the biological parents and the child and find candidate
germline mutations that are only present in the child. The utility of this paradigm crumbles when
the assumption is not true, i.e., the mutation didn’t occur in one of the parents, but occurred
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postzygotically in the child. Acuna-Hidalgo et al. estimate that this may occur for ~7% of de
novo mutations(72). Furthermore, given the relatively low diagnostic rate of clinical sequencing
of children with developmental disorders (36-41%(172)), it’s plausible that these undiagnosed
cases may be the result of PZMs in the child. To test this hypothesis (and to help families), we
need to decrease the influence of this assumption on the study design and analysis. We need to
look for PZMs in the child by using PZM variant callers and, if possible, genotype tissues related
to the disease or at the very least, surrogate tissues in the child. With these changes, it may be
possible to improve the diagnostic rate, end the diagnostic odyssey for families, and improve
disease management.

4.3.2.2 Blood should not be the primary biospecimen profiled in parent-child trio
studies of developmental disorders
In addition to detecting causal mutations, estimating the risk of disease recurrence may also be
an objective of clinical sequencing and genetic counseling. We claim that we can improve this
process by modifying the typical trio study design.
A de novo mutation in a parent could have arisen as a PZM at any point during a germ cell’s cell
lineage. Additionally, the earlier the PZM occurs, the more descendent germ cells will contain
the PZM. Thus, to get the closest representation of the germ cell that was used for fertilization of
the child, it makes the most sense to sequence the germ cell pool of the parents, not the blood.
If the causal mutation is present (and detected) in the germ cell population, this information can
also be used for variant prioritization. Additionally, the fraction of germ cells containing the
mutation could be used to estimate disease recurrence in future children. While recurrence risk
is typically based on empirical data from large case studies(174), knowledge of the mutation
frequency in just the parent may actually be a more precise estimate of disease recurrence. We
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note that failure to detect causal PZMs in the germ pool is also empowering for the family: as
this may lead to a reduction in recurrence risk.
For males, we recommend sequencing ejaculated sperm as it most closely resembles the germ
cell pool and is relatively easy to access. Unfortunately for females, accessing the germ cell
pool is more challenging. We recommend using skin instead: we found skin to be one of the
best surrogate tissues for germ cells in terms of accessibility and detection of gonosomal PZMs.
We recognize that this recommendation is far from perfect, as it will not be possible to detect
germ cell-specific mosaicism or discriminate somatic mosaicism from gonosomal mosaicism.
However, if the skin PZM is high, the mutation may have occurred before germ cell
specification. This means the mutation may be common in the germ cell pool and thus likely to
be inherited.

4.3.3 What are the next TODOs for mosaicism?
4.3.3.1 Determine the effects of PZMs on health and disease
Mosaicism is pervasive in humans and yet we understand little of its consequences. The next
major and critically important step is to understand the effects of PZMs on human health and
disease. However, before we move to function, we first need bigger and better catalogs of
postzygotic genetic variation in both normal and diseased populations. Even though the
mosaicism community has spent the last five years generating increasingly more
comprehensive catalogs of PZMs in normal populations, we are still in the infancy of
characterizing the mutational diversity within and between individuals. There are still many
biological aspects that are largely unknown, e.g., what is the genetic variation within and
between individuals for non-point mutations (e.g., postzygotic structural variation, short and
variable tandem repeats, and mobile element insertions)? How does postzygotic variation
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change with time within an individual? When are PZMs useful biomarkers for disease? When do
PZMs contribute to complex traits and diseases? (For a brief dabble into the last question, see
Contribution of PZMs to complex traits and diseases.)
For germline variation, the analogous questions were answered with the help of extremely large
catalogs of germline variation, e.g., 1000 Genomes Project(175) and gnomAD(114). These and
other similar projects had a tremendous impact on revealing much about our biology. In
germline variation, where there is one genome defined per person, simply sequencing blood
and calling germline variants with mature methods in many people was sufficient to describe the
genetic diversity. However, in postzygotic genetic variation, where it’s posited that no two cells
in the same individual have the same genome(1), the methodology and catalogs are arguably
more complex and are still in their infancy.
In the following sections, we outline some of the key steps that are required to build the requisite
catalogs of postzygotic genetic variation. These will serve as invaluable resources for
understanding the effects of postzygotic genetic diversity on human biology.

4.3.3.2 Determine the optimal experimental designs for PZM detection
Several experimental designs have been used to detect PZMs including whole genome
amplification of single cells(29), clonal amplification of single cells(12, 176), organoids(13, 54),
sorted cells(177, 178), microdissected tissues(49, 179), and bulk tissue biopsies(61, 180).
These methods each come with their own advantages and disadvantages regarding sensitivity,
specificity, cost, and required technical resources.
Additional experimental choices include which nucleic acid to sequence (DNA or RNA), what
part of the genome to sequence (e.g., genome, exome, or targeted regions), whether to use
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unique molecular identifiers, and which sequencing platform to use (e.g., short reads with
Illumina technology or long reads with PacBio technology).
While determining optimality depends on the specific mosaicism questions of interest, at the
very least, the community should prioritize learning how these various design choices affect
PZM detection. A head-to-head competition of different methods on the same reference
samples would be extremely helpful in benchmarking current and future protocols. We note that
mutability and heterogeneity in samples will make it challenging to create reference samples.
Using synthetic nucleic acids or synthetic PZMs from combining germline variants of different
samples at various ratios may be one way to overcome these challenges. However, the
generalizability of these alternatives to real PZMs may be affected.

4.3.3.3 Design and evaluate better bioinformatic methods for PZM detection
Over the past decade, there has been a plethora of new methods to detect PZMs (see (27) for a
review). However, the field still needs more comparative studies using independent datasets to
benchmark and compare mutation callers. Several comparative studies have been published in
cancer and/or in silico settings(181–186), however, at the time of writing, there have been no
benchmarking studies for normal PZM variation. Such comparisons are needed because
mutational properties of PZMs in cancer and titrated germline variants made to look like PZMs
may not be representative of normal PZM variation. For example, due to clonal growth, PZM
VAFs in tumors can become appreciably large whereas in normal tissue, PZM VAFs may be
biased towards smaller VAFs. In this thesis, we have shown that the mutational properties of
germline variants and PZMs are different. Thus, performance metrics based on test germline
data may not be generalizable to real PZMs.
We recognize that PZM detection is immensely challenging due to the low single-to-noise ratio
especially for low VAF PZMs (e.g., < 5%) and PZMs detected from RNA-seq. Methods with
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FDRs as high as 82% have been published in high impact journals(61). Nonetheless, PZM
variant callers are incredibly useful. This sentiment is only true if the method’s limitations are
known. Therefore, we implore authors to robustly evaluate and transparently report the
accuracy of their variant calling methods.
One area for technology development is the development of methods to predict PZMs from
related samples. As multi-tissue, high-throughput single-cell, longitudinal, and intergenerational
PZM study designs become more common, it will be critical that future algorithms leverage the
shared information among related samples. Matched tumor-normal algorithms and de novo
mutation detection in trios represent subcases of this generalized framework., i.e., mutations are
not expected in some samples and the sample size is very small. To our knowledge,
LachesisDetect is one of the first PZM methods to take advantage of related samples. Future
methods could use unsupervised or supervised approaches to model phylogenetic relationships
(e.g., directed trees for single-cell data and directed acyclic graphs for bulk tissue data), and
dynamics. Algorithms will need to consider variable detection power (e.g., allelic dropout in
single-cell sequencing) and scalability. For example, for single-cell PZM tree reconstruction,
where the sample space is extremely large, the tree could be initialized with a tree based on
transcriptome similarity.
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Chapter 5
Supplement
5.1 Supplementary figures

Figure 5-1: GTEx tissue coloring convention. The same coloring convention used in GTEx
was used(64).
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5.2 Supplementary tables & files
Table 5-1:
List of filters applied to the PZM call set and the number of PZMs removed
or added by each filter.
Filter
Input (# of sites with ≥ 2X
alternative coverage)
Blacklist samples
- Low RIN
- GTEx blacklist tissue
- Transplanted GTEx tissue

Variants removed

Variants added

#

#

%

Remaining #
of variants

%

927,604,333
93,237,551

10.1%

834,366,782

87,176,943

10.4%

747,189,839

298,581,071

40.0%

448,608,768

18,803,931

4.2%

429,804,837

Putative germline variants

1,331,121

0.3%

428,473,716

Alternative coverage ≤ 5X

414,983,074

96.9%

13,490,642

Putative RNA editing sites

2,095,884

15.5%

11,394,758

Sites with high nucleotide
diversity
PZM FDR correction

7,140,260

62.7%

4,254,498

3,100,562

72.9%

1,153,936

Biased alignment metrics

448,032

38.8%

705,904

In segmental duplication

83,632

11.8%

622,272

In repeat masked region

32,453

5.2%

589,819

Hypermutated samples

455,466

77.2%

134,353

2,005

1.5%

33,289

20.4%

129,790

43,131

33.2%

86,659

30,074

34.7%

Blacklist genomic regions
- Known RNA editing sites
- Immunoglobulin genes
- Variants near exon
boundaries
Variants that overlap with GTEx
germline SNVs and indels
Total coverage ≤ 20X

Call multi-tissue variants
Balance mutation burden in
genotyped and non-genotyped
donors
Large background error rate
(pilot validation dataset)
Large background error rate (all
validation datasets)

30,731

22.9%

163,079

56,585
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Table 5-2:

List of sample filters and the number of samples removed by each filter.

Filter

Samples removed
#

Remaining # of samples

%

Input

17,382

Low RIN
(RIN < 6)
GTEx tissues with poor overall quality
(Bladder, Spleen, Cervix - Ectocervix, Cervix Endocervix, Fallopian Tube, Kidney - Medulla)

1,674

10%

15,708

230

1%

15,478

0

0%

15,478

806

5%

14,672

Sample derived from a transplanted tissue
Hypermutated samples

Table 5-3:
•

Experimental and in silico validation results.

Sheet Validation results summary: Summary of results for experimental and in silico
validation experiments for non-hypermutated and hypermutated samples. To save the
reader a few clicks, this subtable is also printed below.

Non-hypermutated samples
Statistic
Total number
mutations
tested

Number
validated
mutations

Number NOT
validated

Number NOT
callable

Definition

Experimental validation
AmpliconAmpliconseq
seq (pilot)
(full-scale)

# validated + # NOT
validated + # NOT callable
1) VAF is significantly
greater than the
background error rate & 2)
the mutant allele has the
highest non-reference
coverage in the validation
data
1) Mutation is callable & 2a)
VAF is not significantly
greater than the
background error rate or
2b) the mutant allele does
not have the highest nonreference coverage in the
validation data
Detection power is not high
enough to reliably detect
the PZM in the validation
data
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ENCODE
DNA

ENCODE
RNA

47

43

218

97

45

25

5

23

2

17

0

50

0

1

213

24

Positive
predictive value
(PPV)
False discovery
rate (FDR)

Statistic

Total number
mutations
tested
Number
validated
mutations

Number NOT
validated
Positive
predictive value
(PPV)
False discovery
rate (FDR)

# validated / (# validated +
# NOT validated)
1 - PPV

Definition

95.7%

59.5%

100.0%

31.5%

4.3%

40.5%

0.0%

68.5%

In silico
validation
Phasing of
PZMs and
heterozygo
us germline
variants

# validated + # NOT
validated
PZM segregates with 1
parental haplotype (FDRcorrected P-value
significant)
PZM does not segregate
with 1 parental haplotype
(FDR-corrected P-value not
significant)

41

31

10

# validated / (# validated +
# NOT validated)

75.6%

1 - PPV

24.4%

Hypermutated samples
Statistic
Total number
mutations
tested

Number
validated
mutations

Number NOT
validated

Definition

Experimental validation
AmpliconAmpliconseq
seq (pilot)
(full-scale)

# validated + # NOT
validated + # NOT callable
1) VAF is significantly
greater than the
background error rate & 2)
the mutant allele has the
highest non-reference
coverage in the validation
data
1) Mutation is callable & 2a)
VAF is not significantly
greater than the
background error rate or
2b) the mutant allele does
not have the highest non-
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ENCODE
DNA

ENCODE
RNA

14

1628

40

55

0

58

0

1

0

1407

2

41

reference coverage in the
validation data

Number NOT
callable
Positive
predictive value
(PPV)
False discovery
rate (FDR)

Detection power is not high
enough to reliably detect
the PZM in the validation
data

14
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38

13

# validated / (# validated +
# NOT validated)

NA

4.0%

0.0%

2.4%

1 - PPV

NA

96.0%

100.0%

97.6%

•

Sheet Validation results: Table of variant information (e.g., genomic coordinate and
validation status) for the PZMs where validation was attempted across the four
experimental validation datasets. Due to privacy, sample IDs were converted to
deidentified sample IDs.

•

Sheet Valid. results - column defs: Description of columns used in Sheet Validation
results.

•

Sheet Amp.-seq pilot samples summary: Number of non-hypermutated and
hypermutated samples used in the amplicon-seq pilot validation dataset.

•

Sheet Amp.-seq pilot samples: List of samples used in the amplicon-seq pilot validation
dataset.

•

Sheet Amp.-seq large samples summary: Number of non-hypermutated and
hypermutated samples used in the amplicon-seq large validation dataset.

•

Sheet Amp.-seq large samples: List of samples used in the amplicon-seq large
validation dataset.

•

Sheet ENCODE samples summary: Number of non-hypermutated and hypermutated
samples used in the ENCODE validation datasets.

•

Sheet ENCODE large samples: List of samples used in the ENCODE validation
datasets.

Table 5-4:
List of regions amplified for the pilot amplicon-seq validation experiment.
Coordinates are in hg19.
Table 5-5:
List of regions amplified for the large-scale amplicon-seq validation
experiment. Coordinates are in hg38.
Table 5-6:

List of primer pairs used for the amplicon-seq large validation experiment.
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Table 5-7:

List of PZMs. Spreadsheet has the following sheets:

•

Sheet List of mutations: Table of PZM information (e.g., genomic coordinate and
sequencing read coverage). Due to privacy, sample IDs and donor IDs were
deidentified.

•

Sheet Column definitions: Description of columns used in Sheet List of mutations.

5.3 Supplementary notes
5.3.1 PZMs in hypermutated samples are likely false positives
A small subset of normal GTEx samples (~5%) had an extraordinarily high PZM burden.
Hypermutation is observed in cancer at relatively low rates (~17% of adult cancers) and can
result from both extrinsic and intrinsic mutagenic exposures, e.g., UV light(187). We
hypothesized that the GTEx hypermutated samples may be a novel form of hypermutation in
normal tissues. We used experimental validation data to determine if these PZMs represented a
technical artifact or a biological phenomenon.
Across the four experimental validation datasets, we attempted to validate 1,737 putative PZMs
across 17 hypermutated samples. Validation data was informative for 1,509 PZMs. The average
FDR was 98%. Thus, the overwhelming majority of PZMs in hypermutated samples are likely
false positives. As a result, the observed hypermutated phenotype is likely a technical artifact.
Given that the validation data was generated from tissue biopsies different from the ones used
for the original mutation calling, it is possible we may have been underpowered to detect PZMs
in the validation sample (e.g., due to tissue mosaicism). However, since non-hypermutated
samples had a much lower FDR, this possibility is not very likely.
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5.3.2 Preservation method does not likely affect mutation burden and
spectra
During biospecimen collection, GTEx used different tissue preservation methods. Eleven of the
thirteen brain regions were processed from fresh frozen tissue whereas the remaining two brain
regions and all non-brain tissues (N = 35) were processed from PAXgene preserved tissue
(Figure 5-2). This less than ideal choice of systematic differences in sample collection was
likely driven by necessity as frozen brain samples were processed by a designated brain bank
and the remaining samples were processed by GTEx.

Figure 5-2:

Overview of the GTEx preservation schema.

While fresh frozen is the gold standard for tissue preservation, alternatives like PAXgene are
commonly used. PAXgene is a fixation method used to simultaneously preserve morphology
and biomolecules. Importantly, PAXgene does not involve crosslinking or other chemical
alterations to biomolecules(188). Several papers have found that PAXgene preserves the
integrity of nucleic acids and produces results similar to fresh frozen samples (e.g., high
correlation in expression(189) and high correlation in methylation (190)). To our knowledge,
there have been no studies that have compared variant calls in fresh frozen and PAXgene RNAseq data. The closest study was Högnäs et al. where they compared experimental error rates in
targeted DNA sequencing data(191). No differences in mismatch rate or the distribution of
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incorrect basecalls types were detected between samples that were fresh frozen and samples
that were preserved with PAXgene. This suggests the fidelity of DNA mutation calling from
PAXgene preserved RNA may be high.
Given the lack of precedent of calling PZMs from PAXgene preserved tissue, we hypothesized
that the differences in preservation method among tissue types might drive differences in
mutation burden and spectra. We focused our analyses on the cerebellum and cortex samples
because these brain metaregions each contained a pair of fresh frozen and PAXgene samples
(N = 152 paired cerebellum samples; N = 115 paired cortex samples). These paired samples
were taken from the same brain metaregion but unfortunately were most likely not from the
same biopsy/core.
For the cerebellum metaregion, no difference in normalized mutation burden was detected
between PAXgene and fresh frozen tissues (P-value = 0.44, Wilcoxon signed rank test). For the
cortex metaregion, PAXgene samples had slightly larger mutation burdens (0.08 PZMs/Mb vs.
0.03 PZMs/Mb, P-value = 0.03, Wilcoxon signed rank test) (Figure 5-3).
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Figure 5-3: Normalized mutation burden in paired frozen and PAXgene preserved brain
regions. Left: paired cerebellum tissues; right: paired cortex regions. Tissues are colored in
their canonical GTEx tissue colors. Top and bottom of the boxes denote first and third quartiles,
respectively; horizontal black lines denote median; whiskers denote 1.5× the interquartile range;
and outliers are plotted with transparency to disambiguate overlapping values.
We next compared the mutation spectra between paired fresh frozen and PAXgene preserved
tissues. Mutation spectra was associated with preservation method for both cerebellum and
cortex (P-values = 2.6E-6 and 1.7E-7, respectively, Pearson’s Chi-square test). Post-hoc tests
on the specific mutation types showed that C>A burden was higher in PAXgene tissues than
frozen tissues for both regions after Bonferonni correction. The T>C burden was lower in
PAXgene tissues for cerebellum (Figure 5-4). While statistically significant, we note that the
effect sizes are small, e.g., in cerebellum, the median fraction of T>C mutations is still 0 in both
frozen and PAXgene samples. Due to the relatively small number of mutations observed in a
sample, this analysis may not have had adequate power to detect all differences.
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Figure 5-4: Mutation spectra in paired frozen and PAXgene preserved brain regions.
Top: paired cerebellum tissues; bottom: paired cortex regions. Top and bottom of the boxes
denote first and third quartiles, respectively; horizontal black lines denote median; whiskers
denote 1.5× the interquartile range; and outliers are plotted with transparency to disambiguate
overlapping values.
To increase the power of detecting differences between frozen and PAXgene samples, we
expanded the analysis to include all tissues in GTEx. This was done to increase the sample size
and increase the dynamic range in mutation burden (total and by individual mutation type).
However, this approach has the limitation of not being a well-controlled study, i.e., the vast
majority of tissues do not have matched frozen and PAXgene tissues. We attempted to account
for this by adding relevant covariates into a generalized linear mixed-effects model. For each of
the six mutation type burdens and the total mutation burden (N = 7 models), we used Poisson
regression to fit the following model:
𝑌 ~ 𝑝𝑟𝑒𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛_𝑚𝑒𝑡ℎ𝑜𝑑 + 𝑡𝑖𝑠𝑠𝑢𝑒 + 𝑅𝐼𝑁 + 𝐴𝐺𝐸 + 𝑆𝐸𝑋 + 𝑠𝑒𝑙𝑓_𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑑_𝑎𝑛𝑐𝑒𝑠𝑡𝑟𝑦
+ 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒_𝑑𝑎𝑡𝑎 + 𝑡𝑟𝑎𝑛𝑠𝑐𝑟𝑖𝑝𝑡𝑜𝑚𝑒_𝑠𝑖𝑧𝑒 + 𝑠𝑎𝑚𝑝𝑙𝑒_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟
+ (1|𝐵𝐴𝑇𝐶𝐻) + (1|𝑆𝑈𝐵𝐽𝐸𝐶𝑇)
where 𝑌 was the mutation burden (total or specific mutation type) and 𝐵𝐴𝑇𝐶𝐻 and 𝑆𝑈𝐵𝐽𝐸𝐶𝑇
were modeled as random effects.
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We fit the data again with equation 5-1, only this time, we dropped the 𝑝𝑟𝑒𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛_𝑚𝑒𝑡ℎ𝑜𝑑
covariate. Models were fit using R package lme4 (v1.1-26)(126). Next, we determined if
including the preservation method improved the model fit by comparing the Akaike information
criterion (AIC) of the nested models. For all seven models, adding 𝑝𝑟𝑒𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛_𝑚𝑒𝑡ℎ𝑜𝑑 did not
substantially change the AIC (maximum absolute change in AIC = 2.5%). Therefore, PAXgene
does not appear to affect mutation burden and spectra of PZMs.
In summary, while there are systematic differences in preservation method across the GTEx
tissues, preservation method does not appear to have a large effect on the mutation burden and
spectra of PZMs detected. The small differences detected in the matched brain regions were
not replicated when all tissues were examined. This suggests there may be some subtle
differences. A large, well-controlled study is needed to determine the extent of these
differences.

5.3.3 Prevalence of expressed CHIP mutations in GTEx
Clonal growth of hematopoietic cells (regardless of the underlying cause or disease state) is
known as clonal hematopoiesis. Clonal hematopoiesis of indeterminate potential (CHIP) is a
clinical subclass in which cancer-associated variants (most often in ASXL1, DNMT3A, and
TET2) are detected in the blood of individuals without apparent hematologic malignancies(48).
Since larger clones are more likely to be clinically meaningful, the field generally requires CHIP
mutations to have a VAF, a measure of clone size, to be ≥ 0.02(48). While CHIP mutations are
rare within a donor, CHIP appears to be a common phenomenon across donors. Detection of
CHIP increases with age: CHIP is detected in < 1% of individuals younger than 50 but is found
in 10% of individuals older than 65(42).
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5.3.3.1 Definition of CHIP mutations
We defined putative CHIP mutations as single point mutations that were observed ≥ 5× in
haematopoietic and lymphoid cancer samples in COSMIC v92 (N = 2,289 variants at 2,076
genomic sites).

5.3.3.2 Expressed CHIP mutations are observed at expected rates
We asked whether CHIP could be detected in the GTEx donors. The motivation was threefold.
First, to provide additional evidence about the validity of the variant calling method. Second,
unlike other large cohort studies that use exome and targeted sequencing with limited coverage,
RNA sequencing offers the possibility of thousands of fold coverage and thus the potential to
detect very low VAFs. Such results would expand the field’s knowledge about the prevalence of
CHIP at sub-clinical VAFs. Lastly, detecting mutations in RNA versus the routinely used DNA,
would offer new insight on the potential function of mutated genes.
To detect CHIP mutations in GTEx, we scanned the PZMs detected in whole blood (N = 746
samples) and EBV-transformed lymphocytes (N = 174 samples) for overlap with the set of
putative CHIP mutations.
Six unique CHIP mutations were detected in 7 samples (Table 5-8). Two of the mutations (IDH2
R140Q and MYD88 L273P) are in the 99.99th percentile of recurrent mutations in
haematopoietic and lymphoid cancers and have been shown to have gain-of-function
properties(192, 193). 0.1% (1/746) of whole blood donors and 3.5% (6/174) of EBV-transformed
lymphocyte donors had a CHIP mutation. Of note, none of the CHIP-positive donors had a
history of non-metastatic cancer. The observed CHIP prevalence in GTEx is similar to what we
would expect given the age demographics of the cohort and published prevalence rates(42).
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Table 5-8:
List of CHIP mutations detected in GTEx samples. Genomic coordinates are
relative to GRCh38 and are 0-based with exclusive end coordinates. GTEx recurrence is
defined as the number of times the mutation was detected in GTEx blood and LCL samples.
COSMIC recurrence is defined as the number of times the mutation was detected in
haematopoietic and lymphoid tissue cancer samples. COSMIC recurrence percentile is defined
as the percent of recurrent COSMIC mutations with the same or lower recurrence as the
mutation.

We strongly caution that the CHIP prevalence and CHIP burden are likely underestimates.
Since we valued specificity over sensitivity during variant calling, the filters used were very
aggressive. As a result, 67% (1,534/2,289) of the defined CHIP mutations were removed by one
or more filters. This list includes DNMT3A R882H, a highly recurrent mutation observed in CHIP
studies(42, 47) and JAK2 V617F, the most recurrent mutation observed in haematopoietic and
lymphoid cancers(194). A list of the most recurrent CHIP mutations and their filter status is
visualized in Figure 5-5.

166

Figure 5-5: Several commonly observed mutations in haematopoietic and lymphoid
cancers and CHIP studies were excluded in this study. For the top 30 recurrent mutations
observed in haematopoietic and lymphoid cancers, we annotated whether the genomic position
was removed by the mutation calling method (yellow) or retained (blue and teal) and plotted
their recurrence in cancer from highest to lowest. Genes commonly mutated in CHIP studies are
outlined in black; grey otherwise.
In addition to the constraints imposed by our variant calling method, we were also constrained
by detection power stemming from the expression and background error rate.
To calculate the PZM detection power for a given sample 𝑠, at position 𝑖, with PZM VAF 𝑣, we
set up the hypothesis test as:
𝐻0 : 𝑎𝑙𝑡. 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒𝑠,𝑖 ~ 𝐵𝑖𝑛𝑜𝑚(𝑝 = 𝑒𝑟𝑟𝑜𝑟 𝑟𝑎𝑡𝑒𝑖 , 𝑁 = 𝑡𝑜𝑡𝑎𝑙 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒𝑠,𝑖 )
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𝐻𝑎 : 𝑎𝑙𝑡. 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒𝑠,𝑖 ~ 𝐵𝑖𝑛𝑜𝑚(𝑝 = 𝑣, 𝑁 = 𝑡𝑜𝑡𝑎𝑙 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒𝑠,𝑖 )
and defined the statistical power as 1 − Pr (𝑇𝑦𝑝𝑒 𝐼𝐼 𝑒𝑟𝑟𝑜𝑟). We next calculated the average
power across all samples at a given position for each position in genes associated with CHIP.
The detection power for a representative CHIP gene is shown in Figure 5-6.
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For many CHIP genes, detection power was very limited. This likely contributed to
underestimating the true CHIP prevalence.

Figure 5-6: Mutation detection power in CHIP genes is greater in EBV-transformed
lymphocytes than whole blood. ASXL1 is shown as a representative CHIP gene. Distribution
of average power to detect a variant in ASXL1 across all samples as a function of VAF in EBVtransformed lymphocytes (left) and whole blood (right). Each point in a boxplot represents the
average power across all samples at a given position in the gene. Tissues colored in their
canonical GTEx colors. Top and bottom of the boxes denote first and third quartiles,
respectively; horizontal black lines denote median; whiskers denote 1.5× the interquartile range;
and outliers are plotted with transparency to disambiguate overlapping values.
Additionally, we are underpowered by biology and study design to detect several classes of
CHIP mutations. Since mutations are detected at the RNA level, nonsense mutations which can
contribute a large fraction of single nucleotide CHIP mutations (e.g., 27% in (47)) may be
undetected due to nonsense-mediated decay. To avoid false positives from spurious alignments
at splice junctions, we ignored all mutations near splice junctions. Lastly, we did not call
postzygotic indels.
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5.3.3.3 Elevated rates of CHIP mutations in EBV-transformed lymphocytes
compared to blood is likely due to technical reasons
The enrichment of detected CHIP mutations in EBV-transformed lymphocytes compared to
whole blood may be the result of mutations occurring in vitro rather than in vivo. While we
cannot rule out this possibility, we did observe that EBV-transformed lymphocytes samples had
greater mutation detection power than whole blood samples at CHIP genes due to the
differences in expression levels (Figure 5-6). Thus for technical reasons, we would expect EBVtransformed lymphocytes to be enriched for CHIP mutations compared to whole blood.

5.3.3.4 Summary
In summary, LachesisDetect was able to detect expressed somatic cancer drivers in individuals
without apparent hematological malignancies. This result provides additional evidence that the
mutation calling method has high specificity and moderate sensitivity. To our knowledge, this is
the first time CHIP mutations have been detected at the RNA level and thus suggest expression
of these mutations may have a functional role in clonal growth.

5.3.4 PZM deleteriousness validation
5.3.4.1 TwinsUK validation dataset
We ran our variant calling method on a novel, independent dataset, TwinsUK(121). The
TwinsUK dataset consisted of data from 445 living twin pairs wherein each twin had ~3 tissues
profiled with RNA-seq. In total, there were ~2,500 RNA-seq samples. After filtering PZMs to the
allowable transcriptome, there were 1,507 PZMs of which 1% (18/1,507) were predicted to be
prenatal PZMs. (Of note, compared to GTEx, TwinsUK had lower sequencing depth and fewer
tissues profiled per donor. As a result, the sensitivity to detect low VAFs and prenatal PZMs was
most likely reduced.)
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Encouragingly, the deleteriousness of TwinsUK PZMs was not statistically different than the
GTEx PZMs, suggesting that the GTEx results may reflect global properties of PZMs rather than
technical artifacts (odds ratio of GTEx prenatal PZMs over TwinsUK prenatal PZMs = 1.14,
FDR-corrected q-value = 0.84 (GTEx low VAF) and odds ratio = 0.57, q-value = 0.37 (GTEx
high VAF); odds ratio of GTEx postnatal PZMs over TwinsUK postnatal PZMs = 0.98, q-value =
0.84) (Figure 5-7).

Figure 5-7: PZM deleteriousness results are replicated in TwinsUK data.A. PHREDscaled CADD score CCDFs of GTEx PZMs and TwinsUK PZMs. TwinsUK PZMs were not
partitioned by VAF due to the small sample size and decreased sensitivity to detect low VAF
PZMs. Random neutral CADD CCDF shown for context. B. Left: odds of detecting deleterious
mutations in a given dataset compared to TwinsUK prenatal PZMs. Right: odds relative to
TwinsUK postnatal PZMs. Vertical line at odds ratio = 1 indicates no difference in odds of
detecting deleterious mutations in a given dataset compared to reference dataset. Error bars
represent 95% confidence intervals.
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5.3.4.2 Yizhak et al. validation dataset
We next compared the deleteriousness of PZMs with PZMs from Yizhak et al.(61) These PZMs
were generated from an earlier version of GTEx. Thus, this validation dataset is not entirely
independent from the one in this study. However, a different mutation calling method was used
to call PZMs from RNA-seq. PZMs were detected from ~6,700 RNA-seq samples across 488
donors and 29 tissue types. After filtering PZMs to the GTEx pass QC tissues and allowable
transcriptome, there were 4,454 PZMs, of which we predicted 0.8% (36/4,454) to be prenatal.
All VAFs were larger than the low VAF cutoff and thus were defined as high VAF PZMs.
Yizhak et al. high VAF prenatal PZMs were as deleterious as prenatal high VAF PZMs (oddsratio = 1.8, FDR-corrected q-value = 0.13). Yizhak et al. postnatal PZMs were slightly less
deleterious than postnatal PZMs (odds-ratio = 1.2, q-value = 1.5E-8) (Figure 5-8). However, this
difference may be due to differences in tissue composition between the different GTEx versions.
Therefore, we compared deleteriousness of postnatal PZMs by tissue.
Due to the lower dataset size, we only compared tissues with at least 100 PZMs in Yizhak et al.
Additionally, we used the same tissue grouping as Yizhak et al., e.g., skin includes GTEx
tissues Skin - Not Sun Exposed (Suprapubic) and Skin - Sun Exposed (Lower leg). Yizhak et al.
tissue-specific postnatal PZMs were as deleterious as tissue-specific postnatal PZMs for 80%
(8/10) of tissues. The exceptions were brain (odds-ratio = 0.62, q-value = 5.9E-3) and skin
(odds-ratio = 0.87, q-value = 0.04) (Figure 5-9). The differences may be due to differences in
tissue composition across the two datasets since the tissues represent multiple GTEx tissues.
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Figure 5-8: Global PZM deleteriousness results replicated in Yizhak et al. data. A.
PHRED-scaled CADD score CCDFs of GTEx PZMs and Yizhak et al. Random neutral CADD
CCDF shown for context. B. Left: odds of detecting deleterious mutations in a given dataset
compared to Yizhak et al. [high VAF] prenatal PZMs. Right: odds relative to Yizhak et al.
postnatal PZMs. Vertical line at odds ratio = 1 indicates no difference in odds of detecting
deleterious mutations in a given dataset compared to reference dataset. Error bars represent
95% confidence intervals.
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Figure 5-9: Tissue-specific PZM deleteriousness results replicated in Yizhak et al. data.
A. PHRED-scaled CADD score CCDFs of GTEx postnatal PZMs and Yizhak et al. postnatal
PZMs by tissue. Random neutral CADD CCDF shown for context. B. Odds of detecting
deleterious mutations in a given tissue in Yizhak et al. relative to the odds of detecting
deleterious mutations in the same tissue in this study. Vertical line at odds ratio = 1 indicates no
difference in odds of detecting deleterious mutations in a given dataset compared to reference
dataset. Error bars represent 95% confidence intervals.
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5.3.4.3 García-Nieto et al. validation dataset
We next compared the deleteriousness of PZMs with PZMs from García-Nieto et al.(62) Like
Yizhak et al., these PZMs were generated from an earlier version of GTEx and thus, this
validation dataset is not entirely independent from the one in this study. However, a different
mutation calling method was used to call PZMs from RNA-seq. PZMs were detected from
~7,600 RNA-seq samples across 547 donors and 36 tissue types. After filtering PZMs to the
GTEx pass QC tissues and allowable transcriptome, there were 282,561 PZMs, of which we
predicted 9.6% (27,251/282,561) to be prenatal. All VAFs were larger than the low VAF cutoff
and thus were defined as high VAF PZMs.
Surprisingly, García-Nieto et al. prenatal and postnatal PZMs were as deleterious as common
standing germline variation (population allele frequency = 1-10%, odds-ratio = 1.2, FDRcorrected q-value = 0.17) and did not validate the patterns observed with the PZMs presented
here and the other validation studies (Figure 5-10). Given the low fraction of deleterious
mutations, their similarity to germline mutations, and their dissimilarity to the other four datasets
(the PZMs presented here, TwinsUK, Yizhak et al., and Brazhniek et al.), we suspect this
dataset may be contaminated with common germline variants from the donors.
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Figure 5-10: PZM deleteriousness results not replicated in García-Nieto et al. data. A.
PHRED-scaled CADD score CCDFs of GTEx PZMs and García-Nieto et al. PZMs. Random
neutral CADD CCDF and germline variation CCDFs shown for context. B. Left: odds of
detecting deleterious mutations in a given dataset compared to García-Nieto et al. prenatal [high
VAF] PZMs. Right: odds relative to García-Nieto et al. postnatal PZMs. Vertical line at odds
ratio = 1 indicates no difference in odds of detecting deleterious mutations in a given dataset
compared to reference dataset. Error bars represent 95% confidence intervals. AF = population
allele frequency.

5.3.4.4 Brazhnik et al. validation dataset
We next compared the deleteriousness of PZMs with PZMs from Brazhnik et al.(54) Brazhnik et
al. detected PZMs from single human hepatocytes, liver stem cells (LSCs), and organoids
derived from LSCs. Importantly, these PZMs were detected from samples independent of GTEx,
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were detected in DNA, and used a different mutation calling method and thus, represents an
independent validation dataset. Hepatocytes are an appropriate validation cell type because
bulk liver is primarily composed of hepatocytes(195). Thus the comparison between single-cell
hepatocytes and bulk liver data will likely not be confounded by cell composition issues.
PZMs were detected from 62 DNA single-cell multiple displacement amplification libraries
across 12 donors. After filtering PZMs to the allowable transcriptome, there were 414 PZMs of
which the majority were from hepatocytes (88% (363/414)). Since all samples were generated
from the same tissue, we did not try to predict prenatal PZMs. Additionally, since PZMs were
generated from single-cell data rather than bulk data, we did not try to predict the VAF of the
PZM in bulk tissue.
Hepatocyte PZMs were as deleterious as postnatal liver PZMs (odds-ratio = 0.84, FDRcorrected q-value = 0.21). LSC PZMs were also as deleterious as postnatal liver PZMs (oddsratio = 1.8, FDR-corrected q-value = 0.09). Surprisingly, LSC PZMs may be less deleterious
than hepatocyte PZMs; however this result was not significant after multiple test correction
(odds-ratio = 0.46, P-value = 0.014, q-value = 0.08) (Figure 5-11). The lack of a significant
difference may be due to small sample size. This observation raises an intriguing hypothesis
that stem cells may be under stronger selection than differentiated cells to constrain the
functional impact of PZMs.
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Figure 5-11: PZM deleteriousness results replicated in Brazhnik et al. data. A. PHREDscaled CADD score CCDFs of GTEx PZMs and Brazhnik et al. PZMs. Random neutral CADD
CCDF shown for context. B. Left: odds of detecting deleterious mutations in a given dataset
compared to Brazhnik et al. hepatocyte PZMs. Right: odds relative to Brazhnik et al. LSC
PZMs. Vertical line at odds ratio = 1 indicates no difference in odds of detecting deleterious
mutations in a given dataset compared to reference dataset. Error bars represent 95%
confidence intervals.

5.3.5 Characterization of germ cell PZMs
5.3.5.1 Germ cell PZMs can be detected in bulk male gonads
We hypothesized that PZMs detected in bulk gonads could be used to study PZMs in germ
cells. We used a bottom-up approach by first investigating if the transcriptomes of germ cells
and bulk gonads were similar and then determining if the specific genes with PZMs were
enriched for genes expressed in germ cells.
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We first determined if germ cell PZMs could be detected in bulk female gonads. We tested if the
bulk ovary transcriptome was similar to the oocyte transcriptome. We performed hierarchical
clustering of published human mature oocyte transcriptomes(196) with GTEx tissue
transcriptomes. The oocyte transcriptomes did not closely cluster with the ovary transcriptome,
suggesting that bulk ovary expression is a poor proxy for female germ cell expression (Figure
5-12). This result is expected given that ovaries primarily consist of interstitial stroma, a
heterogenous mixture of somatic cell types(197). We therefore concluded that PZMs in bulk
ovary could not be confidently mapped to PZMs in female germ cells.

Figure 5-12: Bulk ovary and single-cell oocyte transcriptomes are dissimilar. Data from
single-cell RNA-seq of oocytes (red) is from (196). Oocyte data consists of three biological
replicates (oocyte_1, oocyte_2, and oocyte_3). Oocyte_1 had two technical replicates
(oocyte_1_a and oocyte_1_b). While oocytes form a clade, oocytes and bulk ovary (blue) do
not, suggesting that oocyte and ovary transcriptomes are dissimilar.
Next, we determined if germ cell PZMs could be detected in bulk male gonads. We tested if the
bulk testis transcriptome was similar to male germ cell transcriptomes. We performed
hierarchical clustering of human single-cell testicular biopsy transcriptomes with GTEx tissue
transcriptomes (Mahyari, et al. in review.). Mahyari et al. classified the single-cell testicular
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biopsy data into five germ cell types and seven somatic cell types using differential expression
analysis (N = 12 total cell types). The bulk testis and germ cell transcriptomes formed a clade
and were more similar to each other than to any other tissue or cell type, suggesting that bulk
testis expression is a reasonable proxy for male germ cell expression (Figure 5-13). This result
is expected as 85% of cells in a normal adult testis are germ cells (Figure 5-14).

Figure 5-13: Bulk testis and male germ cell transcriptomes are highly similar. Testis
single-cell RNA-seq data from Mahyari, et al. Germ cell (red) and somatic testicular cell types
(green) were defined from differential expression analysis in Mahyari, et al. Testis (blue) and
germ cell transcriptomes form a clade and are more similar to each other than any other tissue
or testicular somatic cell type transcriptome.
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Figure 5-14: Majority of cells in adult testis are germ cells. Data from Mahyari, et al.
Average percent of cell types in testis across six normal adult males. Germ cell types are
marked in shades of reds; somatic cell types are marked in shades of greens. Percent of each
cell type listed in legend.
We next determined if the PZMs were likely to have originated from genes expressed by germ
cells rather than somatic cells. For each germ cell PZM, we defined the probability that the PZM
was in a gene expressed in germ cells as the ratio of expression from germ cell types to the
expression of all 12 cell types in the testis. Each cell type was weighted by its prevalence in the
testis. The germ cell PZMs were partitioned into gonosomal (i.e., PZM detected in testis and at
least one other tissue) and germ cell-specific (i.e., PZM detected only in testis) groups. Both
groups were more likely to have originated from germ cells than somatic cells. On average,
gonosomal PZMs were 64% likely to be expressed in germ cells and germ cell-specific PZMs
were 76% likely to be expressed in germ cells (Figure 5-15). The lower probability in gonosomal
PZMs is expected: since variants were detected from RNA-seq, putative gonosomal PZMs are
likely to be in genes that are broadly expressed across the body whereas putative germ cellspecific PZMs may be broadly expressed or show testis-specific expression.
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Together, these results suggest that the majority of PZMs detected from bulk testis RNA-seq
are PZMs in germ cells. Thus, we can use such PZMs to measure properties about mutations in
the male germline.

Figure 5-15: Complementary cumulative distribution of the probability that PZMs
originated from germ cells. The majority of germ cell-specific (gray) and gonosomal (green)
PZMs are more likely to have come from germ cells than somatic cells. Gonosomal PZMs have
a lower probability than germ cell-specific PZMs because they are ascertained from transcripts
broadly expressed across the body and thus are less likely to be germ cell-specific.

5.3.5.2 Gonosomal and germ cell-specific PZM class labels are likely correct
As an extra level of precaution, we next assessed the validity of the gonosomal and germ cellspecific class labels by checking if each group manifested expected properties. The results are
summarized in Table 5-9.
Table 5-9:
Confusion matrix for potential mislabelling of gonosomal and germ cellspecific PZMs. Matrix cells represent all possible correct and incorrect labellings of predicted
gonosomal and germ cell-specific PZMs. Cells that represent correctly labelled classes are
shaded in green; incorrectly labelled classes are shaded in red. Cell text describes the expected
patterns in the data if the scenario were true. Check marks denote the pattern was observed;
X’s denote the pattern was not observed. Since all of the correct labelling patterns were
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observed and none of the incorrect labelling patterns were observed, the gonosomal and germ
cell-specific PZM datasets are likely correctly labeled.

For observed gonosomal PZMs, we first determined if the predicted mutations were actually
inherited germline variants. The RNA-seq cumulative VAF from all tissues with the gonosomal
mutations was significantly lower than the RNA-seq cumulative VAF of germline variants in
GTEx donors (P-value = 5.3E-44, Mann Whitney U test, Figure 5-16.a). Additionally,
gonosomal PZMs had lower population allele frequencies than the GTEx donors’ inherited
germline variants (P-value = 4.9E-13, Mann Whitney U test, Figure 5-16.b). Together, these
results suggest that even with complexities due to allele-specific expression, gonosomal PZMs
are likely not germline variants.
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Figure 5-16 Gonosomal and germ cell-specific PZMs have signatures distinct from
germline variants. a. VAF distribution of donor germline variants, gonosomal PZMs, and germ
cell-specific PZMs. All VAFs are measured from RNA-seq data. b. Distribution of minor allele
frequencies of germline variants, gonosomal PZMs, and germ cell-specific PZMs. P-values from
Mann Whitney U tests. To reduce noise in estimates, only donor germline variants with at least
10× coverage were used. For computational ease, only donor germline variants on chr22 were
used. Top and bottom of the boxes denote first and third quartiles, respectively; horizontal black
lines denote median; whiskers denote 1.5× the interquartile range; and outliers are plotted with
transparency to disambiguate overlapping values. NFE AF = allele frequency in non-Finish
Europeans.
Next we determined if the predicted gonosomal PZMs were actually germ cell-specific PZMs.
This scenario would require false positive PZM calls in at least one other tissue. The FPR of the
full set of PZMs was estimated to be 1%. The FPR for germ cell-specific PZMs is likely very
similar. Therefore, most predicted gonosomal PZMs are likely not germ cell-specific PZMs.
Lastly, a predicted gonosomal PZM may actually be noise. This case is likely not common as
experimental and computational FDRs were reasonably low.
After ruling out mislabelling opportunities, we then confirmed the gonosomal PZM burden had
expected properties, namely, the burden was not associated with age. We fit the gonosomal
burden with the following linear model:
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𝑔𝑜𝑛𝑜𝑠𝑜𝑚𝑎𝑙_𝑏𝑢𝑟𝑑𝑒𝑛 ~ 𝐴𝐺𝐸 + 𝑛𝑢𝑚_𝑡𝑖𝑠𝑠𝑢𝑒𝑠 + 𝑠𝑒𝑙𝑓_𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑑_𝑎𝑛𝑐𝑒𝑠𝑡𝑟𝑦 + 𝑚𝑒𝑑𝑖𝑎𝑛_𝑅𝐼𝑁
+ 𝑚𝑒𝑑𝑖𝑎𝑛_𝑠𝑎𝑚𝑝𝑙𝑒_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟
+ log10 (𝑔𝑒𝑟𝑚 𝑐𝑒𝑙𝑙– 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑢𝑟𝑑𝑒𝑛 + 1)
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where 𝑔𝑜𝑛𝑜𝑠𝑜𝑚𝑎𝑙 𝑏𝑢𝑟𝑑𝑒𝑛 was defined as the number of gonosomal PZMs in a donor
normalized by the median transcriptome size of all samples in the donor. 𝑚𝑒𝑑𝑖𝑎𝑛_𝑅𝐼𝑁 was
defined as the median RIN of all samples in a donor. 𝑚𝑒𝑑𝑖𝑎𝑛_𝑠𝑎𝑚𝑝𝑙𝑒_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟 was
defined in a similar manner. 𝑔𝑒𝑟𝑚 𝑐𝑒𝑙𝑙– 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑢𝑟𝑑𝑒𝑛 was defined as the number of germ cell
specific PMZs in a donor. Only male donors with genotype data available were used.
As expected, gonosomal PZM burden was not associated with donor age (P-value = 0.28).
Together, this data suggests that putative gonosomal PZMs are correctly labelled.
We applied a similar framework for the predicted germ-cell specific PZMs. This class is also
unlikely to be highly contaminated with germline variants. The predicted germ cell-specific PZM
VAFs were significantly smaller than the RNA-seq VAFs of donor germline variants (P-value =
2.2E-308, Mann Whitney U test, Figure 5-16.a) and the PZMs had significantly lower minor
allele frequencies than donor germline variants (P-value = 8.2E-72, Mann Whitney U test,
Figure 5-16.b).
In order for a putative germ cell-specific PZM to actually be a gonosomal PZM, the mutation
must have been a false negative mutation in all somatic tissues containing the PZM. This likely
does not explain the majority of germ cell-specific PZMs since the power to detect gonosomal
PZMs was reasonably high for moderately high VAFs (Figure 5-17). (Due to their timing,
gonosomal PZMs are predicted to have relatively high VAFs.) At the median gonosomal PZM
coverage ([100, 1000)) and median gonosomal PZM VAF (0.05), the power to detect gonosomal
PZMs was 95%. (Note that these power estimates include the desired case (i.e., a gonosomal
PZM is mislabeled as a germ cell-specific PZM) but also include the case when no PZM was
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detected in any somatic or germline tissue. Therefore, these power estimates will likely be
underestimated when just the desired case is considered.)

Figure 5-17: Gonosomal PZM detection power as function of VAF and expression level.
Gonosomal PZMs were simulated in male testis donors across a wide range of VAFs. The
percent of simulated variants that were correctly recovered as gonosomal (present in testis and
at least one other tissue) was recorded. Coverage of the gonosomal PZM was defined as the
median coverage across all sampled tissues in the donor at the particular genomic position.
Since coverage is an important component of power, simulated variants were partitioned in
three coverage groups. For some coverage groups, gonosomal PZM power curves do not
saturate to 100% power due to constraints from differences among tissue transcriptomes and
the GTEx tissue sampling structure.
A predicted germ cell-specific PZM may actually be noise. This case is likely not common as
experimental and computational FDRs were reasonably low.
After ruling out potential false positive scenarios, we confirmed germ cell-specific PZMs had
properties of true germ-cell specific PZMs. We expected that germ cell-specific PZMs would
show an age dependence and would have lower VAFs than gonosomal PZMs.
We fit the germ cell-specific burden with the following linear model:
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𝑔𝑒𝑟𝑚_𝑐𝑒𝑙𝑙– 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐_𝑏𝑢𝑟𝑑𝑒𝑛 ~ 𝐴𝐺𝐸 + 𝑠𝑒𝑙𝑓_𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑑_𝑎𝑛𝑐𝑒𝑠𝑡𝑟𝑦 + 𝑅𝐼𝑁
+ 𝑠𝑎𝑚𝑝𝑙𝑒_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟
where 𝑔𝑒𝑟𝑚 𝑐𝑒𝑙𝑙– 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑢𝑟𝑑𝑒𝑛 was defined as

log10 ( # 𝑔𝑒𝑟𝑚 𝑐𝑒𝑙𝑙−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛𝑠+1)
.
𝑡𝑟𝑎𝑛𝑠𝑐𝑟𝑖𝑝𝑡𝑜𝑚𝑒 𝑠𝑖𝑧𝑒
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(This

transformation produced the best fitting model of all models tested. Sample batch was not
included as a random effect because very few batch levels were repeated and the models
resulted in singular model fits suggesting overfitting.) Again, only male donors with genotype
data available were used.
As expected, germ cell-specific PZM burden was positively associated with donor age (P-value
= 0.03). Additionally, as expected, germ cell-specific PZMs had lower VAFs than gonosomal
PZMs (P-value = 1.3E-14, Mann-Whitney U test, Figure 5-16.a).
Collectively, these results suggest that the gonsomal and germ cell-specific PZM class labels
are likely accurate; however there may still be some misclassification at an individual variant
level.

5.3.5.3 Study design and model assumptions did not affect germline surrogate
tissue analyses
5.3.5.3.1 Donor genotype status does not affect prenatal PZM burden
An important confounder in the gonosomal PZM surrogate tissue analysis is that blood was
used to define (and later remove) germline variants from the donors. These predicted germline
variants might actually be high VAF PZMs that were incorrectly labelled as germline variants
during germline variant calling on blood WGS. Thus, at first glance, the result that blood was the
worst tissue to detect gonosomal PZMs may be explained by blood having a higher rate of
gonosomal PZMs removed from the germline variant filter.
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The GTEx study design offered a unique opportunity to examine the validity of this hypothesis:
for 6% of GTEx donors, a non-blood tissue was used for genotyping and for 12% of donors, no
genotyping data was available. (We note that while we excluded non-genotyped donors from all
germline analyses, including non-genotyped donors for this analysis allowed us to investigate
the strongest effect of genotyping on PZM variant calling.) To determine if using blood for
germline variant calling affected the surrogate analysis, we compared various mutation metrics
between donors who were genotyped using blood DNA, donors genotyped using non-blood
DNA, and donors not genotyped. To increase the power of detecting a significant difference, we
expanded the analysis to all prenatal PZMs rather than just the subset of gonosomal PZMs.
If germline variant filtering removed [high VAF] prenatal PZMs from blood, we would expect
blood genotyped donors to have fewer prenatal PZMs detected in blood than non-blood
genotyped donors and much fewer prenatal PZMs than non-genotyped donors. We fit the
following model:
# 𝑝𝑟𝑒𝑛𝑎𝑡𝑎𝑙 𝑃𝑍𝑀𝑠 𝑖𝑛 𝑏𝑙𝑜𝑜𝑑 + 1
~ 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒_𝑠𝑜𝑢𝑟𝑐𝑒 + 𝑅𝐼𝑁 + 𝐴𝐺𝐸 + 𝑆𝐸𝑋
𝑡𝑟𝑎𝑛𝑠𝑐𝑟𝑖𝑝𝑡𝑜𝑚𝑒_𝑠𝑖𝑧𝑒
+ 𝑠𝑒𝑙𝑓_𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑑_𝑎𝑛𝑐𝑒𝑠𝑡𝑟𝑦 + 𝑠𝑎𝑚𝑝𝑙𝑒_𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛_𝑝𝑜𝑤𝑒𝑟 + (1|𝐵𝐴𝑇𝐶𝐻)
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where 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒_𝑠𝑜𝑢𝑟𝑐𝑒 was blood, not_blood, or not_genotyped. We fit the data again with
equation 5-5, only this time, we dropped the 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒_𝑠𝑜𝑢𝑟𝑐𝑒 covariate. Models were fit using
R package lme4 (v1.1-26). Next, we determined if including the genotype source improved the
model fit by comparing the AIC of the nested models. Adding 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒_𝑠𝑜𝑢𝑟𝑐𝑒 did not
substantially change the AIC (percent change in AIC = 0.1%). This suggests that the use of
blood for germline variant filtering did not affect the prenatal PZM burden and thus poor
detection of gonosomal PZMs in blood is not the result of overzealous germline variant filtering
in blood.
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5.3.5.3.2 Step 2 of LachesisDetect does not reduce inter-tissue variation in VAF
We investigated if the similarity of tissue VAFs for a given gonosomal PZMs could be an artefact
of LachesisDetect. An assumption of the mutation calling pipeline is that if a mutation is found in
multiple tissues of the same donor, the tissue VAFs will be similar. Recall that in step 1 of
LachesisDetect, the variant calling algorithm identifies mutations in a sample independent of all
other samples. In step 2, the algorithm uses the aforementioned assumption to perform more
sensitive variant calling.
We defined the inter-tissue variation in VAF of a given multi-tissue PZM as the variation in VAF
across all of the donor’s tissues with the PZM. To test if step 2 biased multi-tissue PZMs to have
more similar VAFs, we compared the inter-tissue variation in VAF of multi-tissue PZMs detected
in step 1 with multi-tissue PZMs detected in step 2. If step 2 artificially shrank the tissue VAFs to
be more similar, we would expect a reduction in inter-tissue VAF variation after step 2.
To increase power, we used all prenatal PZMs rather than just the gonosomal PZM subset. We
used the median absolute deviation (MAD) of VAFs normalized by the median VAF to estimate
the variation in VAFs within a multi-tissue PZM. MAD was chosen to robustly measure variation
due to the relatively small number of tissues in a multi-tissue PZM. We fit the following linear
model to the data:
𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑀𝐴𝐷 ~ 𝑃𝑍𝑀_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑠𝑡𝑒𝑝 + 𝑛𝑢𝑚_𝑡𝑖𝑠𝑠𝑢𝑒𝑠 + 𝑃𝑍𝑀_𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛_𝑠𝑡𝑒𝑝
∗ 𝑛𝑢𝑚_𝑡𝑖𝑠𝑠𝑢𝑒𝑠
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The relationship between normalized MAD and the covariates is shown in Figure 5-18.a. The
interaction term was significant, i.e., the relationship between normalized MAD and which step
identified the PZM in multiple tissues was different when the number of tissues increased. When
the number of tissues was small (< 8), there was no difference in normalized MAD between step
1 and step 2 multi-tissue PZMs. When the number of tissues was large (≥ 8), there was a
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significant difference; however, the sign was in the opposite direction from what we expected:
step 2 PZMs had greater variation than step 1 PZMs (Figure 5-18.b). The majority of multitissue PZMs (94%) occurred in the former case.

Figure 5-18: Step 2 of LachesisDetect does not reduce intra-tissue variation in VAF a.
Normalized MAD of multi-tissue PZMs as a function of the number of tissues containing the
mutation and which step the multi-tissue evidence was detected in. b. Predicted difference in
normalized MAD between step 1 and step 2 multi-tissue PZMs as a function of the number of
tissues containing the mutation. Error bars represent 95% confidence intervals. MAD = median
absolute deviation.
Together, this analysis shows that step 2 does not artificially decrease variation in VAF. The
implications are two fold: first the assumption about VAF similarity is appropriate (MADs were
generally small) and second, the similarity of germ cell and somatic tissue gonosomal PZM
VAFs is likely a biological rather than technical result.

5.3.6 Paternal Age Effect Mutations
During selfish spermatogonial selection (SSS), pathogenic gain-of-function mutations in
spermatogonial stem cells clonally expand. This can result in testicular tumors and fathering
children with paternal age effect (PAE) disorders (reviewed in (124)). SSS is thought to be a
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general phenomenon, however detection of SSS may only be possible in donors of advanced
age, since the rare mutant cells need time to expand to appreciable levels. (Indeed, in published
studies, enrichment-based assays and extremely high sequencing coverage are often used to
overcome this signal-to-noise issue(198, 199).)
We examined if the testis samples had evidence of SSS. We scanned the testis PZMs for
pathogenic and likely pathogenic variants that cause PAE disorders. We defined three
overlapping sets of variants, each with a different level of evidence to cause PAE disorders. A
list of curated variants (N = 11 unique positions) that are known to cause PAE disorders ((148,
200)) (defined as the curated dataset). The curated set represents the highest quality set but is
very small. To increase our sensitivity to detect PAE variants, we expanded the search space to
two broader catalogs, at the risk of losing some specificity of true PAE variants: a list of variants
(N = 468 unique positions) that are pathogenic and likely pathogenic for PAE disorders taken
from Clinvar (defined as the clinvar_var dataset) and a list of variants (N = 269 unique
positions) that are in genes from the curated dataset, but are pathogenic and likely pathogenic
for any disease from Clinvar (defined as the clinvar_gene dataset).
For all PAE disorders except Multiple Endocrine Neoplasia (MEN), Clinvar was queried using
the advanced search with Disease/Phenotype set to the disorder of interest on 11/02/2020. For
MEN, Clinvar returned 0 results when using the advanced search for Disease/Phenotype =
MEN2A or MEN2B or any of the aliases for MEN2A and MEN2B listed in OMIM. Therefore, a
general search on “Multiple Endocrine Neoplasia” was used and the results were subset into 4
non-disjoint sets: hits containing “Multiple Endocrine Neoplasia” (men), “Multiple endocrine
neoplasia, type 2a” (men_men2a), “Multiple endocrine neoplasia, type 2b” (men_men2b) or
“Multiple endocrine neoplasia, type” (men_men2).
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We did not observe any overlap between testis PZMs and the PAE variant sets. Therefore, we
set to determine if low PZM detection power could explain this result. We simulated each set of
PAE variants at various VAFs in the testis samples and then measured how frequently they
were detected by LachesisDetect. Power was extremely low to detect the expected very low
VAFs (Figure 5-19). Additionally, the PZM filters originally designed to improve variant calling
specificity, had the unfortunate consequence of removing potential variants (e.g., 4/10 (40%) of
pathogenic and likely pathogenic variants associated with achondroplasia, a PAE disorder, were
removed) (Figure 5-20).

Figure 5-19: Power of detecting PAE variants in testis as a function of VAF. Left:
detection power for clinvar_gene variants; middle: clinvar_var variants; right: curated variants
as a function of VAF. Each boxplot represents the distribution of observed power across the
testis samples and variants at that VAF. Top and bottom of the boxes denote first and third
quartiles, respectively; horizontal black lines denote median; whiskers denote 1.5× the
interquartile range; and outliers are plotted with transparency to disambiguate overlapping
values. The median VAF of PAE variants observed in (199) is denoted by the red dashed line.
To provide additional context for the VAFs, the VAFs of observed mutations in testis is plotted
as a histogram in all facets(frequency listed in right Y-axis). At the expected VAF of PAE
variants, the power is extremely low for all variant sets. This suggests that the lack of selfish
spermatogonial selection signal may be due to technical rather than biological effects.
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Figure 5-20: Percent of pathogenic and likely pathogenic PAE variants removed by
filters used during mutation calling. Removal fraction partitioned by PAE-associated disease.
N is the number of known pathogenic and likely pathogenic SNVs for the disease. Pathogenicity
labels from Clinvar. On average, 31% (range = 7 - 67%) of known loci were removed by filters.
Together with the low power, aggressive filtering, and the fact that the GTEx donors were
younger than published SSS studies (median age 54 vs. e.g., 83 in (199)), the lack of detecting
PAE variants in testis PZMs is not surprising.
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Appendix A
Contribution of PZMs to complex traits
and diseases
1.1 Introduction
It’s become increasingly clear that monogenic mendelian diseases can be caused by
postzygotic mutations(1). In such cases, disease presentation can be variable due to the
specific timing of when and where the mutation occurred during development and aging. On the
other end of the spectrum of genetic complexity, cancer results from the correct constellation of
inherited germline variants and postzygotic mutations in tumor suppressor and oncogenes.
We hypothesized that other complex diseases and traits, especially those that show age
dependence, may result from postzygotic mutations. Similar to Knudson’s two-hit theory of
cancer causation(201), we speculate that a subset of complex diseases and traits may be the
result of multiple PZMs in key pathways of cellular function (Figure A.1-1). If this hypothesis
were true, then we predict that disease/trait associated genes will be enriched for genes with
PZMs.

Figure A.1-1: Complex disease and traits may be the result of PZMs in key pathways of
cellular function. The ovals represent a diploid cell over time where mutagenic events
(lightning bolts) eventually lead to both copies of an important component of cellular function to
be mutated. As a result of abnormal cell function, a complex disease/trait arises.

1.2 Methods
The goal of this analysis was to determine if complex disease/trait associated genes are
enriched with genes that have PZMs.
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We first needed a catalog of disease/trait associated genes. We used the NIH’s catalog of
human genome-wide association studies, a catalog of ~4,200 complex disease/traits and
~192,000 SNVs derived from ~3,800 studies. As GWAS calculates the association between
SNVs and a disease and not a gene and disease, we next needed an efficient way to map
GWAS tagged SNVs to genes. To hone in on causal GWAS SNPs rather than SNPs in linkage
disequilibrium, we pruned the list of SNPs such that no two SNPs were within 1Mb of each other
using a greedy algorithm that prioritized higher GWAS significance levels.
As a first pass, for each tissue, we simply assigned GWAS SNVs to the closest gene. (Ties
were broken by selecting the gene with the highest expression in that tissue.) While routinely
done in the literature, this method is known to incorrectly map some SNVs to the incorrect
genes. (In later iterations, we experimented with assigning a GWAS SNV to 1) all genes in the
same haplotype block and 2) all genes in the same topologically associated domains. These
latter methods most likely had higher sensitivity at mapping GWAS SNVs to the correct gene(s),
however, the specificity was most likely much lower than the initial approach. As a result, we
had very low power for detecting significant associations between GWAS genes and genes with
PZMs with the latter methods. Therefore, we chose to use the simple closest gene approach.)
For each GWAS trait and tissue, we calculated the significance of the overlap between GWAS
genes and genes with PZMs in that tissue (Fisher’s exact test). Due to the thousands of
hypothesis tests, we used a permutation-based FDR cutoff to limit the number of type I errors
(Figure A.1-2).

Figure A.1-2: Overview for estimating the enrichment of PZMs in GWAS genes.
To calculate the FDR, for each GWAS trait and tissue, we created scrambled lists of GWAS
genes. Here, we permuted which genes were associated with each GWAS trait. Since mutation
detection power is correlated with expression level, we constrained the permutations on
expression: a gene in the top quartile of expression in the given tissue was only scrambled with
other genes in the top quartile of expression, etc.
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At a given false positive rate, 𝛼, and P-value cutoff k, the FDR is
𝐹𝐷𝑅𝛼 =

# 𝐹𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
# 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑡𝑒𝑠𝑡𝑠 @ 𝑃𝑟 ≤ 𝑘

and the estimated FDR is
̂𝛼 =
𝐹𝐷𝑅

𝐴𝑣𝑒𝑟𝑎𝑔𝑒 # 𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 𝑖𝑛 𝑅𝐴𝑁𝐷𝑂𝑀 𝑑𝑎𝑡𝑎 @ 𝑃𝑟 ≤ 𝑘
# 𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 𝑖𝑛 𝑅𝐸𝐴𝐿 𝑑𝑎𝑡𝑎 @ 𝑃𝑟 ≤ 𝑘

1.3 Results
35 GWAS trait-tissue pairs were significantly enriched for PZMs at an FDR of 10% (Figure A.13). Many significant associations involved liver and blood related traits. Encouragingly, several
of the significant traits were disease related (e.g., Alcoholic chronic pancreatitis), exposure
related (e.g., erythrocyte cadmium concentration in never smokers), age related (age-related
macular degeneration (geographic atrophy)) or a combination of thereof. Some associations
represent putative cognate relationships, e.g., alcoholic chronic pancreatitis genes are
associated with PZMs in the pancreas. These results generate many interesting hypotheses
about the etiology of disease and complex traits.

Figure A.1-3: Enrichment of tissue PZM genes in GWAS genes. Matrix cell color represents
the enrichment of PZM genes in a given tissue (column) and GWAS genes for a given trait
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(row). GWAS trait-tissue pairs with a q-value ≤ 0.1 annotated with “*”. Only tissues and traits
with at least one significant association are plotted.
One striking set of associations is liver and age-related macular degeneration (AMD). Liver
PZMs were associated with both geographic atrophy AMD and choroidal neovascularization
AMD. AMD is a common disease: in the US, 9% of adults over 50 have AMD and prevalence
increases with increasing age(202). AMD results in blurred to no vision in the center of the
visual field. While the pathogenesis is still unclear, it’s thought to occur from scarring of the
retina due to an increase in cellular debris (i.e., drusen) in the retina. Cholesterol is a major
component of drusen, and cholesterol metabolizing genes are associated with AMD. The
immune response is also thought to play an important role in AMD(203).
The genes with PZMs in liver were related to cholesterol metabolism and synthesizing
components of the complement system. As the liver is a major source of cholesterol(204) and
complement components(205) biosynthesis, a connection between dysregulation of normal liver
function and AMD seems plausible. Moreover, the observation that these genes also contain
PZMs in liver suggests that perhaps PZMs may be the linchpin to unravel normal liver function
and result in AMD. Given that liver PZM burden had the greatest association with age of all
tissues (Figure 3-4.d) and the fact that AMD is an age-related disorder lends additional
credence that PZMs may play a role in the disorder.

1.4 Discussion
This analysis has several caveats and limitations. We stress that this analysis can only show
correlation between PZMs and disease — it does not prove that PZMs cause disease.
Furthermore, since we tested this prediction in GTEx where we do not have much information
about the donors’ complex diseases/traits, we may be underpowered to detect signal. However,
since the development of complex diseases may be a gradual process, we may have some
power to detect associations for common diseases that take many years to develop. Another
limitation is that since PZMs are detected from RNA, only genes with expressed PZMs are used
in the analysis. True disease causing PZMs that lead to nonsense mediated decay or other
downregulation of its expression will be undetected. This will reduce the power to detect
associations. A simple strategy to avoid this drawback is to use PZMs detected from DNA.
Lastly, power to detect significant associations may be diluted when using PZMs from bulk
tissue rather than PZMs from specific cell types. PZM catalogs from single cell experiments may
have better power and be better able to elucidate disease mechanisms.
A better powered analysis would be to first have deep phenotyping on the donors (e.g., in UK
Biobank) and then search for associations between GWAS genes and PZMs in just the donors
with the trait of interest. We had plans to perform such an analysis with TwinsUK since this
cohort had rich phenotyping performed, however, the PZM call set was thought to be too small
to warrant further analysis.
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Appendix B
Co-authored manuscripts
This section includes my co-authored manuscripts that are not described in the main text of the
dissertation. A short introduction describing my contributions is given for each manuscript.
Separate PDFs of the manuscripts are provided as supplementary files.

1.1 Zhou et al. 2015
X. Zhou, D. Li, B. Zhang, R. F. Lowdon, N. B. Rockweiler, R. L. Sears, P. A. F. Madden, I.
Smirnov, J. F. Costello, T. Wang, Epigenomic annotation of genetic variants using the Roadmap
Epigenome Browser. Nat. Biotechnol. 33, 345–346 (2015).
I beta tested for the new software, performed data analysis, and helped write the manuscript.

1.2 Sankar et al. 2016
S. Sankar, D. Yellajoshyula, B. Zhang, B. Teets, N. Rockweiler, K. L. Kroll, Gene regulatory
networks in neural cell fate acquisition from genome-wide chromatin association of Geminin and
Zic1. Sci. Rep. 6, 37412 (2016).
I performed analyses of ChIP-seq profiles of Geminin in different cell types and helped edit the
manuscript.

1.3 Zhou et al. 2017
J. Zhou, R. L. Sears, X. Xing, B. Zhang, D. Li, N. B. Rockweiler, H. S. Jang, M. N. K.
Choudhary, H. J. Lee, R. F. Lowdon, J. Arand, B. Tabers, C. C. Gu, T. J. Cicero, T. Wang,
Tissue-specific DNA methylation is conserved across human, mouse, and rat, and driven by
primary sequence conservation. BMC Genomics. 18 (2017), doi:10.1186/s12864-017-4115-6.
I performed comparative analyses of epigenome profiles for this project and helped write the
manuscript.
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1.4 Drubin et al. 2018
C. W. Drubin, A. Ramu, N. B. Rockweiler, D. F. Conrad, Somatically mutated genes under
positive and negative selection found by transcriptome sequence analysis include oncogene
and tumor suppressor candidates. bioRxiv (2018), , doi:10.1101/396739.
I contributed to the project design, provided data, preprocessed input data, mentored the first
author on the project, and helped edit the manuscript.

1.5 Mahyari et al. 2021
E. Mahyari, J. Guob, A. C. Lima, D. P. Lewinsohn, A. Stendahl, K. A. Vigh-Conrad, X. Nieb, L.
Nagirnaja, N. B. Rockweiler, D. T. Carrell, J. M. Hotaling, K. I. Aston, D. F. Conrad,
Comparative single-cell analysis of biopsies identifies pathogenic mechanisms in Klinefelter
Syndrome. In review.
I helped write the manuscript and assisted with figure design.

[218]

Appendix C
Teaching experience
In addition to research, I love and am committed to mentoring and teaching the next generation
of scientists. During graduate school, I spent a substantial amount of time and effort teaching in
both informal and formal contexts. I was the head teaching assistant for both core courses of
the Computational and Systems Biology PhD program (CSE 587A: Algorithms for
Computational Biology and Bio5488: Genomics) for multiple years, developed and gave
workshops to ~600 participants around the world on scientific computing and genomic data
analysis, taught a course on scientific communication and graduate school preparation for
underrepresented minorities, gave guest lectures for an undergraduate biology course,
completed the Teaching Citation program through WashU’s Teaching Center, and founded an
outreach program to teach programming and robotics to underrepresented minorities in the St.
Louis Public School District.

1.1 Teaching philosophy statement
The teaching philosophy statement is a document often provided when applying to academic
positions with a teaching component. The purpose of the document is to explain one’s teaching
values and goals and to demonstrate their teaching effectiveness to the hiring committee.
This section includes my teaching philosophy statement. Since I am not currently applying to
faculty positions at primarily undergraduate institutions, I have left institution names and other
variables as X.
I vividly remember my first computer science course in undergrad. The instructor’s approach to
teaching was to let her students teach themselves with no direction. I found this approach
extremely difficult and frustrating: I didn’t know how to teach myself something that I had no
background in. Teaching a subject to students with little background in it is exceptionally
challenging. Students must be prepared and equipped for a journey up a steep learning curve.
In my preparation for teaching undergrads in similar situations at University X, I have been
practicing and reflecting on how to create an environment for students that sets them up for a
successful journey. I have found that this expedition requires resilience, confidence, and
reflection for both the students and the teacher. To cultivate these characteristics, I 1) create
hands-on guided learning experiences for students to improve their resilience and confidence,
2) reflect on my teaching effectiveness 3) provide early exposure to STEM for the next
generation of students to boost their confidence. In the following paragraphs, I demonstrate how
I have applied these teaching principles to my academic teaching and STEM outreach efforts.
My first teaching tenet is that students, especially those at the beginning of their
undergraduate careers, benefit immensely when teachers create an environment where
the teacher sets the direction, but the students have the freedom to move at their own
speed in that direction. I used this conviction to improve an entry-level graduate course on
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genomics that has a large bioinformatics lab component. I was the head teaching assistant for
the course for two semesters. During the first teaching assistantship, I realized two main
challenges: 1) students did not receive adequate feedback to learn how to improve and 2)
students often lacked sufficient knowledge of probability and statistics, a prerequisite of the
course. The following year, I improved the frequency and method of returning feedback. I invited
students to meet with me as often as they needed. During these meetings, I went over the
student’s work and discussed what they were doing well and how they could improve. In case a
student was uncomfortable meeting one-on-one, I included this type of feedback on all students’
graded assignments. Lastly, to cover the case where a student might not read the feedback, I
went over the common issues from the assignments at the beginning of the following lecture.
Together, these modes of dialog created structured time for students to reflect on how they’re
doing in the class and improve their confidence and skill set.
To solve the problem of students being unprepared for the course, I incorporated probability and
statistics “mini courses” into the curriculum. I made sure to start from the basics so that no
student was left behind. Additionally, after discussing the knowledge gaps of graduate students
with faculty and graduate program directors, I proposed that the students would benefit greatly
from extending the mini courses to a full course. The following semester, along with another
graduate student, I developed and taught a weeklong bioinformatics course to incoming
graduate students. After a resounding first year of success, I helped expand the course to a full
semester course that is now required for all incoming graduate students in biology and
biomedical sciences. I have also collaborated and shared what I’ve learned about developing
and teaching data science courses with other departments at Washington University School of
Medicine. From the student evaluations, I learned that the students valued and benefitted from
the extra time and structured practice to develop their skills. As a result of the improvements I
implemented, students are now better equipped for a successful learning journey in their
graduate career.
To improve this learning journey for my students, I must also work on how to be an effective
guide. My second teaching tenet is to reflect continuously on my teaching so that I can
improve. In graduate school, I mentored an undergraduate freshman on his own independent
research project. Throughout this experience, I kept a journal where I documented my teaching
approaches and reflected on my effectiveness as a teacher. I found the journaling very helpful
as it forced me to analyze which teaching methods needed improvement and as a result, I
enhanced my teaching. For example, early in the mentorship, I realized that my mentee did not
have the experience to know what questions to ask. To address this, I started asking him the
questions to get him to explain scientific concepts rather than me telling them to him. This style
was mutually beneficial as it allowed my mentee to learn what types of questions to ask, it
reinforced his knowledge by explaining concepts in his own words, and it allowed me to better
gauge which areas he knew well and which areas needed improvement.
In addition to reflecting by journaling, I also reflect on my teaching by recording my classroombased teaching experiences. I watch the lectures by myself as well as with my faculty advisors
and other teaching professionals to get advice on how to become a better educator. I also have
students fill out evaluations at the beginning, middle, and end of my courses and workshop
attendees fill out evaluations after the workshops. I use these evaluations to identify areas
where I can improve. For example, I learned that students wanted to learn how to write better
code. Simply passively posting homework code solutions was not sufficient for all students.
Therefore, I created a more active way to include students in this endeavor. After the
assignment was due, we spent ~50% of the next class discussing common pitfalls and how to
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avoid them. I created PowerPoint slides to show examples (and posted for later reference) and
had students discuss solutions at the blackboard. I encouraged discussion at the class level and
in small groups on how to write better code. It was important to do this in a timely manner so
students would be less likely to forget what mistakes they made. It was also important to guide
students to realize why the wrong answer was wrong and why the correct answer was correct
so they would have the independence to do this when their professor or teaching assistant was
unavailable to help them.
My third teaching tenet is to inspire students to pursue a career in STEM fields. As a
female in STEM, I have felt the systemic forces that have tried to exclude me from these
disciplines. I resisted and continue to resist by the help of mentors and programs that
encourage me to say I belong. I am passionate about helping the next generation realize they
too belong in STEM. I developed a curriculum for teaching programming and engineering
principles using LEGO robots for K-12 students. I used this curriculum to teach
underrepresented minorities in the St. Louis Public School District during their spring breaks and
at local STEM expos. For younger children, we programmed a robotic dog to avoid obstacles
during a walk using distance sensors. For older children, we challenged them to design a robot
that could deliver medicine to ICU patients. If accepted as a faculty member of University X, I
would volunteer with students and teachers in the X school district to improve K-12 STEM
education.
Through my years as an educator, I have followed three simple teaching principles to improve
the experience and results of students’ learning journeys: 1) provide students with structured
and guided time so that they can improve; 2) reflect on my teaching so that I can improve; and
3) inspire students to pursue STEM careers so that we can improve our future. I hope to bring
these principles to University X to enrich the lives of the next generation of STEM professionals.
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